var title_f28_36_29248="Imprinting--pedigree";
var content_f28_36_29248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54712&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of a pedigree showing imprinting",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 362px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFqAbwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAormvGHjjw/4Plso/EF69tJeBzAqW0sxfZt3cRq2Mbl6+tYH/C5vA3/QUvP/AAV3f/xqgD0SivPP+FzeB/8AoJ3n/gru/wD41W/4R8b+H/F0l3HoF81xLahTNHJbyQsobO04kVSQdp5HpQB0lFFFABRUN3cwWdtJcXc0UFvGNzySsFVR6kngV5Lrf7RXw90u+a2XULq/2/els7cvGDkjG4kZ6dRkc9aAPYKK53wd428OeMrVp/DWrW18q/fRSVkT/eQ4YfiK6KgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPPfFn/ACWf4f8A/Xpqf/oENehV574s/wCSz/D/AP69NT/9Ahr0KgArgNE/5Ld4q/7A9h/6MuK7+vI7/wAL2Pib41eIU1CfUYRBpFiV+xXstsTl587vLYZ6d6APXKK8R+LfgWw8N+AdR1TStT8RxXkMluqO2tXLAB540bgvj7rGuw/4VToP/P8A+Jf/AAeXX/xygD50/a7+IN3qHipvCOn3TJpdgqNdJGwxNORuwcdlBAwe+eOBXzpXpn7Q/hKTwh8T9Rtg1xJZ3Src20s8jSM6MMHLsSWIYEZJzxXmdAG14P8AE2qeEdftdY0O5e3u4GzlTw691Ydwe4r9JPCWuW/iXwzpetWeBBfW6TquQdpI5Ukdwcg+4r8w1BZgFBJPAA71+kPwe0S48OfDHw5pV6CLqC0UyqRgozEuVPJ6FsfhQB2NFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5x8RYtYtPHnhDXdK0K81m3sIb6KeO0eNXUyrEFPzso/hP5VY/4TrxB/wBE58R/9/rX/wCO139FAHAf8J1r/wD0TrxH/wB/rT/47UHgVdY1D4ieIde1PQL7RrW4sLS2iW7eJmdo3lLY2M3HzivRqKAPPP2gP+SUav8A9drP/wBKoa9Drzz9oD/kk+r/APXaz/8ASqGvQ6AOE+LPwz0b4k6KtpqY+z30PNtfRqDJCe491PcV8ta1+zH46s71otO/s7UbbqsyXAj4ycAq+CDjnjI5619wUUAfOvwf/ZvtvDeqQax4xurbU7yA7obOFSYEbszFgCxHpgDPrX0VRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcZ8T/EmreHbLQ08P29jPqGqapFpyC9Z1iTejtuJTnqg/OgDs6K878z4s/wDPt4F/8CLv/wCIo8z4s/8APt4F/wDAi7/+IoA9EorzvzPiz/z7eBf/AAIu/wD4ijzPiz/z7eBf/Ai7/wDiKAPRKK878z4s/wDPt4F/8CLv/wCIo8z4s/8APt4F/wDAi7/+IoA9EorzvzPiz/z7eBf/AAIu/wD4ijzPiz/z6+Bf/Ai7/wDiKAPRKK878z4s/wDPt4F/8CLv/wCIqjr2r/FPRND1HVbqz8Evb2NtJdSLHPdFiqKWIGUAzgeooA9Sory/RtU+KmraRY6jb2nghYbyCO4RXuLoMFdQwBwhGcGrnmfFn/n18C/+BF3/APEUAeiUV535nxZ/59vAv/gRd/8AxFL5nxY/59fA3/gRd/8AxFAHodFeeeZ8WP8An18Df+BF3/8AEUeZ8WP+fXwN/wCBF3/8RQAftA/8kn1f/rtZ/wDpVDXodeD/ABmf4in4c6mNbt/CS2Hm23mG0nuTLn7RHtwGQD723Ptmu18z4r9rXwN/4EXf/wARQB6HRXnnmfFj/n18Df8AgRd//EUeZ8WP+fXwN/4EXf8A8RQB6HRXnnmfFj/n18Df+BF3/wDEUeZ8WP8An18Df+BF3/8AEUAeh0V555nxY/59fA3/AIEXf/xFHmfFj/n18Df+BF3/APEUAeh0V555nxY/59fA3/gRd/8AxFY+g+JPidrV9rVra2PgxJNKu/scxknugGfy0fK4U8Ycdcc5oA9borzzzPix/wA+vgb/AMCLv/4ijzPix/z6+Bv/AAIu/wD4igD0OivPPM+LH/Pr4G/8CLv/AOIo8z4sf8+3gb/wIu//AIigD0OivPPM+LH/AD7eBf8AwIu//iKTzPiz/wA+3gX/AMCLv/4igD0SivO/M+LP/Pt4F/8AAi7/APiKy/EXiX4keGLCLUtasvCEmni6t4JVtJrky4llWPK7lA439zQB6xRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV518Yf+Pv4f8A/Y0Wv/oqavRa87+MAzeeAP8AsaLX/wBFTUAeiUUUUAFFFFABRRRQAUUUUAFcz8T/APkmni3/ALBF3/6Jeumrmfif/wAk18W/9gi7/wDRL0AT/D7/AJELw1/2DLb/ANFLW/WB8Pv+RC8Nf9gy2/8ARS1v0AFFFFABRRRQB53+0F/ySbWP+u1n/wClUNeiV53+0D/ySbWP+u1n/wClUNeiUAFFFFABRRRQAUUUUAFef/DH/kZPiJ/2Hf8A22gr0CuA+GP/ACMnxE/7Dv8A7awUAd/RRRQAUUUUAFFFFABXn3x1/wCSev8A9hHT/wD0rir0GvP/AI68/D5/+wjp/wD6VxUAegUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAfKX7QXxi8aeDfibe6RoGpxQafHBC6xtaxuQWQE8spPWvJtZ+OXjvWH059Q1O3kawulvbfFpENkqhgG4XnhjweK1/2tf8AktOo/wDXtb/+ixXjVAHr/wDw0Z8Sf+gzb/8AgDD/APE19e/BLX9R8UfC7QtZ1qZZ9QukkaWRUCBiJXUcAADgCvzjr7K+EHxFbwj8E9BkvfCviC40+3RlN9bpCYWL3DAYzIG+8wXkDmgD2zxt4mtvCmhtqFzDNcyvItvbWsAzJczOcJGo9T+gBPauXh8FeIPEA+1eNfE+oQSMSV07Qp2tbeEdgZAPMkPqSQM54xisU65P4m+L3hC31XQdV0eC0tr27gi1ERATThUUFdjtkqrOexGcivYKAPOJ/BviPw4PtfgvxLf3hQhn0vXJzcwzLxkLKR5kbdcHJGccAV1fgzxLaeK9Bi1OyjlgJZop7addstvKpw8bjswP9D3rcrzvwPi3+K3xDs7YgWhNjdlFxhZ5ImDn6kIhP1z3oA9EooooA8s8U22p+IPjEuhQ+JNZ0fT4tBW92adKiFpTcMmTuVu2PyqzffCya/srizvPHnjKa1uI2ilja6hw6MMMD+66EE1Kn/JxEv8A2Kqf+lbV6LQB5tafC64s7SC2tfHvjOK3hRY441uocKoGAB+67AVJ8Km1C217xpo9/rGoatDpl9DHbzXzq8gV7dHIJUAdWPavRa8++Hv/ACUH4lf9hG1/9JIqAPQaKKKACuW8deKH0COwstOtvtuvarKbfT7U52lgMtJIRyI0Byx/xrqa87slW7+PWqPdNmSw0KBbRD2EszmVgPXKIMj1x3oArXHwwufEtmT4+8TatqU0uGe0sZjaWcZBDAIi8sAQMFyTwDwaW80bxR4HjOo+H9Yv/EOjwAyXWk6m3nXBjAJP2eYDcWAxhHznnnJr0yigDP0DV7LX9FstV0uYTWV3EJYn6ZB7EdiOhHYgitCvOfgqRFa+L7GHH2Ky8R3kNqoAwiHY5UY7B3f6dO1ejUAFFFFABRRXG/GPWbjw/wDC7xLqdkSLmGzYRsDgqzYQMPcbs/hQB4/8X/2k4tB1WfR/BNta6hcQHbLfTEtCGB5VFGN2P72cfWvGvCXx+8Y+HtX1C9ZrG9XUbj7TdRTQBQ77UXcCuCp2oB6d8ZryMksSSSSeST3pKAP0V+EPxQ0j4laM9xYD7LqMHFzYu+54/RgeNyn1x7V39fn/APsy65c6L8YdES3JMV+zWcybsBlYHBP0IB/Cv0AoA8a8B2/j3xh4Xt9c/wCFgPYi5lnUW66PbSCMJM8YG4gE8Jmuh/4RHx7/ANFNm/8ABHa074A/8kp0n/rvef8ApXNXoVAHk/ijRfH2ieGdX1ZfiPLM1jZzXQjOi2qhyiFsZxxnFeheEbyfUfCmi3t2we5ubKCaVgAMs0aknA6ck1R+Jn/JN/Ff/YJu/wD0S9cB4d+J0ujeFvCtndeC/Exa5t4LS1dEt9tw4hz8v73uqkjOOKAO/wDiD4x0vwL4Yudb1pn+zxYVI48F5XPRFB7/AMgCa+N/iN+0H4n8XB7O2gs9O0kTpMkKxiR2KOrpvZvRkB4AHXrWv+1r4t1DXdZ0GxutH1HR7e3t3nWC+CB5Gdtu7COwxhMDoeteAUAfTPw4/ah1OC9itfHdrDdWbfKby1j2SoSfvMoO1gB6AHjvX1ta3EV3bRXFtIssEqB0dTkMpGQQa/LCvu/9kvVbnU/g9aR3TbvsN1LaxHJJ2DDDOfTeR9AKAPZaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA+D/2tTn41al7W1uP/ACGK8br9H/E/wt8F+KNYl1XXtCgvL+VVV5nkkUkKMDgMB0FZf/Cjfhv/ANCra/8Af6X/AOLoA/PSvsTSDn9jjTv96H/04rXo/wDwoz4b/wDQrWv/AH+l/wDi6qfF7RNO8OfA++0rRbVbTT7eW1EUKkkLm8iY8kk9STQB0vxG8PX2r2mn6l4feKPxDo1x9rsjLwkmVKyQseyupIz64pvh34jeH9Yd7ae6/snVosibTdTIt7iMj/ZJ+YdwykjBFdjWVrvh3RdfRE1zSbDUVT7ourdJdv03A0AYPiP4jaDpMi2dlcf2zrUpCw6bppE8zk4wSAcIvOSzEDGetTfDjw7e6Jpl5da5LHNr+rXLXt+8WdiuQAsaZ52ooVR9K2dD8P6NoETR6HpVjp0b/eW1gWIH67QM1qUAFFFFAHnSf8nES/8AYqp/6VtXotcn4t+HfhXxdqMV/wCIdJW8vIohAkvnSRkICW2/Kw7sT+NYv/Ckvh7/ANC8P/Ay4/8AjlAHo1effD3/AJKD8Sv+wja/+kkVRf8ACkvh7/0Lw/8AAy4/+OV0/hDwfoPg62uLfw3p62UVxIJZQJHfewGMksSegoA36KKKACuE8f6PqVtrmleMPDsJuNQ01Ht7yzX795ZsQzonI+dSNyg8E8V3dFAHKeHfiD4Y163L2urW0FwnE1nduILiBu6vG2CCDx6ZHU1meJPiLZGZ9F8GvHrviaYFIorU+bDatyPMuHBwiKRyM7jwAOa6PXPCXh3X5ll1vQtL1CVeA91apIw/EjParuj6Rpui2gtdHsLSxthz5VtEsa/kAKAMzwF4cHhXwvaaY07XVyu6a6uW6zzuxeR/xYn8MV0NFFABRRRQAVl+KdFt/EfhzUtGvf8Aj3vrd4HO0HbuGNwB7g8j3FalFAH5k+NvCuq+DPENzo2uW7Q3UJ+U/wAMidnU9wawa/TfxX4Q8P8Ai20Ft4j0m1v41+6ZU+ZOc/Kw+Yfga4fR/gB8OtLvUuk0M3LrghLqd5UzkHO0nB6d+KAPEP2Q/h3e3viVfGOo2xj0uzR1s2kUfvpiNpZQeygnn+9jHQ19iVHbwQ20CQ20UcMMY2pHGoVVHoAOlSUAee/AL/klWk/9d7z/ANK5q9CrzyD4SaDaxmKy1HxLaQb2cQ2+s3EcalmLHChsDkk/jUn/AAqzSv8AoN+Lf/B7c/8AxVAG38TP+Sb+K/8AsE3f/ol64bUf+QN8Gf8Ar9tf/SGWtq5+Eui3NvLBc6v4plglUpJHJrdwyupGCCC3II7VF49sodO1D4ZWNopW3ttZjhjUnJCraTADPfgUAcd+1b8N7zxf4etNb0SBrjVNKDK9vFHueeFiCQO5KkEgc9TiviZ0aN2SRSrqcMpGCD6Gv1SrjfEnwv8ABXiW8N3rXhywuLoks0yqYncnHLFCC3TvmgD87dC0bUdf1SHTtGs5729mOEihQsT7+w9SeBX6KfCXwengTwFpmhB0knhUvcSqoG+Vjlj74zgE9gK0fCvg3w74ThMfhzRrLT9w2s8UfzuM5wzn5m/E1v0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFcRq3xM0TTdcv9Ja11u7u7FlS4+xaZNcIjMgcAsikZwwNAHb0V5/8A8LW0f/oD+K//AARXP/xFH/C1dH/6A/ir/wAEVz/8RQB6BRXAf8LV0f8A6A/ir/wRXP8A8RUE/wAX/D9vNbwz6f4limuGKQo+i3AaRgCSFBXkgAnjsKAPRqK4D/hauj/9AfxV/wCCK5/+Io/4Wro//QI8Vf8Agiuf/iKAO/rzz4//APJKNX/67Wf/AKVQ1J/wtXR/+gR4q/8ABFc//EVxPxl+Iml6t8OdSs4NM8RRSSS2xD3GkXESDbcRscsygDgcepwKAPdaK4A/FTR/+gR4q/8ABFdf/EUf8LV0f/oEeKv/AARXP/xFAHf0VwH/AAtXR/8AoEeKv/BFc/8AxFH/AAtXR/8AoD+Kv/BFc/8AxFAHf0VjeEvEmn+KtIGpaSZ/s/mvCVnhaJ1dGKspVgCCCK2aACiiigAooooAKKKKACiiigAooooAKKKKACimyyJFE8krqkaAszMcBQOpJrlP+FleB/8Aob/D/wD4MIv/AIqgDraK5P8A4WV4H/6G/wAP/wDgwi/+Ko/4WT4I/wChv8P/APgwi/8AiqAOsork/wDhZPgj/ob/AA//AODCL/4qj/hZPgj/AKG/w/8A+DCL/wCKoA6yiuT/AOFk+CP+hv8AD/8A4MIv/iqP+Fk+CP8Aob/D/wD4MIv/AIqgDrKK5P8A4WT4I/6G/wAP/wDgwi/+Ko/4WR4I/wChv8P/APgwi/8AiqAOsrgPif8A8jD8PP8AsPj/ANJp60/+Fk+CP+hv8P8A/gwi/wDiq4j4ieO/CV5rvgWS18TaLMltrQmmaO9jYRJ9nmG5sHgZIGT6igD2OiuT/wCFk+CP+hv8P/8Agwi/+Ko/4WV4H/6G/wAP/wDgwi/+KoA6yio7eaK5gjnt5ElhlUOkiHKspGQQR1BFSUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeffDz/koHxJ/7CVt/wCkkVeg15/8Pf8AkoHxJ/7CVt/6SRUAegUUUUAFef8AxC/5H/4b/wDYSuf/AEklr0CvP/iF/wAj/wDDb/sJXP8A6SS0AegUUUUAFeeftAf8kn1f/rtZ/wDpXDXodeeftAf8kn1f/rtZ/wDpVDQB6HRRRQAUUUUAcB8Ff+Rd1n/sPal/6UvXf1wHwW/5F3Wf+w9qX/pS9d/QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBmeKP+RZ1f8A685v/QDXJ/CjQtIm+GHhOWbSrCSR9KtmZ2t0JYmJcknHJrrPFH/Is6v/ANec3/oBrF+EX/JK/CH/AGCbX/0UtAGz/wAI9ov/AEB9O/8AAZP8KX/hHtF/6BGnf+Ayf4Vp0UAZn/CP6N/0CNO/8Bk/wrgPB2j6ZJ8WfiHC+m2TQxJpuxDApVcwvnAxxmvUq888F/8AJYPiR/uaZ/6JegDsP+Ef0b/oEad/4DJ/hR/wj+jf9AjT/wDwGT/CtOigDM/4R/Rv+gRp3/gMn+FcF410fTI/if8ADmFNNslilmv96CBQGxasRkY55r1CvPfHP/JVfhp/131D/wBJGoA6/wD4R/Rv+gRp3/gMn+FH/CPaL/0CNO/8Bk/wrTooAzP+Ee0X/oEad/4DJ/hXN/EnQtIi+HXimSLSrBJE0q6ZWW3QEEQtgg4rt65r4nf8k28Wf9gm7/8ARL0ATfD/AP5ELw3/ANgy2/8ARS1v1gfD7/kQvDf/AGDLb/0Utb9ABRRRQAUUUUAFFFFABRRXEfGTUbyx8B3UGmSCK+1KaHTIZT0iaeRY95xyMBicjvigCre+NtW1jUbnT/AGjR6kLZjHNqt7KYbFH5G1CAWmIIOQuAMYzzUZ1H4naSpuNR0jw3rdsoy0GlTS284Hcr5uVY+2V6fSu18P6PZeH9EstJ0qFYLK0jEUSAdh3PqScknuSTWhQBi+E/Elh4o0lb7TTKmGMc1vOnlzW8g6xyIeVYen4jIOas+I9UXQ/D2qatJE0yWFrLdNGpwXCIWwD2ziuA8S3mn+Cfi7pGqz3Ntp9h4jtZrW/kmlWKMzQKHilYtgA7SyZzzlRVj4i+OfCd18PfE9vbeKNCmnl0u6jjjj1CFmdjEwAADZJJ4xQBHp/jrxrqOn217Z/DWeS2uYlmif+2rYbkYAg4PI4PesTw5eeP8ASPEXifU2+Hcsq6xcxXCxjWbUGIJCkeCc8525/GvSPh//AMiF4b/7Blt/6KWtS21Owur26s7W9tZru1wJ4I5VaSHPI3qDlc+9AHnt98Q/E2jrBc+IvANzp+mNcQ28tyuq28xjMkiop2KcnlhXptef/HT/AJJ+3/YS0/8A9K4q9AoA57xh4u03wpb2zX/nz3d2/lWllax+bPcv6In5ZJwBkZIrgddX4g69rXh7W4vCWn2kWj3ElylncaqPPmDQtHtO1Cin5sj5vritj4Xxf29rfiHxneAtPdXcunWOSf3NpA+zaB2LSK7H8K9HoA5Hwp43tta1SXRtRsLvRfEEEYkk0+8Ayy9C8TqSsiZB5X8hXXVxHxg0lr3wdcanZN5WsaHnU7CfONkkQ3EH1VlDKQcgg11Hh/Uo9Z0HTdUgVlhvraO5QMMEK6hhn86AOL1Px5rn/CW61ofh3wdNrP8AZJhWecajDbjMsYkUBX56H9K5r4iXXj/xb4QvNFj+Hctq1w8LiVtZtWC+XMknTI67MfjXS+Bf+SsfEz/rtp3/AKSivQ6APPP+Eu8d/wDRM5//AAd2v+Nb/gDxM/izQXv5tPfTp4rqa0ltnlEpR4nKN8w4PIPSukrgPgt/yLus/wDYe1L/ANKXoA7+uE1b4jW41O50vwtpGo+JdTt3MUwslC28EgxlJJ3IRT7DJHfFSfFrUbyDQrHSNJme31HXr6PTIriM4aBXy0ki+6xq5HI5x9D0GmWGk+EfDiW9ssNjpdhBlnYhQqKvLue5wMlj160AeX+CPE2oeAtMvoPHXhjVdKtbjULq/wDt8Oy8t4VmlZ8SNESUxnGcY78V7FaXMF5aw3NpNHPbzIHjljYMrqRkEEdQRWB4N8Y+HvHWlz3Xh2+iv7VHMMylCpU46MrAHBHtg1xej6pYfDr4ian4c1HULWw8N6jbnVtPa7nWKO3kL7ZoELMAFyQ6qAMbmx0oA9P1K7Fjp11dspdbeJ5So6kKCcfpXm+j/EDxlrGk2epad8NriWyvIUnhk/tq2XcjAFTg4I4PQ1s+JPHnhCbw7qkcXirQHke1lVVXUYSWJQ4AG6rfwi/5JX4Q/wCwTa/+iloAx/8AhL/Hv/RMZ/8AweWv+NZ3iH4leLPDmkXGq638Obi20632maYaxbybAzBQdq5J5I6V6tXnP7RH/JG/Ef8AuQ/+j46APRqKKKACiiigAooooAKw/F3izRPCFjDeeI75bK2mlEMbmN33OQTjCgnop/KtyvP/AIof8jF8O/8AsPj/ANJp6AMrXvjL4CutC1GCDXw8sttIiL9knGWKkAfcrL+G/wAXPBGk/D7w1p+oa2Iby1063hmiNrOSjrGoYZCY4I7V7TRQByvhP4g+FvFt9LZeH9Wju7uOPzWi8uSNtmQNwDqMjJHT1FdDqV9baZp91fX0ohtLaJpppGBIRFGSePQA1xF9/wAl50j/ALF26/8ASiCtf4rf8kx8W/8AYJuv/RTUAYY+Nnw5I/5Guy/75k/+JrjfDHxU8DWfxJ8balP4lsks9QWxFvIQ+H8uJ1bHHYkV8RUUAfovYfGDwDqF/bWVl4ms5rq5lWGKNVfLuxwB93uSK72vzS+GH/JSfCv/AGFbX/0atfpbQBHcTRW0Ek9xIkUMal3kdgqqo5JJPQV4F48+MfgZfiN4Pu4taW5t9Ilu2upLeF5FUSQNGuCBhvm9M+teeftf/EC6vfEq+ENPnaOwsFWS7CMR5srDIVsHkKpHHqT7V830Afpx4T8W6F4usWu/Dmp21/Cpw/lN8yH0ZTyOncVuV+ZfgXxXqXgzxLZ6zpEzJNA4Zo9xCSr3RgDyCM1+knh7VYNc0LT9Vszm3vYEuI+c8MoP9aANCvM/ir450JfD/iHw3aXMuo69c6fcW62OnwPcyKzRso3hAdvJGc4rS+J2p6g8mjeF9Buns9V12Z4zdoMta20a7ppB6NjCqeOW6g4rpPDXh3SvDOmJp+h2UVnbKSdqDJYk5LMx5Y89STQBx/wy8daBcaPovh6a7ksNdtrKCB7DUIXtpSyxqPlDgbunbNejVkeKPDek+KNMax1yyjuoMhkLZDxsDkMjDlSCByCK534XarqDx6v4c1+5N3rGgXAt3umADXMDqHhlI7EqcHryp5PNAHc0UUUAFFFFABRRRQAVyvxP0C48SeC7+y05xHqcey6spD/DcRMJI/zZQOfWuqooA57wP4ptPFmhxXtuDBdp+7u7KQgS2swJDRuvVSCD16jmuhJABJ4Arj/E3w/0rWtTOrWtxf6NrhAB1DTJzDJIAOBIOVkA44YHgY6VmP8ADa41MiPxR4w8Q6zYjrZmSO1ilB6iTyVUuOBwT/M0AUY4rL4i/EhbxraC/wDDPh2CSCKWVVlhuryXG4p1VljQYJ/vN7Zrk9S8PaKt78blXSNOAtLCJrcC2T9yTYFspx8pzzx35r3PTNPtNK0+3sdNtorWzt0CRQxLtVFHYCvMLLS5Nb8XfGbSoZFjlv4LW1R36KXsdoJ9hmgDu/h//wAiH4b/AOwbbf8Aopa4/wACfCDTfB/xC1vxVa6leXE2o7wlvJjbFvYM+W6vyBjOMD160mjaZ8U9K0ix06C68EPDaQR26M8N0WKooUE4brgVc2fFj/n48C/9+Lv/AOLoAf8AHT/kn7f9hLT/AP0rir0CvKPEXhv4j+J7GHTdZvPCEdh9qt7iVrSG5EuIpVkwu5iOduORXq9AHnHw1mHh3xDr/gy9LI8d1LqemllwJrWZ95CnuUkZgec8jtXo9YPi7wppXiuzhh1WKQS28nnW11byGKe2kHR43HKn9DjkGuZ/4RDxxF+5tPiNL9jHANxpEMs4Hf8AeAgE+hK/XNAFv4v6s9t4Ul0XTwZdb17Om2MKjJLSDDueDhEQsxJ447Zrq9C06LR9E0/TLbPkWVvHbR5OTtRQo/QVh+E/BNh4f1C41SW5vNV125QRz6lfSb5Suc7FAAWNMn7qgDp6CuqoA888C/8AJWPib/1207/0kFeh15pd+GvG2m+OfEms+Fbvw39k1hrd2j1KOdnQxQiPjYQOcE96sbPix/z8eBf+/F3/APF0Aeh1wHwW/wCRd1n/ALD2pf8ApS9R7Pix/wA/HgX/AL8Xf/xda/wz8Pah4a8OzWusT2k9/cXtzeytahhEGllZ8Lu5wM96AM34xRTW2j6R4igQyjw9qUWozxqMloAGjlwO5CSMw5H3e/Q9ey6f4h0IqwivdK1G3+qTRSL/ACIP61eIBBBGQeoNeeSeBdY8P3E8/wAPtdTT7aWQzNpF/B59nuPXYQQ8Q74UkegFAG38PvAegeAdMnsfDdq0Mc8nmyvI5d3PbLHsBwB/ia5iys9P8b/FjVtRntLa+0jQrT+yFM8SyJJdM4ebAYHOwKi545LDntZm8M+OvEUb2/ijxPY6bp7DZJB4ft2SSZT1zNKWZPT5R+IrudE0qx0PSrbTdKt0trK3XbHGnb1JPUknkk8knJoA8k0nw3obav8AFdW0bTSttKghBtY8Rf6FGfl44554713nwi/5JX4P/wCwTa/+ilrB8K2rX3ir4rWiMEa4u4Ygx6AtZRjP61V8N6L8UtA8P6bo9pd+CZLewto7aN5YbouyooUE4YDOB2AoA9Vrzn9oj/kjfiP/AHIf/R8dP2fFj/n48C/9+Lv/AOLrF8ZeGPiZ4u8OXmh6ne+DYrO72CV7eG5EgCurfLuYjqvcUAeu0UUUAFFFFABRRRQAV5/8UP8AkYvh3/2Hx/6TT16BXnvxcjv45/CGpafpN9qq6bq4uZ4LJA8uzyJVyASB1Yd6APQqK88/4WTe/wDRPvGv/gJD/wDHaP8AhZN7/wBE+8a/+AkP/wAdoAfff8l50j/sXbr/ANKIK1/it/yTHxb/ANgm6/8ARTVy3h6+1LxH8W7TWJPDWt6RYWujT2rSalEibpGmiYBdrt2U/lXX/EezudQ+H3iWysYWnu7jTbiKGJOru0bAAe5JoA/M6ivQB8GviGf+ZT1L/vkf40f8Ka+If/Qp6l/3yv8AjQBjfDD/AJKT4V/7Ctr/AOjVr9La+CvAPwm8eaf468O3l54Y1CK2t9Rt5ZZGUYRVkUknnoAK+9aAPgn9qjRbnSvjFqtxOp8nUUjuoXxgFdgQj8CpryGv0e+Knw40b4kaIljrHmRTwFmtbqL78LEY6dx0yO+O1fMepfsseMYbt00/UtGubYH5JJJHjYj3XacH8TQB4BGjSyLHGpZ2IVVAyST2r9LvhvpM+g+APDulXn/HzaWEMMox0YIMj8DxXkvwb/Z3svB+p2+t+JLxNT1a3cSW8UIKwwMM4bnlz0I4ABHevfaAPPPG0g0n4n+CdZusLp8y3WkvKTgRSzBHiz/vGIr9SOa9DrM8S6Fp3iXRbnStZt1uLK4XDoeCD1DA9mBwQR0NcVG/xF8LJ9mSzs/GdipxDOblbK9CnOBIGHltjgbgQT1x1oA9Irzr4esNU+Ivj7XbUhtPea202KQdJHt0bzCPYNJt9MqeTUco+IfitPs01taeDNOc4mlS5W8vWXjIjKjy0zyNxJIznGRXceHdE0/w7otrpOjWyW1hbJsjjXt3JJ7kkkknkk0AaNFFFABRRRQAUUUUAFFBOBk9Ki+0Q/8APaP/AL6FAEtFR/aIf+e0f/fQo+0Q/wDPaP8A76FAEleeeBf+SsfE3/rtp3/pIK777RD/AM9o/wDvoV574GmiHxX+JZMqAGbT8HcOf9FFAHo9FR/aIf8AnrH/AN9Cj7RD/wA9Y/8AvoUASUVH9oh/56x/99Cj7RD/AM9Y/wDvoUASUVH9oh/56x/99Cj7RD/z1j/76FAElFR/aIf+esf/AH0KPtEP/PWP/voUASUUUUAFFFFABRRRQAUUUUAef/D7/kf/AIk/9hK2/wDSSKvQK4D4ff8AI/8AxI/7CVt/6RxV39ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBgfEHjwF4lI6/wBmXP8A6KauC+H3wq8Dah4B8NXl54Y06a6uNMtpZZGjOXdolLMeepJJrvfiF/yIPiX/ALBlz/6KaoPhf/yTTwl/2CLT/wBEpQBk/wDCn/h//wBCnpf/AH7P+NL/AMKg+H//AEKel/8Afv8A+vXd0UAcJ/wqD4f/APQp6X/37/8Ar1w/g/4aeDLv4k+P7G58OafJaWMtiLaJo/liD2wZsfU817nXnfgX/krPxN/67ad/6SCgCz/wqH4f/wDQp6X/AN+//r0f8Kh+H/8A0Kel/wDfv/69d3RQBwn/AAqH4f8A/Qp6X/37/wDr1xV38M/BifGTTdMXw5p40+TQ7i4eDy/lMizxKG+oDEfjXuFefXv/ACXvSf8AsXbr/wBKIaAJv+FQfD//AKFPS/8Av3/9ej/hUHw//wChT0v/AL9//Xru6KAOE/4VB8P/APoU9L/79/8A164b42fDbwdofww1vUtI8O2FpfQCIxTxJhkJmQHH4E17pXnX7Q//ACRzxF/uw/8Ao+OgD0WiiigAooooAKz/ABFK8Hh/U5YXZJI7WVlZTgqQhIIrQrM8U/8AIsav/wBec3/oBoA8v8BeApde8EaBq17428cC6vrCC5lEesuF3ugY4GOBk1vf8KsT/odvHf8A4Om/+JrY+EX/ACSvwh/2CbX/ANFLXW0AeY23wesbW5uri28W+NYp7pw88iauQ0rBQoLHbyQABz2FWf8AhVif9Dv47/8AB03/AMTXotFAHh3hzwdc6j4/8YaLceNPGos9JWyNuV1hw582Nmbccc8gY4FdZ/wqxP8AodvHf/g6b/4ml8Ff8lh+JP8Au6Z/6IevRKAPOv8AhVif9Dv47/8AB03/AMTR/wAKsT/od/Hf/g6b/wCJr0WigDw/xN4NudN8ceDdIt/GnjX7Lq0l2twW1hywEUBddpxxyOetdX/wqxP+h38ef+Dpv/iad45/5Kv8M/8ArtqH/pI1eh0Aedf8KsT/AKHfx5/4Om/+Jo/4VYn/AEO/jz/wdN/8TXotFAHkXjL4fSaN4P13U7Txt44NzZWE9zEJNZcrvSNmGRjkZAr0PwTPNdeDNBuLmR5Z5tPt5JJHOWZjGpJJ7kmqnxN/5Jt4s/7BN3/6Jep/AH/IieG/+wbbf+iloA3qKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiuS+JniqXwtoEL6fClxrOo3Men6dC/3XuJDhS3faMEn6Y70AR/FjXdK0fwJrqarqNpaSXOn3EcCTSqrSsYyAFB5Y5I6etZ/wAGvFmgat4H8OadpusWNxqFrpltFNbJMPNRliQMCvXg8Z6Vd8I/D7S9Gk/tLVEXV/EkxElzqd4okk8wjkR5H7tBzhVxgGr/AIs8D+HvFVsY9V06I3AXEV5CojuICM4KSD5lwST6e1AHS1Fd3ENpazXN1IsUEKGSSRjgKoGST7ACuN+Hmr6kuo6z4W8QzfadU0dkaK7xzdWkgPlSN0+f5WVuAMrkda2PiD/yIXiT/sGXP/opqAMP/hb/AMP/APobNL/7+/8A1q4fwh8S/Blp8SPH99c+I9PjtL6WxNtK0nyyhLYK2PoeK9I+GNvCfhr4TJijJOkWmSVH/PFK6b7NB/zxj/75FAHFxfFrwFNKkcfirS2d2CqPN6k8AV3Neb/H+GJPhRq7JEikTWfIUD/l6hr0igCO5nhtbeSe5ljhgjUs8kjBVUDqSTwBXieo/EnwsPjDZaxHqL3GlW2jXFnLeW1tLNEsrTRMF3IpH3VYk9BjmuhS0T4k+MtWXVQJ/COg3ItIrM5C3d6m1nkkwfmVMhQpBUkk9sV6XBBFbwLDBFHFCg2qiKFUD0AHagCloOuaX4gsFvdEv7a/tWOPNt5A4B9DjofY1o15p8Q9CHhgXPjnwnbx22qWYE2pQRDamoWq5MisoON4BLB8bsjHOa9D0+8g1Cwtr20cSW9xGssbj+JWGQfyNAHP+IviB4T8OaibDXNfsLK9ChzDLJhgD0JHavMvjd8S/BmtfC7XNP0rxHp91ezLEI4Y5Ms2JkJx+AJrrfBkaSfGP4leYithdLxuGf8Alg9eh/ZoP+eMX/fIoA4n/hb/AMP/APobNL/7+/8A1q6jw7r+leJNO+36DfwX9nvMfmwtuXcOo+vIq99ng/54x/8AfIrz/wCCgAsvGAAAA8UakAB/11oA9FooooAKyvFbKvhjVyxAH2SbknH8Bqj498Tr4V0H7XHbNe6hcSpaWNmjBWubhzhEBPAHUk9gDXOWfwyttXxe/EK7m8Rai5L+RK7R2dtn+COEHaQOBubJO0Hg0AbHwgZW+FfhHaQcaTag4PQ+UtddXnd18KtKsc3Pgi4uPCuqL92WyZmgf2kgJ2OD9AeBzwK2vh94nn8Rafdw6raLY67pk5tNQtVbcqyAAh0PdGUhh+I5xQB1VFNlkSKN5JGCIgLMzHAAHUmvhf42fHDW/F2s3dhoN9NYeHYpCsKwMY3uAP43YHOCRkDp070AfU/gwAfFz4iSB1IkTTduD6QvXodfltYaje6fdLc2F5cW1wpyssMhRh+Ir6//AGYvjHfeLbiTwz4quFm1WOLzLO5Iw06KPmVj3Ydc9xnPSgD6KoorxH4WfD/w/wCLfBNprniCPULzVLu4umnnOp3KbyLmRRwsgA4UDgdqAOs8cj/i63w0PpNqH/pK1ehV50/wX8DPJHI+mXrSR52MdUuyVyMHB83jisbxz8K/Cel+CfEN/Y2l/Fd2mnXE8Mn9qXTbXWJmU4MmDggdaAPXqKw/AjvL4I8PSSszu+nW7MzHJJMS5JNfL/7ZetapYeOtEgsNSvbaD+zfM8uGdkXcZXBOAeuAPyoA+mfiUu/4c+KlHU6VdD/yC1T+BFKeB/DyHqunW4/8hLX5uyeJNcljeOTWtTeNwVZWupCGB6gjPIpU8S66iKia1qaooAVRdyAAeg5oA/T2ivnn9jHULzUPCHiB7+7uLp1v1AaaRnIHlj1NfQ1ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnXxUK2XiPwBq9yubG01jyZnxnyzNC8UbHPAUOy5JPGR3r0WszxLodj4k0K80jVojLZXSbJFBKkdwQR0IIBB9RQBn/ETQLrxT4J1fRNP1CTTrq8h8tLlM/Kcg4OOcEDafYmsr4M+Dr/AMCeBbXRNV1Q6lcxyPIXBJSINj92medoxnnuTWXbaz4w8Fw/Ytd0O78T6XAAsGqaVh7kxjCqJoGIZpO5ZCQc5wMGnyeNvFGvxNb+EPBmp2c7fL9t8QoLSGA/3jGCXk7cKMe/FAD7Mfbfj/qNxbYaLTfD8dpckdpZZ/MRfrsUnn1HrXT/ABB/5ELxL/2DLn/0U1M8EeF4fC+mzx/aJLzUbyZru+vZfvXE7dWx/CoxgKOAAB71P43gmuvBev29tE8s8un3EccaDLOxjYAAdyTQBU+F/wDyTTwl/wBgi0/9EpXTV4/4L+IcmjeDtC0u78D+Ojc2VhBbSlNGYqXSNVODu6ZFbP8AwtVP+hG8e/8Aglb/AOKoAf8AtB/8kl1j/rtZ/wDpXDXoleHfE/xjdeL/AAVeaHpngrxrHd3Utvse50hkjASeNyWbJxwp7V7jQB558H5Psh8WaHcDZf2GuXUroerRTuZo3HsQ5H/ATXodcZ4w8J3t1q8PiLwpewab4lhiEDSTx74buDdu8mUDkDI4ZfmGT1rOXxh40t0aG9+HV5LeLwHs9St2gc9iGYqygn1Uke9AG/8AEnVoNE8Ba9f3R+SOzkVVzy7spVVHuWIH41L8PtMn0bwJ4d0y8AFzZ6fBBKB2ZY1B/UVzdh4a1/xRrFpqvj77Hb2VlKtzY6HaN5qRTLnbLNLgb3GeAMKOvWvRKAPOfBP/ACWT4l/7ul/+iHqH48af491Hw3Zx/De58i7FwGuRHKsUrp22uxAAB6jOTx7g5Ta3d+EPix42u7nwx4m1Gz1NLD7PPpmntOh8uFg2WyB1YD862v8Ahaqf9CN49/8ABK3/AMVQB3GgJqEeh6emtSxTaotvGLqSEYR5do3lR6E5rifgr/x6eMf+xp1L/wBG03/haqf9CN49/wDBK3/xVP8AgjFeDRPEF1fadfacb/Xr29igvYTDL5UjhlJU9OKAPRKKKKAPOviDu/4Wd8NftG7+z/tV7nP3PtH2f9zn/ax5mPxr0Wuc8e+GE8VaAbNLlrK/glS6sbxFDNbXCHKOAeD6EdwTXN2vxOg0UCy+IllP4e1BDs+0vG0llc4/jjmUYAOAdrYI3AcmgD0evO9C2/8AC9PFX2L/AFP9k2X23b0+0b5dm738vH4Ulz8VtL1AG28C2tz4q1NuFjs0ZIE9TJOw2IB+J5HHNbfw+8MTeHNPu5dUuxfa5qU5u9QuguFeQgAKg7IoAUD8eM4oAm+Ja3D/AA68TrZeZ9qOmXIi8s4bd5TYx75r8z6/VNlDKVYAqRggjIIr4t+Nf7P2uaNrF3qvg6xbUtEnkLra2wLzW2cfLt6suTwRk46gdaAPn6vR/wBndLp/jN4XFkJC4uSX8s4PlhWL59tuc+1cvpvg3xLqd4lrYaBqs9w/RFtXz/Kvr39m/wCDE/gQza74lEDa5cRiOGGM7vsqEZYE9Cx4BxkADgnJoA94rzz4Af8AJKNI/wCu15/6VzV6HXkHwQ8XeG9N+GmmWmo+INItLuOa73wz3scbpm6lIypYEcEH8aAPX65r4m/8k28Wf9gm7/8ARL0v/CeeEP8AoatA/wDBjD/8VXPfEXxt4Vufh94ngt/E2iTTy6XdJHHHfxMzsYmAAAbJJPagDp/AH/IieG/+wbbf+ilr5R/bZ/5KFof/AGCx/wCjZK+rvh+f+KD8N/8AYNtv/RS18oftsMD8RdFXuNKU/wDkaSgD54ooooA+xf2I/wDkTPEX/YQX/wBFivo+vm/9iI/8Ub4iH/T+p/8AIYr6QoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACkZVYYYAj0IzS0UAIqKgwihR6AYpaKKACiiigAooooAKwJPBfhaSRnk8NaIzsSzM1hESSe5+Wt+igDnv+EI8Kf8AQsaH/wCC+L/4mj/hCPCn/QsaH/4L4v8A4muhooAbFGkMSRQoscaKFVFGAoHQAdhWbqvh7RdXnSbVtI06+mRdivc2ySsq5zgFgeOTxWpRQBz/APwhHhT/AKFjQ/8AwAi/+JpP+EI8Kf8AQsaH/wCC+L/4muhooAo6TpGm6PE8WkafZ2MTtudLWBYgx6ZIUDJq9RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVQ1rWdN0KyN3rN/a2NtuC+bcShFLHoBnqT6DmgC/RWDo/jDw/rN4LTTtWtZbwjctuzbJWX1CNgke4GK3qACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4LwvFa38+qeNdd2ySxT3MNmZBuFjawu0Z2Dsz+Wzsw5O4L0UCu9rgLbUF8D3moadr0Mi+G7m4lurPUQhkih81y8kE2M+WA7MVY4UqwXIK8gEfhnxJ4T+M3hq8NjHcSW9tP5eZo/Kmt5cZWWNgSVYZyGByMV0PgDUbvUfDcf9qOJNQtJ57C4lAwJXhlaIyY7btgbHbdiub0zxJ4N0Syk074cW2maleTuXSy0II0ZkPG6WSPKRrwMsxGB0BOAes8G6PJoXh63s7mVJ7xmkuLqVBhZJ5XaSRgPTe7Y9sUAc94y8VarbeN9A8J+HlsYr7UoZrqW7vo3ljiijxwsashdiT/eGMd6q+MPibbfD+ztF8ZW4e5aEPLLp89uEb5ymUhlmWY9mIVX25xubBNdV4k8LaR4kazfVrV3ns3MltcQzyW80LEYOySNldcjqAeawtR+FPg3UAftWkyHdaizk8u9uI/OiDbtsu1x5h3fNufJzznNAGVqHxl0Sz1LXLRdI8Q3MejRmW7u7ezVrdVEXmD5y4ALDgBsEn86pxfGXTX1C2nurXVdK0p7C4vmTUdMMckiRBT5iP5v3TuAA8ttxzyK7IeA/DYtNdthpv7jXFVNQXz5P3wVNgGd2V+Xj5cU+78D+HLyW0ku9MjmNrYvpkQkkdlFswAaMqThsgDkgn3oA4eD4++E5tJ1C+S31NhZfZ2eCIQTSOszbUK+XKy8EgFSQwzjbnir/wATfHuoaV8F9Q8V6Np2oWF7sVYo9Qtljlti0oj3yRsfxA5+8pIxnG6/w38MyaSdLnt9QuNOzEVtrjVbuWOPyyCmxWlIQAgcLjgY6cVueKPD+meKdCutG122+1abc7RLD5jJu2sGHzKQRyoPB7UAeczfGTw/4Zu7fQtfn1SXVIBAl7Lc/ZBJC8vKh1jdQ2ARnyVcKMZNaCfF/SZNVNhBo2tyyHVbjRY5FSAJLdQjLIMyggEEYYgDnkiunvvBWiXmtS6sYby21CVUWaay1C4tTME4XzBE6h8DgbgeOKgg+H3hi3vI7qLTNs8epy6wrfaJTi7kADyY3Y5AHy/dHYUAcve/G7w5aeFLDxE9pqB0+7WQhWltY5kKOUZTG86s5yp/1YfisiX4vW2jeLPEl1rN7LJ4dW10x9Nt0jjVzJcxu+NzbcZAyS7AAA8iurb4QeCDbxQro0kcccEtqPKvriMtDK5d42KyAspZmOGyBnjFXpvhp4SmjnSXSFYTRW0LN9ol3KtuMQlW3ZRlHRlIb1JoAtfD/wAa6V460efUdF80RW9y9pKkpQlZEwSNyMysMMCGViCDwa6aqGi6Tb6NaNb2kl7JGzmQm8vZrp8kAcPK7MBx0zjrxyav0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxWneIvFWrrd3GleH9Eayivbqzje51mWKR/IneEsVW1YLkxk43Hgjmu1rhPCx1Jfh7rx0JYm1YahrRs1l+4Zvt1zsDe27FAGj9u8cf9C94b/wDB9P8A/IdavhPV/wDhIPCujaz5H2f+0bKG88nfv8vzED7d2BnGcZwM+lc18G28bN4Pz8ShENb+0Ps2eWG8nC7d3l/JnO7p2xnnNaHwn/5JZ4N/7Atl/wCiEoA6qivKfitqk1r458KWmtapd6P4NnSdrq8t7p7RXuAB5cck6EMi4yR8wyfpxzHxB+LcnguytbbwrfpqyRWC3if2paszXEXmldwuHnjaT5emyKUkLuJIJIAPfaK8L1D4n+MWn8c3mm2fh8aN4bhEmLgTG4dng3oMBtrDd1OV46c81Wm8f+MLDVdLvNY0zTry9uNBu9Ut7XS7i62uiqjRqyM+wtktk7GIGNp9QD32ivnOP42+Kj4T1LUltfDk08f2IwbJ4ztMzhXSWGK5kdcE8M208cqDxXovxC8V+JfBXwhu9fv4dGl8RWpiEkcAle0+edU4yVc/Iw7jn24oA9Horwy5+KfifT9dubS6j0W4t7LxLa6HMY7WWNpY51JDrmVgrLjodwOe2OcjWPi/f6r4g1Dw5H9jutJvbbVbYyfZPs08DwwOwBX7RIxHGCXjjz1UdQAD6Kor5i0v4p+IfC/hjwpo2ladpUcMWg2dxFNqs8UCXhIUOqSyTxKm0Z6CQ56qBzX01BIZYI5Cu0uobbkHGR0yOD+FAD6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK4rTvDvirSFu7fSvEGiLZS3t1eRpc6NLLInnzvMVLLdKGwZCM7RwBxXa18iftI/GzXIvFV74X8J3sum2dg3lXN1bkpNNLj5gH6qq9OMEkHnGKAPpH7D44/6GHw3/4IZ/8A5MrV8J6R/wAI/wCFdG0bz/tH9nWUNn52zZ5nloE3bcnGcZxk49a+BPBvxj8b+F9Vju4tevr+AMDLaX87TxyjPI+YkqT6rg198eD9ftfFXhfTNcsARb30CzKrdUJ6qfcHI/CgDYorC8ZeLNE8GaONU8S3wsbEyLCJDG8mXOSAFQEnoe3aqmq+NdPsdb0HSre3u9Qu9Zjae3FqE2rCoUtK7OygKAwPGSewNAHUUVzvgXxZbeM9EGr6bZXsGnSOy281yIx9oVWKl1CuxAyp+8FPtXRUAFFZXhvxDpfiWxlvNFuvtNvFPJbO/lsmJEOGXDAHg9+lWtWvotL0q8v7hXaG1hed1QAsVVSxxkjnAoAt0VyMvj/R4PhsvjedLuPR2tVuwhjBm2sQFXaCRuJIHXHPWuk0u6kvtPguZrO4sXlXcbe4KGSP2bYzLn6E0AWqKKKACisHTfFFlqHi7WfDsMVyt7pUUE0zuqiNhKCV2nOSflOcgfjW9QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX59/tG+Er/AML/ABS1qe6hcWWq3Ml9az4O2QSNuYA+qsxBH0PQiv0EriPFXiD4c6rFcaR4p1vwrcrDIUltb69gJikXIIKs2VYHI7EUAfnRa2813cxW1rFJNcSuI4441LM7E4AAHJJPav0f+EXh658KfDXw/ot/j7XbWw84A52uxLsue+CxGfaua8NS/Brwxefa9B1HwVZXeCBOl/AZFB6gMXJA+len2lzBeWkN1ZzRT20yLJFLE4ZJEIyGUjgggggigDzj4ofDq9+IHiXREvr9bXwzYQzPKkBU3Elw42j5XjZNoXPJ5+Y8Dg1yvhz4N6omp+GpfFK+H9Tg0jTbnTWZ1aV5kJP2ckPHj5FOOvHbOa92ooA+dv8AhROrx+D/AAppiXGlNJpy3Q1G0R1jhupJSQswd7eUF1Xau5oiQANpXANdDoHwu1PSvEVrfajZaN4ktEsra1ii1m9aaXTTFwTA/wBnKvnhs7YzkAcda9oooA+ev+FIazB4en0qxbQ7dE1r+0A8RC/b7fLlYJ1aB1XZu+UESpyfl9Zp/gzrP9maNaqNNvbWyt72AafqeoNPDA833Jo2W2VcqSSF8tccYb09/ooA8l8Q/DPUtU/Z+tvA4k01tZgtreJJ5WYwpJG6lmVthYfKGAO3POO5rF8T/BrUb3xpJqenT240sC1+xwQ3KWT6d5IxthP2WbCk84Qx5zht3Ue6UUAeFWvwYvh4hj1G8XRJlbxPearOW3M8tjMoAgOU+Y5yShO3nqaxL74J+L7nwZpegNc+GpY7S2uYlldQZoZHmd49kz27sIwCoKp5ZyOGr6QooA8I1j4QeJtRs9cUa1Zwz39hpdvkSOwne2QrKkpKH5HJ4OGz3XtXe/CLwfc+DNFv7O5Cxi4vHulhjvFuI03AZ2BbeBYxkH5FTA7dcV3VFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfmt8WP+Sp+Mv8AsNXv/o96/Smvz7+JvgHxjefEnxZdWfhPxBPbT6tdyRSxadM6SI0zkMpC4IIIIIoA8vr9KvhP/wAks8G/9gWy/wDRCV8Af8K48cf9Cb4k/wDBXP8A/E1+gnwytp7P4beE7W8hlguYNJtI5YpUKvG6woCrA8ggggg0AZHxe+Ia/D3RbO6i0x9Wv7ucxQWSTeUzhVLu+7a3CgencVgax8WQ/iDwhaaKo+wavYNqlxcHTri8ZYQAQkaxY+b7wLfNtwMjoD13iT4f6H4m8U6frWvwHUPsNvJBDY3KRy2o3nLOUZSS/AGc44HGeayfDPwl0Pw7e6ZcWV7qsn9mwXNtbRTSoyJHO25l4QHAJOOeM85oAx/AHxdtNR8IWet+LLmO1n1F52tbKz0y6aRY4sljxvMyhcEyKoQcjqDjr4PiJ4Zury2tbC/m1Ce4gjuVWwsp7rbG/wBxnMaMIwf9vFc3N8EvC8mh+H9NMl439hpLHa3EyW87skjFmV0liaNuTx8mR25rV0b4aWGhasNR0LVtT0y4khhgu1tY7VIrtYvub4/J2KQCVzGE49+aAM7wj8YNF1rQp9S1SC70orqDafFC1tPK1w+4hBGBEC7naSUUFl74yKua18VfDVv4cF/peoi7u7m3uJLK3jtZpXd4gd2+NV3oqkfMWCgc8iqN38FvDl1p01hNdai9mdROqW8UnkSLazMSX2B4jvVs8rJvHA6c5lb4P6IIrP7Pf6hZz28NxbedZw2lv5sMww6MiQCP/gSqG569KANHQPHtqnwo0rxl4tmhsYJ7WGa5eGKRkRpCFAVRubG5gO9SxfE7wnJfJZ/2jPHcNerpxSawuItlw33Y3LRgIW7bsZwcZxTdS+HGkah8MofA01zfrpMUUMImSRBORG6uuWK7c5UZ+X8qq33wq0O9v7y7lutSEl1rFvrbhZEwJ4QQqj5PuHPI6+4oAs698RNHsXv9PhluYtcS0up7W3vdPuIEuDAhZtjOirIBjPyscjkHvWZonxZ0FPCuiX3ie/itdRu9PgvrpLa2mkithLtAZyoYRKWYAF2H1qpD8DvDcWunVvt2rPdFrtsu0JY/aI2jcNJ5XmOAGO3ezbfzBLj4HeFpHsJI5LlJ7SxisPMlt7S682OMAIzLPBIoYAYygXNAHqYIYAqQQeQR3paZDGsUSRoAFRQoAAHA9hxT6ACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Imprinting. An example of a pedigree demonstrating genomic imprinting is presented. At this locus, the paternal allele is normally repressed and the maternal allele is normally expressed. ~50 percent of offspring of affected women are themselves affected, whereas no offspring of affected men are affected. However, the grandchildren of affected males will be affected if the mutation is passed through a carrier (unaffected) daughter, but not if passed through a carrier son.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29248=[""].join("\n");
var outline_f28_36_29248=null;
var title_f28_36_29249="Patient information: Circumcision in baby boys (The Basics)";
var content_f28_36_29249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15615\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/30/2530\">",
"         Circumcision",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/5/1107\">",
"         Patient information: Circumcision in baby boys (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Circumcision in baby boys (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/circumcision-in-baby-boys-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H214238820\">",
"      <span class=\"h1\">",
"       What is circumcision?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Circumcision is a surgery that removes the skin that covers the tip of the penis, called the &ldquo;foreskin&rdquo; (",
"      <a class=\"graphic graphic_picture graphicRef57074 \" href=\"UTD.htm?2/30/2530\">",
"       picture 1",
"      </a>",
"      ). Circumcision is usually done when a boy is between 1 and 10 days old. In the United States, circumcision is common. In other countries, fewer boys are circumcised. Circumcision is a common tradition in some religions.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214238827\">",
"      <span class=\"h1\">",
"       Should I have my baby boy circumcised?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no easy answer. Circumcision has some benefits. But it also has risks. Your doctor won&rsquo;t tell you what to do. In the end, you will have to decide for yourself what is right for your family.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214238834\">",
"      <span class=\"h1\">",
"       What are the benefits of circumcision?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Circumcised boys seem to have slightly lower rates of:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Urinary tract infections",
"       </li>",
"       <li>",
"        Swelling of the opening at the tip of the penis",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Circumcised men seem to have slightly lower rates of:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Urinary tract infections",
"       </li>",
"       <li>",
"        Swelling of the opening at the tip of the penis",
"       </li>",
"       <li>",
"        Penis cancer",
"       </li>",
"       <li>",
"        HIV and other infections that you catch during sex",
"       </li>",
"       <li>",
"        Cervical cancer in the women they have sex with",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Even so, in the United States, the risks of these problems are small &mdash; even in boys and men who have not been circumcised. Plus, boys and men who are not circumcised can reduce these extra risks by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cleaning their penises well",
"       </li>",
"       <li>",
"        Using condoms during sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214238841\">",
"      <span class=\"h1\">",
"       What are the risks of circumcision?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Risks include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleeding or infection from the surgery",
"       </li>",
"       <li>",
"        Damage to the penis",
"       </li>",
"       <li>",
"        A chance that the doctor will cut off too much or not enough of the foreskin",
"       </li>",
"       <li>",
"        A chance that sex won&rsquo;t feel as good later in life",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Only about 1 out of every 200 circumcisions leads to problems. There is also a chance that your health insurance won&rsquo;t pay for circumcision.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214238848\">",
"      <span class=\"h1\">",
"       How is circumcision done in baby boys?",
"      </span>",
"      &nbsp;&mdash;&nbsp;First, the baby gets medicine so he won&rsquo;t feel pain. This might be a cream on the skin or a shot into the base of the penis. Next, a doctor or nurse cleans the baby&rsquo;s penis well. Then the doctor uses special tools to cut off the foreskin. Finally, the doctor wraps a bandage (called gauze) around the baby&rsquo;s penis.",
"     </p>",
"     <p>",
"      If you have your baby circumcised, his doctor or nurse will give you instructions on how to care for him after the surgery. It is important that you follow those instructions carefully.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H214238855\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/5/1107?source=see_link\">",
"       Patient information: Circumcision in baby boys (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?28/36/29249?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15615 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-07C7D38949-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29249=[""].join("\n");
var outline_f28_36_29249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214238820\">",
"      What is circumcision?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214238827\">",
"      Should I have my baby boy circumcised?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214238834\">",
"      What are the benefits of circumcision?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214238841\">",
"      What are the risks of circumcision?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214238848\">",
"      How is circumcision done in baby boys?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H214238855\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15615\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/30/2530\">",
"      Circumcision",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/5/1107?source=related_link\">",
"      Patient information: Circumcision in baby boys (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_36_29250="Tinea corporis 4";
var content_f28_36_29250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea corporis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 285px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple lesions collide in this patient with tinea corporis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29250=[""].join("\n");
var outline_f28_36_29250=null;
var title_f28_36_29251="Capitate fractures";
var content_f28_36_29251=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Capitate fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29251/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29251/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29251/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29251/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29251/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29251/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/36/29251/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper extremity fractures are among the most common of the extremity injuries with carpal fractures accounting for 18 percent of hand fractures and 6 percent of all fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29251/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Of these, fractures to bones of the distal row are less frequent than fractures of the bones of the proximal row (ie, scaphoid, lunate, triquetrum, and pisiform). Isolated capitate fracture accounts for a very small percentage of carpal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29251/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews fractures of the capitate in adults. An overview of carpal fractures in adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=see_link\">",
"     \"Overview of carpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The capitate is the largest carpal bone. It articulates distally with the bases of the third and fourth metacarpals; radially with the trapezoid; proximally with the scaphoid and lunate; and on its ulnar side with the hamate (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"UTD.htm?37/16/38146\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78359 \" href=\"UTD.htm?26/34/27172\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56302 \" href=\"UTD.htm?41/25/42386\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69097 \" href=\"UTD.htm?1/31/1527\">",
"     figure 3",
"    </a>",
"    ). In many ways, it resembles the scaphoid in that its blood supply at the proximal pole is from vessels coursing distal to proximal. The anatomy of the wrist is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14039?source=see_link\">",
"     \"Anatomy and basic biomechanics of the wrist\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism for capitate injuries varies. Cadaver studies suggest that marked wrist hyperextension can cause the dorsal lip of the distal radius to contact the scaphoid, causing a fracture at its waist, and then the force is transmitted to the capitate, which fractures at its neck [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29251/abstract/4\">",
"     4",
"    </a>",
"    ]. Excessive palmar flexion is another reported cause [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29251/abstract/5\">",
"     5",
"    </a>",
"    ]. Isolated fractures can occur from a dorsal blow or crush injury. Falling onto a clenched fist can create an axial load that fractures the capitate, usually in midbody. Of note, injuries sustained from excessive palmar or dorsiflexion under a load (eg, falling onto an outstretched hand) may involve dislocations or fracture dislocations, and involve other carpal bones (eg, scaphoid). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=see_link\">",
"     \"Scaphoid fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An entity known as scaphocapitate syndrome was first described in 1937 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29251/abstract/6\">",
"     6",
"    </a>",
"    ]. This is a unique injury in that a force causes a scaphoid waist and proximal capitate fracture. This can be part of a continuum of injury that can lead to perilunate dislocation as well. There is usually a partial spontaneous reduction and although the proximal pole of the capitate can be seated appropriately in the fossa of the lunate this segment is actually rotated 90 to 180 degrees.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with a capitate fracture typically presents with pain and swelling on the dorsum of the hand. There is tenderness to palpation dorsally over the area of the capitate (just proximal to the third metacarpal). However, if there is a concomitant soft tissue injury, especially with perilunate dislocations, pain may not localize specifically over the capitate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of capitate injuries is similar to that performed for the scaphoid. Initial radiographs should include anteroposterior (AP), lateral, and oblique views of the wrist. However, initial x-rays may not reveal the fracture, so immobilization with follow-up including repeat imaging studies is indicated when suspicion is high but initial radiographs are unrevealing.",
"   </p>",
"   <p>",
"    If a fracture line is seen and the possibility of a fracture dislocation exists, the lateral view should identify if there is rotation of the capitate. If not clearly visualized on plain radiographs, a CT scan is indicated to delineate the fracture and any displacement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29251/abstract/7\">",
"     7",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) can be used for detecting occult fractures and can also reveal early vascular problems within the proximal capitate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29251/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A high degree of clinical suspicion is necessary in any patient who continues to complain of diffuse wrist pain after a hyperextension injury, and repeat imaging studies should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open fractures and those associated with neurovascular compromise require immediate surgical referral. Patients with comminuted fractures, displaced fractures, and those with concomitant carpal fractures or ligamentous instability should be seen by a hand surgeon for definitive care within three to seven days. Capitate fractures are prone to non-union and avascular necrosis and often require operative fixation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is marked wrist swelling, a sugar-tong splint (",
"    <a class=\"graphic graphic_figure graphicRef50501 \" href=\"UTD.htm?36/26/37281\">",
"     figure 4",
"    </a>",
"    ) is used for initial immobilization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is limited swelling a short arm cast can be used instead. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1400?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of definitive fracture management\", section on 'Casting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Icing and elevation of the wrist above the level of the heart should be stressed. For patients with displaced fractures or associated carpal injuries, referral should be made within three to seven days. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Indications for surgical referral'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with non-displaced fractures, or suspected fractures, should be immobilized in a short arm cast if possible, and repeat evaluation and radiographs obtained in 10 to 14 days [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29251/abstract/9\">",
"     9",
"    </a>",
"    ]. If a capitate fracture is still suspected but not proven, reevaluation including repeat radiographs should be performed every two weeks until symptoms resolve or a diagnosis is confirmed. Alternatively, advanced imaging with CT or MRI can provide a more rapid diagnosis. Casting should be continued for six to eight weeks for all fractures with less than 2 mm displacement; however, immobilization should be continued until fracture union is documented on radiographs. CT or MRI can be used if healing is not well visualized on plain films [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29251/abstract/3,6,9,10\">",
"     3,6,9,10",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"     \"Patient information: Cast and splint care (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the acute pain has resolved, patients with non-displaced fractures can return to full activity, including sports, while casted. After definitive casting for six to eight weeks, the patient can use a semi-rigid brace to support the wrist while full range of motion and strength are returned. Athletes should have protective splinting continued for three months or until the wrist has regained full strength and range of motion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29251/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Isolated capitate fractures can occur but are relatively rare. Other carpal bone fractures and fracture-dislocations commonly occur in association with capitate fractures and these should be carefully ruled out.",
"     </li>",
"     <li>",
"      Capitate fractures are caused by several mechanisms. The patient with a capitate fracture typically presents with pain and swelling on the dorsum of the hand. There is tenderness to palpation dorsally over the area of the capitate (just proximal to the third metacarpal). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptoms and examination findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard AP views may show transverse fractures, but radiographs may initially be negative, as with scaphoid fractures. If the index of suspicion is high, immobilize as for a known capitate fracture and obtain repeat radiographs in 7 to 10 days. If radiographs remain negative but suspicion remains, advanced imaging with computed tomography or magnetic resonance imaging is indicated. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Non-displaced fractures (&lt;2 mm) can be treated with short arm cast immobilization for six to eight weeks, but require close follow-up. Comminuted fractures, displaced fractures (&ge;2 mm), and those with concomitant carpal fractures or ligamentous instability should be seen by a hand surgeon for definitive care within three to seven days. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Follow-up care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications for surgical referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a risk of avascular necrosis of the proximal pole as a delayed sequela of capitate fractures.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dobyns JH, Beckenbaugh RD, Bryan RS, et al. Fractures of the hand and wrist. In: Hand Surgery, 3rd, Flynn JE (Ed), Williams &amp; Wilkins, Philadelphia 1982.",
"    </li>",
"    <li>",
"     Eiff MP, Hatch RL. Chapter 5: Carpal fractures. In: Fracture Management for Primary Care, 3rd, Saunders, Philadelphia 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29251/abstract/3\">",
"      Calandruccio JH, Duncan SF. Isolated nondisplaced capitate waist fracture diagnosed by magnetic resonance imaging. J Hand Surg Am 1999; 24:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29251/abstract/4\">",
"      Stein F, Siegel MW. Naviculocapitate fracture syndrome. A case report: new thoughts on the mechansim of injury. J Bone Joint Surg Am 1969; 51:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29251/abstract/5\">",
"      Volk AG, Schnall SB, Merkle P, Stevanovic M. Unusual capitate fracture: a case report. J Hand Surg Am 1995; 20:581.",
"     </a>",
"    </li>",
"    <li>",
"     Seitz WH Jr, Papandrea RF. Fractures and dislocations of the wrist. In: Rockwood and Green's Fractures in Adults, 5th, Bucholz RW, Heckman JD.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29251/abstract/7\">",
"      Welling RD, Jacobson JA, Jamadar DA, et al. MDCT and radiography of wrist fractures: radiographic sensitivity and fracture patterns. AJR Am J Roentgenol 2008; 190:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29251/abstract/8\">",
"      Obdeijn MC, van der Vlies CH, van Vliet C, van Rijn RR. Capitate and hamate fracture in a child: the value of MRI imaging. Emerg Radiol 2010; 17:157.",
"     </a>",
"    </li>",
"    <li>",
"     McCue FC III, Bruce JF Jr, Koman JD. Chapter 24: Wrist and hand. In: DeLee and Drez's Orthopedic Sports Medicine Principles and Practice, 2nd, Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29251/abstract/10\">",
"      Palumbo DM. An uncommon isolated fracture of the capitate bone. JAAPA 2007; 20:33.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 195 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C264CC6E5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29251=[""].join("\n");
var outline_f28_36_29251=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS FOR SURGICAL REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RECOMMENDATIONS FOR RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/195\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/195|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/16/38146\" title=\"diagnostic image 1\">",
"      Normal adult wrist AP xray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/195|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/34/27172\" title=\"figure 1\">",
"      Anatomy wrist dorsal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42386\" title=\"figure 2\">",
"      Anatomy wrist radial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/31/1527\" title=\"figure 3\">",
"      Anatomy of the volar aspect of the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/26/37281\" title=\"figure 4\">",
"      Distal sugar tong splint",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14039?source=related_link\">",
"      Anatomy and basic biomechanics of the wrist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1400?source=related_link\">",
"      General principles of definitive fracture management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=related_link\">",
"      Overview of carpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1848?source=related_link\">",
"      Scaphoid fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_36_29252="Sweet syndrome plaques on legs";
var content_f28_36_29252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sweet syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwC2wJhHy7VJyyY5xVaQ7SSjxhjxwM8e9XQuAsnyB34I3E1VksoJEK5QuG3YK4H1NeR6ntkL53Fg4bd7cgjvVdXL7x5h3E+nI9K0BZosjY43LkZ6Go5YBG2EiBYjGMinZAVBHklsuCRggtVeVBtOTwfvFv8A61aKrgBQXzk4JGSKjliyxTAyOnYfjQIzXQhdvboSe9VmQAkrwT/ER+lamEB5JBzj2PsahlRAGwME5IBpoGZ2Pm6EE8/jSOvG4sAOpOen1qw0TEryRnuOtQyxq6mN1Ug8OD3HvQSRMD1J/rUZYqwB79MVY2cEA8Co2XKncMelA0Z+sWEWpWM1tIB864DY6Hsa8euoJLS6lt5gRJGxVq9sZSpPJxXDfEHSdyJqUCksvyTY7jsa3ozs+Uwrwuro4gGnKaipQa6zkTJQccitCxuSjDmswEVIjY5BqWrmkZHb6bdBwMZxXSWM5IAzg47157pl1ggE11en3GSCTxjFclSB2QndHWRv3HXHFSjcTleB6GqVnNvwMcVcAK9/esGjUmReBhQSRipCRuC98dKiVjnkjb2FG4FQFO3tmkMcyYYvj5jxj0qZUOcLhgOvNIjK+G/hzjI605mAZgMgYzigBsvyttA688evrULYIUdDnJqSUFhwTz39KiYHaGBJYcDnGaAFhQZ34BY8VKMK+MdFzgUwL8w45A6ZpZd7Bgvf9KAEcK7kKflxgj2qPbwAQBgY+lSIDklRx6+tDKudxwR0IoASFfXqeMelTIAyFS21hk9fzNOSMHZwuBzjv+dK5IjDMoBHUAdqQhXZABuORgAA9Kmt1J3jPJOcgdB7VA23cFYcjkD0q5bgIoI4bkD3pMY/PCEDBPJyOtNjhW4b50PDccdKcHyymQZOD+FWlG3DZwuOfakA+OAqoHDkHKluxpX2uAJApIwQPU0yWVY3YrkgLn61Hb3CvgBQTkZBHSmkDLDl1AcMGK5yO2feq090VIG9F28n6nvUlzMAjAjJIzgHr6VzeoXTD5Yhtc8Nz0raEebcylKxoPejzBlgWzyalS7VuBn0wTxXPM2xN7/KAf4hz+VWLbewX73zn7pGSfwroVJGXtGdAZVZMOVLZ6Y6Cmy3IjZgMAEYAA61nJFICcqFGc47/j/hSmKQoqs5weigY3fWl7JIfOy5HdmQHY4XIxuZeatxsJISDIBkAFx8uD7ViRWyzXHyyzEoeE6AflxWxa2yxlA0i5zwucBv8amUEhptkzLIRtVmIP8AESDUF5ZRSIsuApbgtnofpUh3srSBcOGI+Y8/kO1MzJh43i8zHzcnOKhIGV4fMER3cgnjB+8Px6VK0m5l5O4Hnb3NMdGeIOsgyzZAUY49xS7wWXcNso5Bx2q7CI2mDkr97jlehAriPiVo/wBrsxqdquZYPllHcp6/hXdy28TgkoowQRJ0Oaiu4925iq7scqejVUJODuiJwU1Y+fiSU28YJzUfU/Suh8Z6GdH1HzIebO4JaIjjaepQ/SufzkDiu+L5lc82UXF2YwiiRAqoVYNuGcDt7U5lHl53fNnkenvUTc496YhtB6mlIx16d6RGwwJUcHoaAF2q27ecCqskBHK5x6Vad97s21RuOcDoKaSM+9O4FE8Eg9RRVx4vMBwpJHORRSGfUksKyqI2lMYJwFBK8+1TpHkMRkbTjD9/eprZncGMK7FABvkHX6Uhj8pYyWbvlm5I+leNY9sYxUAMgLIx+91A/wDrVWMJYhVKhV+Y4HFSTKzREOSTn5T9wU5I2WUFcZI5b6UAVUBkJeJVfJPPAz60ksRUbcj25/rVt4flYlguOfk71E7nBBTC9QG6H6UAZU6Ov3m4boveoFIYurhht9e30rXCsQnyxhupAOcVC1uruSCMc5K/1pgzNCbQc8/zFQNG5OG/HitaS3HAZRu7EHBqCeIjBwWAHQ0EmUwKZAxyOvWo0lDjKYbFXiny8Diqb2wEm5ARnrjp9aBoWRFfthj1rOu4EljkhlAdHyrL7GtM/dwRjHeoZY8+xPpSKseIa3p0ml6lNbPkhTlG/vL2NUga9N8c6Ob/AE43EKZuLf5uOrL3H9a8xBNd9KfPG55taDpysOHFPB96i5pwPrWhCLdvIUcHNdNpN0SAM1yKHFaumz7XGaznG6N6cz0jTpht544zW0hBUFcbRyTXIabcAoCST+NdPZsfLwxA3fiK4ZKzO2LuX1HAKsCx5+lRKGeYk/dFSZUYKryB0pyjGBxzUJlkyMqDC/KnrTpW2joCo61EfmBDD5hyADSfMXK4+XGc+9ACyOqqOf8ACoxjcBzjpT5AAMbevU+lLCvXOR796AFbGDj7xOM46UAAYG72PvTvJYbXBwhzjPelLZXBXkD8qAGPgHO7AxyPf1pUVW6cgjrQwyTuwcCkRh8n8PrjvQBLF8pYkhTjr70zeDu5x/jTbhiFyDx3PpSI+4jCkjHX1NFgJFOCpIwWOB71YjkHmbOrDAOe1QQqoYBRnBzknvU8S92xknn+lDEOdJME5zjofbNaUBLRMGAK7cAVnySkbhGoZ8davQlY9m3gsPm5/SlYZBcCV2iiUY7Gn2lotuqgAsCWLMTUqFTM5LOGk6DstSSAKilG+UcHdVIRWvM4KqAPQ98Vzd6giizIzHLYCjqxrqLiHzBhSRvHLAdPpVZ7MbgSOR69vStacrGc1cxYLMyMgdd0in7mePrW9BYERswjCgnG7PLe9TWFskcgIRWUkcDtitFnVEDFWKnO1QRkfWtfamagUlskQgRjLAZG7OP8+9LJbkncGLgdUjFTQTyFnknMZGcBVGAB6VDdXAGUijUhCM/MeKmU2xqKHLCdyDA6Z2jrUbPDEcSsQxbhXXcfpx0qNrtpYm3KodjnGfyqvNcjeOSXPOF4yfapWo9iZ8p5mZCjFvl3jgenSo5mKoy4VS339nY+w9KoS3MruDGkbL935nxnH9aeXlySUAwch3yRj0qrWRN7lqVldFRgMhe+OR61Vltw5OwnHXJzkfjTjAkzbsFFA3Ag45qTHlxkoWcdlJ4P0oALdgoWN8sf1zT3ff8AMCp6ZXHSqs26XKRblYdd2QAO/NJby7WAkDB1OASaYjL8W6INW0ia3jA84fvI/wDeHSvF3gePzd+EaM7GRuG3d+K+hnZTHuZs5PPrXmvxG8P+W76pbL97AmAXjPZ63ozs+VnNiKd/eR5+eOtNx74p5zn1oI9a6zjIivPT2pZnaTZ5n8A2jjtUzsWhWMgYBJzjmoGHIApAMI4oAywGcc96ceMk9qdNE0WwuR867gA2eKAGNvikdBICVOCyHg/j6UUzFFAH1GkkcNuAd5LHjc1WYZEBAjjdwFzuIziqMxWNRmVlGQSwwM+3NKtyFhZlZlLH05NeRys9y5Zmu0iTdMdjHjcwyQPTFNkuFbYVQbgMK7DINUbm8jTf5aOzEdWXrWadROFRYEDjqc5q1TbJcrG2bqMtltgwc5Gcg07cso/eEuenzMOfSubnYSMT5zLJ0AwOa0NLkdVRZRvx1YHBB96p07E89zSitkacSpGynoWINTvG5VgeWOedvB9qIJxuVmV2U9j0FTQtHtIVWUjJwzZrJlIruigIGYHPt+lRNCrZORkHjHUfhVp5NqjfxzyBzmmkoQc8tnk46flUjsYrQ7WwxXg5FQSxkHaFOf0/Ctq4iEjYIKnGCQO/rVOaLYD8xyfagSMl1OB245qORcqP7w7/ANKtzx4zgEr9arqNvupPT0oKTKU8W4HPftXj/i7SjpWruqDEE2ZI8dMHqPwNe1OA2Rn6D0rl/HOinUtKkaNQZoP3iYHPuK1oz5Za7GVenzx03PIu1GaQ9+1A9813HmpkinB61Ygk2tmqq9TUiE8Umi4yOu0a7wBXY6fcZwO1eaaZOUdee9dppdxkA9SPeuSrDU76Uro7KEgjofrUroN3DHAxVHT5d20k/N0zitBgNuSCRwK5joHocS5yAOmKc2AxyOe+KaeBkAZPpTuRnb34pXAYmZG+U4x6ipB8jE+vTPehCQ5CkDnB5pRnaCPX5hRcB5PC4TgHAz2qJyQQeuTjJ60rNk8E4PemOGDHcucDg00hCD7pAGW9KHHqMkcj3pGlw2ABgjrSKSxyvfg89KYDmHmH5idtLlSp2ZVQOM8n3qN22IwzgnIHtTeMEdTjntTsBHHL+8VQCQeM5/nWxAVVcA8kce/tWZCoA6cHjnmrME28htpBHBoaBO5oRoUQH7x7n0qteT+UDg4JOc/jUzOfJ2sfl68HBrLvVZyq57ZqUrjNGynaTOGJJbvWtEofc74IAwxx+tYdki8Zz8hH3e9bMMmYyVBwR36U2hEzqhVWCsQQNtZ9w0jylU+8OeTwKveYzRtvO05z8vpURjDtuSP5WB600xWJYQQucqFPJ46j/Go7mQlvk2424CDipY49oJYZCpwvv71UuZ0gIYBc/qeOlXHVkS0HB/LVQGCMV67clfaqdxcbn3E5I7k4Gff1rJn1RnJUn5skZHX/AOsKryzq9uGbIUcF88fRfX610Rp9zCU7bGqkyqzbCrO4wQOSfx9KWOLztwZxGAACkZx+tZMUu2Hz5NyoP9WFPzN/U1pWXmGFZMqrZwARx+I9qpwtsEZXZpwQRxygPtJ/hI6/nUqyID5aoDIxwCqkAYpIkKFAWkdmyMqANnHXPrUttFgq5kXI4bnr9TXO33NbECxurlljPzZBkzhQfSgxgxY5wcgcc5+tXJEcfMMgHqzN8v4VWchCuJAvPHG4Z9P/AK9JDsUjGY3YkEjqSRzj2qCdSr4LFQO7AnitmUIjiOT5Xc/KpXrVG6CAFd/PJ2k5x+VVFu9iGirDIIwA6/vG4Vj0NRXcRMTpMA8LKVceoNQPMI2IjYbccgnAP0qazBucqJo8qBtRurnPAzWqRm2rHjniHSZNI1GSBgTCRuicdCvb8az/AJPJbcX87IC+mO9et+MNEOqWksLoI7uJiUPo3p9DXkkyPFKySptkQlSp46da7Iu6OCpGz0Ij04/OoyvOMintgjg/jTGOMY6VZBGeM+tJkenfrU8l0720cBCeVGSV+UA5Pqepqv1wDg+lIAbqelFIRg9eaKAPqJrcXCkFFedByT0B+tILaQgDftdRyFHHP1q+ZEjAkKlQBggngfUVEyNJFl13ncCSxxx2xXlXPYMS5tJFYGRg7Z4wQMD8aZJA5UKGj2g84I/niti7dJLnZhSwXPEfH4ms6aya4Yb2Zoz1HQH8K6YyViZJlJrYkBjFCOcBt2f/AK1XrW1f5QUAHXOf8KuWlhgCJNoRemDxWlBYSRO7kYjx2OR+AockCj1K6x5DDnJ9DimzgqQc4C8Crc2xU+UKpc55TgmqkjkqqKFUFegUkVzPVloou8bALIeQeR0z/hQZtnzRqxGcEDqRTr+3WRGKEnHPFYhaWF/3ZYHtnIpWuO5vblkGWJBxwOmac8Q+YiRvoT0qlbP8g3I2WPBJzg1cQFclgdvTI5x9akdijPGwO3I9xis+SI7jsHuPetp0HmAAHA5Bqnd27JuZVPJ55pDRmnGBkdDmmkBwBkHFWZI8qRjgd/Sq6qVYj1HpQ0O5454+0M6Tq7PCuLS4JdD/AHT3WuY6CvdPFGkrrGiT2zKDKo3xMB0YdPz6V4fNG0bskg2uhKsD2IruoT5469DzsRT5JXWzGA09T0qKgNitrGCZegfDDmun0a6yACe9cjG3Q1padcGOReelZVI6HTSmenaZccAE4AreR+Fx3PrXEaXcgouT16muqspg6Ln0xXDKNjui7mmhyMbsFTwP71KzHnnBz0qKNtijrj19DRnB54Pf3FRYslyrKBjGe/8AWo3JzjJ5PFBYjjI/OmO3IA4wOlNICeIrliG6ineZksQCeefaqcQK5K9KnVuGyQFPIx607ARzqWGOB83UUgOzdknvT2YjPGCoyeO1VZ5MkjPB5FVYQk8u3vkn1qSNg24EgjH51mSznzBuPOOoqzAxK5yMjjFaKAro0olTkcYAxgVYC7V+Xg+mKpQuqjLEZ9TVgS9Rn0qXEV+xJvKR4kJfaQSR2qs8iuefeku5SNxH3QO3SqsJLcsMc9TQoXBM1rRwFAU4P6CtKASGEEOd5GPTPFYsDgMuDhehrXiYLtDKcYyT1x6U5QsLmLVsmPmPLdC30qVHJUtLkAHjHp6Cq8b5YlQQgxgZ6+tElxtOxAPMP3QeQO1ZIdyS4uvJi3bsBgSQK5bU52JlYZVQM4PJyelbV65SBSw+fGD3rmr9zu2ADIwTngAmumlFbmNSRlS3DBo9nzO4ACjgAd8mrhmXzI0mAdFO1s8DPcD17fyqK0iELM6qXldxsYjJA+nTNbei28AmeW4V2eDJg2gFS/vnqB39a6EjnLC2+bomDe7NgNkYKcfdHv8AyrV0+yCiNDheT93n/P1q5bWrS2T38gdfMO9Bs2rjPLD2J9KmtgN/7xg2TkDGCPbNRUlY2pxQ5lYxZVRIMDCdOakiiYb2l2SIcHCjOT/WlkeOMDEpCjC9P5f41JFKE2xAydNvmnt/9euOTuzoQ25haSMMsjRKT0IBwPfPFU7qFgv7rcU6bwMD6/8A1q1kbznMYKgkYLYyfbirsFnG3lja24dSRkD39KSlYHG5y8WnzGFITKzmQ54JaVvw9Kil0+4IlWWIqUHDFdpQepJ610txbEZW1kIDffl6tn05/nUMh53gyOijByODjuatS1uJxOJl0ib7Svmz/uCC2+PDN9OccVkzRNZvuScuOp3Ltrsb+68xkUxAKTnkjI9+v9KpT2kUoDs4YYO/aoP5E963UzGVO+pmWlwt2zFiWfGCc98da4X4haIIUXU7YfIeJQPX1ruJLVoXV4dxPc4ww/Cn3Nul/ay2shHlzqVJx3x19quE7OxhUp3R4QTwTxmh49sKyb0+ckbc8jHc0+9tntLqaCUEPC5jYdOQagPXPrx1rrOITv8ASk9RTsAH5gfqaciBmG0FieBgUCIu2eCPYUVZuLVred4psRyR5BGcke1FOzA+pVmIXAUNGem0ZIJ96WXcYsFFBQ/Lnkt71nCSPeinJeM5XqABQLtllZpgpC9NpJwK8hI9otrGXhkLBpNx4I+WhBDHIhYgSBeh5NUZLmS4gLRJ5g6je20U1QwKEzMzt93jIA9quwjXDxMh3eWHHYNgZpWuw0ZzjOcEbsioBCWlX7q+2OT70SwNJ5qFXUHoxbHH4VDAladWkMZYjjhgvA/Gs6UlPl+V2Hf29atRwlCAu91I+9uyPxpYFYSskisw65wMU00gsUbaVmJKgEHpg9ancFyxKNwOQ1XBFHg7UwuchlYANSm3LBNigqT0B6UNiM9JIM7S5Ax0A4qYRk48ojaeOR1plxAQdgYLIemB2pbUyBQMgex559aloq4yRSDtGSO464pzoSm1uRjBXsaluUZF3tgOV/hPWoIJBJjJIOOQaVh3KN1AoJMZIK9RVKVD1AOfeti6UAEhgB6j0rM+Zy4faMY2tnkj3FDTGmVgN2NpB/pXlfxO0X7JqKahCpEVzw4A6OP8RXrLrxnjj071la/piavpNxaSAZdcqf7rDofzqqc+SVzOrDni0eBYpCKmnieGZ4pFKujFWU9iKiPWvRPMBDj6VZifDA1VpyttoaHGVjrNJvPlAz7Guy0u5RkHJwOa8vsp9jDBrr9Iu8ovzc9xXLVgd1Odzv4ZhIAM96e5LHuf0rKsbrIBLDpitFHPGcc/nXK1Y6k7kp24x1PpS459vrSAcAE4BP5UfdIOMjP5U7AOPyg+pBx34pY8dCeB2pvGSR7jpUcpKBm4BPNNIYsjnbsJycVTnUiP5R09Kcsh8zI60XJwpxnrz71rCJEtDMl+Zjzhhx0qWKUkoSCA36VDNn74B5Gf1p9uOeRkMSAD9c10JGEpGorHHJweOlWlCg4H0JrNVwyoQeMYq3Ex2M3crwKHFApBcFWj56g1XgY7wG4XPb0psshYsqjII7060ceZGzDrnOfakoWHzGlGCFAB5xxWhFMAgUDPbcTWep3BSQOmM/SpoGYcMRtySBSqLQSepdW6UASZOACfx7U0yt9oTaP3IXLHrz9aprL86lO3rTfNKD5uOcHsAKwUDRsnvJ96lwfk5XryRWXdRCUBtp2SAcZ5JHTNSGUyRwqg4bczLnoOuc9qY8+w7doLFVyR0HvW8Y2MZMSGJpEdkYbd3OSOe1bFjFsdARuVR8wHRh3xWbZSxyxqVjBwx2tjGAffv3rYtWzKxYKWHI5wAauTstCYrU1/tzz2wi2t5CjCK3OxB0UH86jhlYbigUqMAZ9/WnwhGjLfNtbgZ7H0pFhJZSUyWODzwPeuSTbep0xiorQZdM4JYOqIcfOTz9PpSqcBCTuAyck8/WpXs45lKSJ+6A4BPBI7U8Wn7raoBwMLjvSRRLbTIVBjZU5yDjtW1ZSSeY4G0KxyU7t71i2FpIzx+YuxgfugZz6CunsrfypMvDnAzk9fpUzsNFfUbM3ERYgsAMo46Z+neoRa5gjjuBJJnBOBgE+tdDBZRs05Z380kMxJ+UAdAOw/Cie2dYy8Shwx+UD1pJjZw2p6NH5zSwQrKxbJVGKFR6njmqwQrFIHRkDDAwOOK7O7sWlUsSI8jHBw3vWK+nBtw6ktlXzkGt4tNamTVjn2sVk3GMbGYZz6Gsia1eMEEEEn5WxjNd/9iCuyrhQOo9TXO6xYXEd0HRd8TcMAc4+lZp6hKN0eH/Ei1WLVI708faRiRQP416n8RXIySIzkoh2dQM5xXrnxI0lrrRZ324eL96uO2Ov6V5Ey7kxjp057V6NJ3ieZWjyyIGbc2RkHt6U2NiWwcg9zmpQuVGMZBoZSCAcFj0FapGQw5bO4seO/rRUrkJGTtG/A5oqxH0ozZJw6ejkckVUeBJmVC2xc5WNCfmHv61qm3wNx2qhB3AClsrddyPbxo7McNIe49q8lNHsCWtu3AMe0DAwOSfc1bt4VjQK7lxkglhg/QUwShMhl8uVDtGfShJt28rkBQRz/ADrOTKSJlIj3IyKMfdAbJH51DevveNSSJCcDPPP4VXkSWRFdGUSNwduOakt2eD92xcjB+diOaajfURYg89CFlJY9QQOKnkCYbbGFGQWJbj8KhhkDE4wWx09vamOUMONwweznJ+lKwD3iB3I8jSqwyFwPl96kjJKI4AAHGM45+lVGudqgRnAHHPGKqLclLg+n94ngmqULktmsGUkCTJAG8FhnA+tDRq67gmEA7nkHtWSL8KSNmFznGSM+9TJqBTkMSD+VPkkO6HXALqxBK89SO9QRGNm378HOMe9WPOFwGKjocc9GqF4SJM+WrEjnHb3+tTaw0Jcp8mSSp9Bzis+dAJRLH90jBBH+eatPNgkHr7nmmQyKzOFw2eMehosDdivwzAkZyOeKh2Etg9evsastGYjkhvLbofQ1E/PzY6DpUNFpnjvxP0r7DrYukUCK6BbgdHHX8+tcWRzXuHj/AE3+0/Dc+wZmt8TJxzx1H5V4iw9O/NdtCfNDU8/EQ5Z36DMUlONJW5zio+D/AFrd0i82OAcYNYGKkhlMbZB6VMo3NIT5Wem6XdYKkdD6V0sEm4AjJNec6NeiSMDJ49K7XTrjfEDuOMY5rjnCx6EJ3Whtr0Oc/wCFK55+XAPqahhkGcE9R1qSQfIWB5A7VnY05hwbfuC544x/WmSpuG316nFNRievTPGakZS2VBxzwfanYOYrwBVcg+lTyp8mG47/AP16Yi+WVHX1zUjHcu0/MxHWt4vQiZiTwnBCkk5457dDUgRSsTH7w+bH1GD/ACq1LHhsgDnjNLIoC88DqB7GtUzCREXBhI4POODzjNWC4Cbc8tjvwKzwWAfcBgHsO3SpQTKqqrduvTpVEERnzcNj+ADPqTmrMbDC5JXa7Jj8OKYlovmTs+f3kB4/2sVWRyk8hYblV42X8iKNg3N62O6MM38YJBb2xUtwQQyg4Ukcf4VDAQFiLYxg/qeah1CUq56n6dsVM9S4DIJhLJKxPCgDn0pb+U+SEUDcxCnPTmoLAswLkZ3ru249DgU63BniuJf7mPKB9c5JP4ClGJTkSACJEXrC4BYnq4U9P6U4afc313HaWqiWWaQRhFOAMjOM+nNK5/dZUkrtK5x+Ax+JqTQrqewdGih3tDujKAZEoI+bd7DjNaJGMpNEwtmsp3tZgUeM/Muer9MfQCtG1cbgqkheo/2j60/xDNapFBLGwkkb5VKMAirjhcdcDJOapW8m9hJtwoGEGMfL0B/SpnEunK+p0tuxkjKIcNjnFSyLsAB5JGSvYVWsyWRVA6/e9qsy8qDtJIOD78VxyjqdaZWVi8hDK4wuME9a0rDc4UY2hTkr/Sq9vCWfBAx2PTFa0UKqgZgS2c57g0NqwJWLyr5bhz0wCB2q/aTRkSLIzPuH4isGSdnOB0Jxj1qfTY90xcbgy8g461KhpdlNnQwPI0iozhbeNcszcZArUjeMQI6gEyfcXk/n2qkltDJatIu6Riu/LD+HPIx71tafA8sQcoFx8oeUZA9do7/XpTUdDOUjFuFY3TiXau3kOex9MVQngjjMhmcDIHIGSf8ACt/UIYjK1uo+Y/Nk8ke9YGoKgCjnbkAlhnB/qelNK+gJjAC+QF+UjCN3I/rWbdKizEP8xyOF6iryecZQ7kEj5fmONo9M9jUV9GPKJk+8wPSqVPXUHI4vxfaRP5kYjHllcADnAPUGvm/WLN9O1K4tmJzEcfh2P5V9QahbBrQghjIOOufpz6V4f8VNPa31i1uSoCzRlHI6Fh0/St8PP3nFnLioXipI4QoFyCTg8k0kQRslhgKOO5pzPhuOvbjimq21JAAASOtdux543JcnceBgc96KIeVG77xPNFMD6yEe2JVQH/dPOaiBd7fJQx/N2PQehqkt0wlLRMV3nJzycd8Cp/PAeSMbi2AxBPFeKtT22Q+WssvmhpPkPIzxmmy3EcM+1z+8K8rnP4mppR5sIKNntjOMmoruFTGV/dqcAZbp/jTEVLe6mnyFQNszgqOAKVWEyxiRFcZyfm4H4VYtZLi0hkt7cqsLHLEoAxP16/hTILZUkwm0fxbcHOPWtbq2hnrcaZZGlLKo8vGASCDn2qS3ljWJjOHMiglFXkD0J9RUnlOoBGfLxwMc0qwSbQX5PRkXnPpSjLlHKNx0MNld3EKxTCASqfNE3CowH8J96p6jYm1uRBIVLLjGw5H+FWTbGRwrK42kZ4GKkmt38mOdJQylsOM8g1tGSZk00zKti1rcJNPAL2NOsBcqXGPUdCKuRaXHcsZrGKVrQBQZyxxEx6K/8qhNsfNLRs24df8AGrNtJPFDNbefIbSfHmRocbq2TTWpnJSTuQTxXVnLIk8flvGfmAOQfxFTxXKSckYYLnPbFOvoo5p4JrZZEZIgjAtnJHf8qzrmV48MM4bjA/nWNSKb0NoSZLfIsoJXHPORWcjEMoztkHQirUM5cAS5PYEVFfxJIWA6jrg4NKENLMcpl2F1uUCscEA9D0NVnUl2jxyo5zVXT7gLOBgqCdp3djWrcQhnBTG8Dr61hONmXGVzMcL80bAMrDGPUV4L4k086Zrd5aEECOQ7P908ivoCaHd8wGCteY/FjTwl5a3yjAkUxP8AUcj9KqhK0yMRG8LnnBFN6VM8ZGOOtM2Gu6x5zI6Q9alZCM54qM07AWLK5a2lBBO3uK7rQdQD7dr5U/rXno61e0y+eylDDJTPK/1rOcOY1p1OVnsUEuQrjpnn2q43TGeDzmuX0a/SeIOjEhhkV0EcpaNSMFiK5HHU71InBUEA4wKeSdrHP4VCH5J7YHIp8hBTjGPrRylXHqwK5B59qRv9YoTIz2FV3l2yDsf51OAC3J59fSqSEwnwGXgdf1qpMHaPdwevHrU8671Kg9O9ORN6gAdD0FaIiRmKGE7ZBO7AHoeP/wBVLAzG4AC8bQfw6GrskGyGMdwSRjr7VFEAIXfBJGcfTr/WtUY21LLK/wBlkOPnIJH4daoOg824QAZaBSv4c1rY24K46hh7CqMn+v8AMOMLHyB6qcGmJF23wTGqYJj/AF4zVa/VpFO3JBbn8QKntAY76ReymM8fxA8fyNWZFQq2w5CcdO44/pSZSKNmzBiI0IUI6kE/w4zTlTAaJc7WjJ3/AN4EH/CnSqYlJQ/N97HqfSi4jVIomXOwqGGP4eTx/OhMTC2Zrd1doxLDAC+wck+g+uTWxHJb6RLBJaRJJIQELMx2AuCW3D+Ij+lYE+5zdeRL5UiqW54JCjNaDMF0a2F1J5l+1hvYk8Kz58s8d9tXExk9SnZxzXzJ5aJ5oQuAT1XJG4/7IHNWNFAkkRk2MnmbUDn7oC8GmadJbf21aWynbGNOSOaXuCqksOe5qzZNHbW1rGR8jkME6FUJOAPTrk+1Jo1i7HQpKscShQVBY7dw5wOrVftZfNU/LnHXHSsCXf5kn7wrk7Nx4G7rgDvnpWkkF3b2tvO0eYpAVEgOVLDnt39u1ZTp3NVURtRbWK/OUwQeB1qzO4dmUZ+nTIrKsbhGcpJ/Fz/jitWOIbGzkrnAJ6ZrkceVm8Xcz4Yj52QxPXmul0eIuMl8Afw44rNjtFeYO2V24JHr7VvWbCJMiPOf4ccD3qpT0sgS1ub9niOHduUl+Mbep7Gp2ndiI0beAQAemfwqnbnPysoXHzKD9KimjLFijybW/wBYM459vQe1Z83QfKWrpE8zzJOZFXBz0I/rVGSM7WlKgk/MGcYx9BT4iwPyAMQOx5A/pVl4nlVhMQ5PG0ccfWmnqDRnvbDygSpcr/e7H1NZ2oxb+C4J6nIIBGORmttUZIS7Z+UEfNnGf61l3QDJu2iNzjP8RNa3uZ7HMXJVlATCr02rnn3JryX4m2H2jSJWT52t283d3HODXrWqcMXJZiODu6CuN1y0W4WRJEG2RShGOoNKPuy5hzXNFo+eTzKxJ4x1Hf8ACo3AHC81e1O0bT7ya3kBGxyAO5HaqMoJHy8AHOa9Naq547VtBr5CgZIJ4H40Usx3hQBzxnsKKd7AfUj+SspCsPPIwPU0xmQqB8jnqWz39KhuAVKGFAWPG5hyoHWmyyxQQRqqKAOQB1Oa8ix7Nyzt2bXQMCq52dQPwpLhd5BaLcvUsvVeKz0mErBWDMF5LbuPoauQMS+Q7vI/Ix0Wi1hXHAGRlJU5Ixj19qltxJtIkCbwcgA/oamVWAVlIJQ/Nu6moEffKwZPLQt1/vGlcYrNv2yOcBG+Y89fQVJDMc71+8R0xgqKbHGVjkDkogbIGcjPrUyWzKySQbdh+Y5PX3pq3UWpKh2xkoC7HluaqnecQn5ixwRxzT2gdicSMM53HpzTNrLMXVQxBHK8EEd+apWuLUkl821DRsyYJGMcgHvn1pEKTNtRlR1ySBwKe8zxzNlSZMFiwPy578VXkZ4pFZYs7hyQOp9a3T00MbFiEBIsk/J03Achqq3NijruJDADJKipoHSQNwFbPUjv6VPIPmBwPl4POMVjKTTNUtDLitdkbBEIAHy54BqrOhXcxA/z1FbEygKX3YKjoTmqV6qPECVOSMn/AOtV05XepEkYs0ZjmyVwrDjPUEVrWbLJEC4GQMEdzWY7h98Lv86nI9cVescAEg8gZ/CqrK6uKm+hJIgGeDkDJA7GuP8AiLY/avC90UHzw4nQ/Tr+ldrICwBxkHpjrVDULZbi2licBldSn4EGuWLs7m7V4tHzltygJIJPNI6bVBJBLdf9kVPcxfZ72SEjJjJUqOMEcUzHP7w9Rnj+Rr11qjx3oQzKFYAdPeoJlBOVHSrRHLAj7w6ioXU5bnAFJoEyt3p6009acOhpWGaei6m+nT/Mcwt1Hp716Vpt4ssa7WBVhkc8V5GCeK3vDOsGylFvMx8pj8pP8JrKcOqN6VS2jPUIz85OfzqRjkdOe9ZdvOCMg9RVtHGTuwW/nWFjsTCQnjB+UdKswsFYbs4Y4qA/Mg4ww5HPWlW4KwCTYc5wVI5zVqxVzQWPcSTjB9KspFtkBONv1/Oq9oWE2JFZQefmGK1baPz4nkDxiPA3q3ylc/zqkhSK4s/NCphlTqJAMhWHr+QptzYCFnWLMiGMSZAwQD94H861IjIkKxKwOTvPofWixnNvdKwJZSjIwPQoeoP4d6tIwbMKWFnhkjXO9FIUg8cYH8sGmRQrKN+Nu4lWGPUAH9a1r61W1vJocEojFQPbHH5iqirlZsEcj8yP/rfyoFfQrRo0c6yEEk2wzn+8pwamJZd8W0khjj8TmnOuWjOCSSQR9Rg0BCLkK3VhhT/Sk0VEiuABHLkZ4zjpyOQKpvlbcMOhkIbnoDjn8/51qFB5iJt3IzqdvfBBGKpzRFhMHPzt930Zgcc/hg00KRmyMySuzhZHCsSoPUYAxW/qdqjWPnwXEM6yKF8uPqqoBgY9ulcqFfefNKtgFWOcHnINakUjvBFHEowiFFIODzzzTItcsaZbOiSzXMIljlO2WQjPzgHCr6Yq3o9sl3eQQupktVw1wwOCqnk8/T8qz5biQPGkRZ4zJyrNtGCOmPpnmtPw5Ir3ctjHgR3O5ZizYDMDlQD+X4Ukr6DvoWLyYzatHLMEaLzCxiZsAjooHp/Wtvw68kNveQrcQpZurTTJOu5UUHHA/vn2rCu1ZLxmlXjJXoRlh2J9Oa6Dw/FHdm4R38sLESSuTu3cAHPTpWugraDIbqL7bJ5CmGASMEjJ5UY6Z9a3LeTfCPukDGMc4PauZltpNKjjeWbzLZlLRyqcqefu/wCNW7OdwUQcjgtg9CelcldaG9F3OpSRd8bsrg5wABWjvZM/OvP/AI6P8aw7ZmMSMGyPQevTNX7La58uRju52jP5iuQ6TaiupBFt4d/5/wD16mWX7hKEMfXsPfvWZGrxog8v5d+OODWjZTAs0gYA9DgZxRYdy0p2Nu2KARjB4z+FShllfAGFA6cgVUjba481vkBPOevrU8TosJYH5euOefpTsRckePaNu4Ybpk5/IVl3cIZJA+W5yD90VpqBJiReFAyMck1W1AxMm4hUdh/Edx+laxM2cZqzBchUHrjriuP1GQmTsR7dzXX6580jDkhj2XAA9q5K7gfy8vllycYrTluiXI8z+JmnrJEl5EhLI+1yB/Cf/r150+WLHOD6V7bqtsuoWU9pKV/eKVyOx7H88V4reRlJDGwxKhKt7EGumjK6szhrRtK66keAR8xwR+lFOdAWZmwMAEY6UVuYn0rc3BdyyzIBEfmAGcetUrmZgWZWwewI+6KuyEt+7iiVcgFsYqD7FhQAdpJy3fNeTGyPXauVLdhuDMSgGeCc/nWxZPuRQcIvcjnNU1tIWBUoCByN3Wm24KXMhchYx/AWz+Qpy1BaGyyxvEcE8dI+596SOALIrHcMjp2FQQqVcSFvlP8AePQegHaorq5EWFVvnY5571k3YtK5ohymFGzc3TuD9amjk3P+9OGXjHrWNCbiUZUso6cLmtKCOYREyO42nJwBu/KoU77IvksWUCFJHkLAg42luBULhfN3M7KG+UL3qKNIcyzPJKoHGCucn6VI0BZfNUM0meAONvvWqM2mRPG0eBkO/wB4nPI/DvTI2XyxsY7y3Ht9BVkK3lENMDLkgA8D2qPapALqHftjgVd0l5kWbKrrsJkEjFQeT6Gr0UgYGN0zwDknpSSK7QtCpASQDK9TkU1VELrlcNyCBzgVLaYK6diIkRM6oCRnGcdqgmbESsOSB3H6VdCqECoQxPXd2qhqI8lXAbdGcc56Uouz0G0c9qkDNA11bk+eh3kY6juD+FaOlyCSNZBwpGVFLDIv3EOM9Qec5qC2iMFwUAPlnlRXS3eJha0rmqwZcEZPHSq0pYqeinHAqyrLtyc8cfj71XuTt2nJw36VytHSnc8K8b2otfE96ijAZhIp/wB4ZrClACqAOR+tdx8VLbZrVpNjKyxYP1U1xJ3PCct8u7OB2r06TvBM8qtHlm0EpbcoAAZh1PSoiCqHoecVJKjFVViGK8njpRIFAZgBgjAOa0MyjIKQdBmpJFx+PWou+KgoUDin5yo44ph9O9PJ5CigDqfDGsH5bad/m/5Zk9x6V1sUuQBkZ75ryleGLBirLyD6Guz0PVPtcAVz++QYI/vD1rKcNbnTSq9GddHJllUn5SeSa2dCtY73URDMdm5G2k9Aw6ZrlorgMqnjcBx6VfivWtpIpIyVdXDqfx6VC0On0NqS8vbJJLC5jPmwyE7JV5Uex9PStDRLxZLeSIfK6qOSOq/Ss3W9VOr3zXs/NzLneYz90genpjtT7SMMIZICqsylA5J257H6HpitI7kvRanRXEqxOHUKI8fKp5wCOn5/zqqs4ciQKHXGABx8voahgkmmtx9pGEbBQ9hViGzeF4n3MqHnI/iz0/8A1Vpa5mizO63NlAjB1kgJ3SEg/LngY9qrmK1n3mDzInyOCfl9OvaifAlMTMfITLBWGMtnPJHOKhJdFEk0ewSEgKeAfrRyisQXCNFcvA6t5oG8A8EnrSNExKOuC3I59e1dfHZ2mt6VayQYj1C0URSBuS/pn2I71z95bPDHJHJEYpFJBU9jUtDjLoU22zKrKCpySAOvP+BxUF9B5tuGXCsX83OcHP3T+p/WlhJPLqzLktwOemGH1yKvMqSxBlbcMYKkc7un68UkU9TmdQt2M7yMgQllyM9SRz+FNjjC7XzhgASAew71sX1qZowWJ3AHaemRnp9azWt2371JznOO9Q2CRTlnZZYzGOIdzEZ4K+ufQVqaRc/YHgnIaUbtyvGNyycc4HqKx7mF43YkYwS3/wBb6e1WtCxHKVdNyqSyg9VJHNNSJcbnRPrcLatELi1NxYKMbnJQ5PfcPQ/yq5Z60trK8FnbBIWZmLOxYuOMZPp1/OsN42aRTtOzncBxkHk59antYiExjK8Fcfzpym0OMOjOjmvop9IFjDGUUTecWc7gMjBC+gptuyxZRFAI+bJHUVUiQwxqjjc5XBOefrmmLKrSpu3AoMEsSa5qs3Lc3hFRNqDUDHMi54bg4GPxrUtLlpwVWQrJ646CuVCmSRVWTK8hfaug0pWRx8uePvk8ZrJpWNEdEZjuUBydo69M1oWLGRBuAjyelYtvHuZWPK/oa045mUx72G/tUFF65uCEwYolYHPLZ4+lVTcyGYSu/wAjDbtCg4PsO1VppzlgxRdvQkYz+NR286+dExYB89MCqh5iaOntN0kMSMGDAcEHtUd2cR8lBjk45/HNQWt203Kl0K8EE53H1HpUd5IduGk3gHGFGPzrS6voZtM5vUV80Hcpx1Ga5jVCEQjcenJHArqrxxuYfwg4HPWuT8QFirKjKg3Z5qoSuyZLQ4+6O26yrHaxwccCvNfHunm214yhMJdL5gK9CehH+fWvSLgYmYE8/eJPbFcp41hbU/C0WoJEYxBNlCTndGflJPpyK3i+WaZzTXNBnnZYrnA4Pb3oqQE4XAxjriiunXocZ9KSOox+7J/vFT1NRzSkKpl3geinNSODDEoTCg889frVKdXunwjuueCB3ryEeyOjd5YmLHYjHBwc4FW7W1VI2VAxY/MHJ549qSBU27yQQvBGOOO/1q9a/ODKWZ1bhQO1VcVh0amWzRCUMmAxPQ0hs5CQ6ojMerE/MKunaqMVjMjD07/jUi7Y0ZgoVj97DYxU3LsVLfJLBCRg84JHPpU7M8f7xHxuOGCjOarNdLIzY38dCMgGoTJJG7ZlAUjjA5FFmxlgWqGeN2mnYHjb/CvpVoCRB+9mQLnAXbhh/jTbVrn7J52HcDq5zwfensROoK4ViPmcjr+FUodyHMZHPF5w27JBnhmQ8VYmhRbbc75UHKgryPao7S3DE+WM4PzAf1rXNvut8tgN/CCev0pSVhHNSN5UjOxCHtzn8ae0wKluOnJ9DUmoWTSPuJwcDcAueRWNNKYfkkYHPXNacl1dE3szRkLLGpG0bu5Pem3AEsPl/Lg8YI71BEySxgMu4Dpg8YqO7uBCysOADznsKjl1sMzDC9veEM24D8Mc1eZBI6v3x+dM1IBlSQYI7n606zdzDsZgWUcjPStU9CHuShsICeVznIqtcbWiYLnPTmpGYAhSQ3fPrVZ5QsnJJBPFS431KucH8UIw+l2NxjmOUoPxHf8AKvMlcAshGSTn2Fet/EWISeHJygHySLJ+uK8naMbiepxXVh37ljixKtO4fdyTkMeTTHI2Z/iJyQP5U5myCcgZGfrSDaYACfm5HPX61ucxXkOQTz6VVPWrbACEKTnrVWQANx0pMYuelO+lRingZxnpSGOU4XoOalgle2lR4jhl5B/pUQz5gPShcFjnrTsCdjutJvku7fevDDhh3BrqLmxj/sC0nQMZpAXYnn2wK8p0+9ltblXQ5xwy+orvfD98lxLAHvWhtTls54Bx0x71i48rOmE+ZFjTrz7POHlBaEgo656g8VpaJfS2V+LePbPazfwse3r9RWLqa/Z7hlC/u35yo7061ncSxsijzF+63c0lodF+ZHosl5FewlLRgy4zGT3HcH3BzVjTb5L61+zPujubcklMZ3Yx09+9cxlPsfnW5+VWyE9D3yaZc37Wl5b3VuzR3Ct8xDfd46H/ABrVu2pnFdDo5bqITrcswktzMYJNnU98j8M10mpW9rJ5n2MrKqESxOwxkY/TjtXLaeYkL3J2rZ3vzbeyOD1A7U9tQOnssgkM9sspi8sjB4OTn8KqMu4Sjcu2MksUIuLOYpJu2kdGVgeB+I6Vc8Q3LyTW89yXLNbr5jHvgkbqzCkCwu6ys0c+QSuTh1OVPt8p/StWV0lstOhkuBNdyRvK3O4KpPERPr1P40PYTepj4Mc5Q/cc5yP4SRzj370oT5SejKdpIPB59KaybE2DcTAdjB+GIHIP1Gfyp8ro0ypj/WL8vucdM/p9azKTIgC86Hjkk4HOfWoblEMp2jjrn0HekWZlcbWKZx8+ecev1HeopCxk2uNpZuT2VumR7VNrlNoo6lHgoYssRx0ySDVaIOt3gAtkZODtPNaEjFlDsAxUFuf1H4VCFDFl2g8E5A5xSSEpGxafvolDhWZScBjhgKsRxCPIXtnAz79Kx7GYQ4YjegOB1OPp3rpLZfNxhgw6syjbnNRPVFxKFzGxRt0bKSTxu4x9aZpx/elDgHkjHNak8XnIFIIB9D+tNSJEdWONwHXua5+bQ1FtYVUgkY+bkN2PtXQWce3Z8+8HsOlYyOAS38J+9noKtxXPlsgbgE4BBqHccUblsclmWTOeCB2P0q35rqoWNwxHylj1FZ9vcbHYIqqp7jvT5ZGclgApzjGeo9aksfdkyA5bMa8n2NQ2yMZAxUGQcpjJFSgINoXLYUgHORTEmMYxKxVic/Ke49KpSA3raYqiNLyAMllPQ1BPcrMubdyMn74POfY1W85jGSd2Cud/t6VXWJCiMhxEw6qOpq4ESIrklkYRqMDpzy1ctrDFImd9oxySeT9K6eZWKHYgiVCVXedpb8O9c/qyNgkqCCcKD/PFEXZiaujj5E8ycNjg9cjAxXO6k0Q0i80+HV4Ps7IwEMkRZlPXaGFdtdW7LHJwXD8Ej074rmtKuJ7SwFqdIuWVQV3Ki/PzwT71q59TFxsrHjZO0YJoq/rFu1tqt3EY2QJIx2OMMoJ4zRXcnoec9GfQso2FTuLbR93Oee5qNHZpAkY3SP0GOlVZpWRFcgvgYVRwPxqSCVUy+Mb+d2fu+wrzuSyuerfUueaSHQnC9CcVL9r8hY1RCzH7qqetZsryMY0RnRG4LfzxVq0tFLcqSOxJ+99fWkkh6mlHqATDO0Ucfr7/AMqfHMbpmUSqyHlcIB+ZNUngffjayqo4+Ucfn0q7YbzkL5hCHHzcAH+tNwVgTdyJrOXz18yZmU/dVQT+tXILFwMZy3UgLg/ia11ty6qCGAPdegqTf5XVt56bugrNPoi2ZgtGhZ9jMVf76gnH4inQriF4kjUkkfvMZYD29KttcqoO/JPcA8mkHlTyKysMZ+ZQCR+daRb6mbRNpcLRsed3OSMdavzESIBghgcgH09qlhjjhAW3j5YdSeajubaSECTG984U56is3uWtjNuxksoA3dAa5vWbJ2VXjIHqG/nXTXKGFnIAQ98c4rLumEqOpLONvJ9a1hLoZSVzkbSXy5trggg9RWuUFxbFXPzggdKqXNsVy6nPPp29KmWR0ILN+7KjoORRU7oUew66RWtgHUYB2/8A16rW6mGJjkfKfmGO1XgPOt94IHHVlqCSIIWYN83Xmpi9LDaGXAWVAT8pGCMCs2dsg57Ht/OtCbhVO48jkVnOAzSKuQcHB9xW8VdEN6mJ4vQv4e1BWHAjLDNePHLgEZAYZBr2bW8SaPdBeSYWGD9K8WjDBQo+gINaUdLo58TumOYfuwFGSoxzTZCX2pt4HHvSyhUZcDjI56YNDkhyWxnrxxXQcpHPEVPzABsZODVSQeoq3cAnHzA89jVZgWJ9RSY0Qj3p4boO1MbrTl6ikMeSDuPc0L09MfrQMZJNLngE9T0oEKpwTtFXNPvHsjkfNG5+ZKqLn5gOMilUZKhuFNDVxptbHoFtqK3tqsgcM6DHT7y+h96fG5CqyEKDwMdq4G0uZLWffGenBB6EeldXYXkVxEAineOqA5IrJxsdEKp0ulX5RnibCs/JH97/AOvUd/JFO7SBgpJCkCs6ORkcZUMMfKPU+lMubi3kuzG26NnAZSeAT3ob01Novqb+nXwgMULMWCnqDng1bv5QJXaRtznLABsA54z/AFrm4bt4pY1T5Cv3eM4960JtQW4dmkKh/Zcj6UKWliup0/hK93iWykJG9wylucAelbUEaMPK80biSPMxgc1xOl3AtwGxhxyOetdJZXbSCJw2ONpI6A+9aRd0KUeqOkQwXCiK9lWKUAGK6wSCMYw/8s1QvbN7eR4plU5AZCpyDnkEGnfNtWRs7TyR1471ZlR5V8iICXI3KO4Pt/hRJELQyDGs0KHHz53Lno3GD+PbFRSQll4DYP3efz/GtBU3yGMgCTHKnjJ/x/rT3iUxkk7scj1zWZZzk6OyZCb+QGA4J54P1q/YaFfXAxFCwcMdqlhuLAdh1ziq13E4kxk5JyGTgg9s+n1rUiuiJLC9vFDuVb5lBUmRTgMffFNeZlNtPQowxPE0sUiFJo+GUZByOv0+lbllI32b5VUkEEY4NMukjn0+bULtpftLPl5FAKjI+4QOv1FQ6bLnaVXJPPXPHsazqQujSnO5oXLiMZJJYHHoRmqkdyhIGVducU6/WRUwowpGCc5INc8nnLclvmJB6HgYrnUDfmOktgd2VyRkhgfSrTNhsgcbRhu1R2roqjoM/Nnt+NLMhdRIpx9O1Q9y09C1b34O5gd2RgUktwWdMtkL69z2qksI2fvFC7fmA7E1aUrxlQVIyCecUKN2HMXVl3qUkcDI7HvTiVKImQQg3AnuRVFlLF3Dqp6AjPT0psOPLHBUjpxkD3NXyBzHRW1y1xADGwweqng4q5bfNC2MgA7drHH5Vi2KyNIh6lfvEjr9K1lkAVUyrHqgYYORUNWHuVLtTHIxfJQnCFeSPes68g5DMDs/hUduOpJrVwTJsjHzDqGOOveor6MCPcoyc4bPPNS9AOJ1myF4qlry5gKZ/wBS20tWK+gtlsalqGeMDza6u8QTRsm1ioyM+gqlcxiONQucAAZqk2S4ps8X+IOnGw1pAJZJBcIH8yQ5Ynoc/lRW98RLee706O8lthELdyOHDZUnHIxxzzRXfSfNBHl1vdmz0GNZWIRQNjkbge4FLGis+WIGxvu+pp9oDL5bY2qM7R/WpZSmRkY2jJJ/pXnOb2PWUbCFlM+9uMdx0PsK0LR+FG8AY3YA/Sucu7jY/JC46AetT2tyR8pOD/dHJJ9TTjFsTaR1qGIDcrfj/nrVq0VCy/MCRyMA1k2sU1zBNPEVaONQztvxx9f8KcZMKoDDI6AE1t7FpEKep00MjZYgMvbr1qO6VzGQBgNz8vX61nWVypkIeUluCQeAK2INsrAMwU9Rg1lyuLuU3czvIaQb94JHdlyamt5/JgCKpk3Hl3+X8gK1xABGwchmzn0qpJZksHRsg9cECq57jUbm3pE1tdKiyLGXx1Qksp96fqLCS427I9rcFmz19xVS0je2VjBIxVsAjoK0LlVmgR3Rmb06c0W1JkrHK6htWYi5dgozgr29qwDId0uT8pbC4Haug1Cye5uV3GJYgMsxGSP/AK9cxOEhlY5do1J3Afw+9bSh7uiMlJXK93Kx4HKgH8abbsrDbjoe3appYw8YZSOOi+9VrEFpWKDCA8+/tWHQst7ZAChAORxz0NVVVgGLncMEkjrVx2BOzHPTA7VVmBjgLMQpzzjiiKuD2KMshJVDkY4FVZf3bLvyCM5/pTrvIbLHODyc9quPp8TRqbi9jhVgCCOfpXZCOljmlPU5jUW3Wt3G2NhRyv5GvGZHxGhAOf7voa9y8QWEFtYSypdq7EMvlqvQFOufrXh8fBYlcgAgfX2qqaabuZV3ew2QeYuM5YmlkcMFDcFRjrT9oKqVYcjpjpimL88buQBk49/rWpzkbDDAYy2OwxUMy/N0qzOqkLj73AGDVeXnnBoAruDmkFPkHOOuKZjmkUOU4B96cQAAeppq9DTjjbQIcwwR7ilP3MH8KYfuKCT9akc7goxgDj60AOQbW55yM0+0uJYJlkido3HO4dajJXdxnpQfuY/iz09qAOo0vVFukDN8so++p7+hWr8jHzkbarjqwYZ/GuJhcpNlCVKnIxXR6XqgugIpl2zj06OPWolGxvCoa1ym1gykkOOKdGGZi0gxjAJ6/SoQSVwrcqevtSwXG5HRlCkYxWb3OmDNdHwoDdOgrbtJ/srASkvAWVwR12+v9K5iOXCBSDjr71et7qWSERq/3Sdueo/+saakabnfWt9Hl4lfzIycR56j2q7PtMMaOzJkfK2MYI57VwmmXTyM7b8Sbcn2IrXsrqea9toWlMcmc5c9D/jVxmiZRsdjcSxyJEl9EvmDKmROJFb1J7jvg00aa8o3QXFvMWDZAbaxwOpBrM0jUftV5NbXMKxOnyh8khsnuPXinPeW7owK3Amh+UgqMk9QD9fWr0Zhcq6rbXFtI0V1E6S4+6y9R14/pTNOacqtvHKALj94hx1IGdyk8bh0+lGoamLyBI4omJjG4Dfl+v3ge30ra0e2eyiuIncbZFaaN9mUDjvn+E44IHXNJJXIlLQbqdsl5o+nKkiJOyllfbhXOeVyOrc/SsPTHdJGimU71bBPQ5FalxvmBWXEce/egjOFjJxyB+FWbpo9Ut2nhhAvbYF7jylGHTpux6560TiVTbiTQv5gZcAqRnBOT9KhNlF5pyAAOQfb3p+mgMApyp9T6VrGzEkZCjaCOAfX0rgnozsjsUI7dRsRmBU5PAzkU4RiOQOXABO3Ga04LLCof4geCOgqF4CpKugHJbnn8qzuWZ1yvHA3Z4w3HFZjTPGxChgEGMEYxW26huArBTnJznmsq+ibcFHzYH3jWtN2ZDI4ryQKFfIfqSAMYrQtLoOd3D5GAARisLZIWCbck98dKuRRSRkEBiSckbttaysyVe50VrdIswDHcEY5Y/w1qpciVgqHeUAIJ4znvWLZuAwAf5WGGUY/OtCEqMOm3c42l85Irne+hr0LlwHG7CbXzkAY6etQXEgXcMqxU5PaoLm4PlgISXT5eT1HqapXLqFkjkjG9hnGcfmf6VtGnfcxc7EF1JG6qLdThRnb6t6Z71wi3Uup21nayX7guZLq8ZGCGFV4Cf7IzXYbSiu7H5fvZ9BXOW095dzQlY7OOHUoZXWMRguQvCl27/SiUbbApXM20tW1TQZ4bmRnSYSRo7dWGSFY+vairem3X2i2QvGqSIzROFPyhlODj29KKlTcdCJUlPVm1b8MrDHOdwxjNQ3dwqKScE1En7tEQ7jjo2f51U1X7me+OMe1c1tTrWhAzNcMXUcjPar8NrK9rvRSYh83rz6mqVgd5QDjf6fyqeaBoLspA8iv02+tdUfdImrnR6Xa6iIYXTEkMgJ8zzBtUZ547V2X9kWI0l2iCyTbcsyMSS2eoJrzu2M0Fn9m/fq+Rt2NwVJ5yO3NdFZXlwzeXNcSlkGMKuB+ldEZKxzSUn1COH98UMRyc5EhHatW0LqAjKQMfKc81lM3mtu8oqQerYGKvQyAjaVOOmU5+vNc1TU3gdJZiHcGzlvdqvmJHnjIVMqc7RwDWJZEeYYlJRcZDY6/Wta2k3BIxkP3YY5+vtXOtzRkolEUrIrCOVuo6j6UjNIWwpUBxtOPvL6/WpUjii34+ZXIUkHn6Ci4tEUEwhIwT0HLfTNaxRnIx44dmqRTOBJHkJ8ylQQeMnmuQv0FprH2bYCTIY2BHBGa7TV0ieIGJUV8EMD9761yuoXFwFdo4gZ3GzzWXLBfb0PvXRGokrMydNvUybR/JMse5coxG496SBAFYq5OT29aatuUBDHLHpxxn1qWCMoiYbJ55A6/WuWTuzVKyJyq+axX7p5YnqaL2FDFgHg/wnoakiUAtuPz45Pb6U1ObaYEgnOc+lXDcT2OVuiqOeVJRhnj3q1dP9otGZWG+JznHf04pkKLLfmF1XYXDEnoRnoatajZf2dcTRDGydFcjBGMnP8Ak13QOKb96xzXiN2j0e4Zz+88tj79K8aV/MjIIw4APWvXfGhddM1AgYzEPyryFMKjZ6jofX2px3ZFboNG0HaSMf3h/WmswQkYyPbpmpHAIjUYAPPuaRckkY6kcVRiNkzlWwfcelMbazHsOn1qXrJICW6dqjI4JUfgabQFZxh+lREVPMPm5BGaixz7VI0NGMf55p7A7VJU7T0NNPDCnMflI9aADqnP4VI7F3THtzTMfKenoKfkeZkA4HvQAH5WJGPSiPlsHq3WkJxHnOCT3p+z98oU8sORjpTAbhld1ByR0xSZxhlyGUj86VTls546UDAVhj5qQHX+F5m1a4W0cEyhdzPnA2j1/OrWp2b2U2HH4kYzWD4W1tdAuJpWtzO00Plg79pTnr710F54tt9YsYLaW12XEbEl2bOV7Kp9fr6VnKKN6c3cntrlhbY43k5JYAmp7jy1dJYshZACR6HocVkoMbH5MByAeh+laMlzGbJIEJYg7umAOKhG6k2x0buHZkb5s5IHf2rds5zI0Ms4Ehz1J5Hp+Vc5FnepVsEfzrW5jdVjwwIzt4po0budXZX08Mv203SzSIckuATntnua1tK1dTFdecyh5jsaSaIHJPP1HNcpYbY7ldoB4yu7+IHqPqDWvCXikjCMpGcqMYPr+PrWsWzFpGvdpGZdxtYUcKqDyht3d/zqae6lnSO3B8qPd9zAALY7+9UopGMBkVQxHKhv4j6ZqY+XNZR3CFfLJw0Rb5l/pjNVoLlEkQi4aK3Vk3fKoHIBz29qv6hFDYSQ21pLcLcCIfa2z8sjnqBjqKqo7RKjosbzbe3SH0J9D+lSWUTCYeZuk3nkt1/+vUTloXGOpr6RAQpLgvnjOK0mQhgwOGx1xwarWpXG2T5S3Ax6VcmLIi4HHQnOTXBN3Z1R0IYJ05Awec8dzSttkQs4IbOApHAqsYSrIYc4b+71NPWWUYWckMOR2P41FilqD222U7gVBGSB/OormzjCklRgrw/c1NJeKXLlfu8c8E1Xa4Rg2Rkg5Un1o5WF0UHhTc4jTacjJK4yKZ9lPzYfDgZHHSrszZKFWUZ6rjINDbsjqR13CrV9idCnHGsav5JR5ejc8k+1PMk2fncEYwcdqsWtsxmBmHy53IAKmnjjXIYAITwMd6aVmJmbG0zPtWRwASMEdR61Olu8g2suGzkMefxqWSJo8OEBU/LwORWjbgKQCuRtyC3U1r7SxnylSe1WJNrEsSeSRkN7Ad/pXnd6+lpMsun63dW8cG9UjFsW8kMfmAYjj6HpXrEwAQguqlhlWx933FcEkt7pmnLY3GjXc8ke5RJCAY58kncSfrzmqguYmehzVheWKqILCUssYzyDlsnluevPeikbTruOXToXgCGHzJJJFPC784iHriinKm29DJVLGw8gbZnIHONpqO6Xf8rcZPbnimww5f5WCMGO7PI+mKH/ANaVG7K857YNcR33KhhMXCn/AOtWhGYzJ84cjGfvdDREQxJbafQdCKliCnJwGPoe3vVKTJauWbdRLMu0bQeuW5PtW7YkglEyEXK7FPB+prNsUCgMNmBzk8E+1acE0KE48vJ4JbkitI1NSXE0IYCxDOysF56cCtG1QGUZcHH8IX/CqVu6MpPXuCTjir9sQynAUE8nmpnJsEXomAbMY29sFasxH5xvC/UjnP0rNUFyFLNjHOPl/WrUK7HVRyep29qzRTehdPzSHzSNgxg46+9XysixqiOxAB2nIGM1nw5Y5LFe45zViWUZV2bH8PByAapMllO4txIJA7jLjkjr+NYWqRKoZeoC4Xb3robgrtO3BC9TnvXN386CTYW/eDpjpUyZUTIuo1VRkn6/hVSGQlwufdhVmdi6/PnPQn0AqshzOCSBj26mhBItEbQBj5SMZPamMw8oqAQAcZIxk0gLRn72S3HtUc75JBBwCBz9K0g7MhlDRIBLrwj6bgw6AknBxwaozymS/ma9Z2WNh5rknjjAX9OlPvUMfmOc7iOg4JNR6zcRTwWqQffkImm2no+Mbf6/jXXGehyTi0/U5T4hXm7RLoIx+d1XpjjPFeUpkBx6ngHpXo3xLcRafGhJ+eXHB9BXnqI+5VBzuGefStKburmFb4rESAM6h/vAYx6/jUkZRpfMbqpIK9se1IVIYleT0PHAoB3SMVb5QOSBxmtUZCIxDM5GMcCknA3g7tw7mkO4HaAG388dqVyCX4wQMjPGKQELLgEHpnINRcgsuamDZRh7gmomyfm6E0hkRGOo6UoPApW57UgHHPQ9aQDlBCnP4UDONx5U8UgyFYDgU5cmHGOBzigAORlSM9/pQXwxySTjg5pUIO5uSuMUhAKoMfU0wHbACMHqPypgztboCOPrTjht7HscAUwfO23v/OkA5CMEsO35UhBVQTwT3pDyCpOB/Og/MgYk8UAdVpWuSy2sNnMEaOLPyY5b8avq0bsGHyN0x2riY5WRvMB+YYwfSuks7lW2gnIZeRWU1Y6KTubke6Mcj0q/t3RKwOSecgc5rIW+lMcSHayR8Bcfe+tX7TVodrq6PCVztKfMAfoalM6Lmxp1xug8mZFZM5STPKn0rfttQZbWOMrG5jwS3U8+h9P5VztreWW0OZSPM+8u3G09iPStC2urL7Q/lXKEuhQ71IHPf6ValYW50GlzNEXj+8u4SIrj9RU0wKq2wb0Y5OBkjPfFZaT20S7vtkZf7y4yRVq01IQyTSRJ9o4BikPCg9/l9armRResgyMyS8FWK5B5A9M963bMbh1+UDsa5qCUMTNuOGPOBnBz3FbdlOMDYQVXknsazkrouJvQwhoiwO7J4HTFWYgcKGxxzu9/Sq1tLvX92ep/KrTHbJHGT1HJ7A1yyi7ljVzNGfuh4yQD6mqs0bMmX+Ynqw7VfaaIKCMYP3zUQcbCoI2NyT6UoxYanO3jsrBABImPvAH+VUnndNu9mHGACCK3L+ONcBEUqrYJbr+dY843ksgVhnjB6V0R7E21IotRK4OQ2M8A1qW8okiwCUYjlh2rBdWbAAJwcYHatPRVYMwY5PXnNVKKaDU6KKB9oy24beg44oks3ciQqVIIBwc4HvWjYozQhynQ8AcHFTTRYkU5YrgkjqTXK3ZlGVHAjKBGAUyd2B3qQjYEW4Bj3E4I7+1W9qIcqoCn7wz0qteJG0TJIoKcFT1INK9x2K8ygwuDGTIikoR6joP5V5k1tHdRaTc3eqXbPfGWO5cTlRHKOQMdsYxivSJG2xyHkOuSQK4QrqOsaZ54sdISzu3MgjkViWOcZbH8XFdNLQwqop6IV/sqMIDNskkj3bsmQhiN+T60Vs6XZSR20aTRwrLHkFYFITHYDPT60Vu52MFC+43ykST51TaWzyOpqrcL5eX59hjmpzN85Iwwx8pPT3qvK4mzIjcsRyf88V5bO9srSqBJuydzDoOKktpfn6HjjPqKrtv+1fd+UDrnrVq3iIkGMpxwO9MaL0EqhOFJOcFTTp3OflJ/PBpg3HeQRkHHIxU0EAPJJbnt3pxQrnS6Y0DQoEiCOFxvds81pxFVwRIeuCUHauftHiEW1QFxx9K2raYFF2ybR6AYrSWpC0LyPk/dwO5Izmn27ESOBjH9081TVoiTHufrjJPX6U+OQbAUDbgeh7/Wo5Rm1D8vzMRkDp6fhVaaUy53qox05qobkhh5bDpycE49qRZ/3hTgnP8An6U+UOpauGcwEsTt6AHoBXMahETceYuUAAzg5rflmVmYgkEDbk9jXO605WL/AFmBkDPTNQ0OLsUJFf5mOCcZ96gUsLgHGVK881adsou7Pc5qizqk20E5Jyc96Iq5UizbOGIAwCBzn0pZwAw465PFRAFZDyNnBGetPWQyk7SMHrx29Kp6EIp3aFuuDxg59PaszyBuAAzg5P0rYkQGRyGzg7QPSo7mMBTsGGA/WrjIlq55X8U3VRZRq27LMxFcCrt5iOmQ4PHNdt8Tju1O2GOkbHg+9cSiAAcnBG6u2l8CZ51f42O3NKX3Yz97JPeo1AUBjgNnBBHWlYGKZlONrY561IEJbDfNx25rQyGyqduBwd2OOmKJMBgdgAPHJpvAZ0YtnqAOmO9LgeQ4bOVbjnmgCOXCK/JOTj0xSEKJGHJGOKdPuJViB06VGc7j6igYx+ARjJzxUZyflqbuDg1G/wB6kAnXqe3enoR5eSMt0AphAwAcEetKvIAPTPApgKOIQnqc07scHAQfnSNxEF25YnO70pXAyEU8Hr9aAGcCMcnJNKT8hb+LPbtSbt3yYwRSgBn6HaDhqAEbG05+9nOPajBdgo6AZoADbcZ6/pSsR5jMnQ9KQCZxGB2JrR0t1dhExw/8J9fas1h8gGe+acG2gOjYcdKTV0VGXK7nWxcsASB6E/ypkrtGTnoeah0y4+1xl2TBztYA9/arUibkAPB6VztWOqMr6l6xuykQYgZK7frViFgq4G47c4J/kao2flqrLJ90/wA60IFYYeNt4ByMfqDTSNYsv6fPz5O7ZlsqccA+hFasMzKGwu05+aPGMc9qxUiXzjlcjsfUVrxv5oiIV2IODz8y/wCIprQq5pWkoG4qwKvyQRgfh6GtWxumimAb7hGOOMVgxlkkyF+qkdPete2/e4yvXg07lo6yyuSykqeg696vrdKyuFbOex9awrWIheD+HrVoLg9Cp9fQ1lNq40SSXbxOwbDZ6c0sV0pXIYg9OVqteIGBYkHAz/n1rMEjRs2x/l9h/nFaQ1KbNie4YjAbr1z0NUvMZGGQvBxlRiqryOdoZt3HTPSpIznOD7kEVUkKLRaW28w7zzz0B4+tb2l2BVm+Q7WPNZenMA2FGQeuRxXaWSvsjKsAOMnHSueo2imtSe3RRGwwVwMYz933pxiPlhhknG0uKtFgyMrR5UZxz96kQA8oWVMfdb0rmbHYyZ4BFMSQqqeXJ71TkACgEMVOTkVsSqkiKFO7cT8xPWqV0ghC7MMynhfUVaEzHkidiHQhWCtweh9M15xpcWlSWplutdmivGYm4ijuhGofJztAHT6V6Nrk9/CkJ0/TlvS5O8CUR7B+PWuXl+3uhZfCFpjoW8yP/CtoMwmiTS44E0uP7LcyXFu7MEleQO3XoTRUkEFw8MSvZJYY3b4Y2B2kngjHHPWipnJt7lRgrHPLOPMAONuMDaKMhG/uknAGev1rF0+cSygqwHbGeprWVkYbMZPY0nTGpXJFw8UgUDdnj0+tWHdUKsygN2OKpwRszbVYkqM/WrFzjaCx+Yrn6VnZl3J7aSPd80hJ9D1+lXImJUtHyq9fUVjQjAXzBhuq+9bFtJgAbtpbr9fSrtYhl+3lEZ3hQAw53c1qWs4QbmABPY85rHV0cq3ORxtzircO1cqQDnuzZxV2J9TTuJVZPmeQjpkfLioVvSkYUMAAOpOTWddyH7oy3bAJINUGkHO4InqMZb8q0jAXMb5vssBvyG/u5x+NXLUs53yAKx6bQB+lc5G4MZJSRsdMnH6VsaY2AGYfe696clZCTuzYd1AKn7uPxzWPqNv5kgEgyo5HPQ1pT/MY0Ixn5sDpxVK9lUJ84CgDP41xy8jeJjXBVPkDd8l89PQVnXMi/aQxG4qOOadcTCV3IQhN3y/7RqtaMZnZP7vAU9KFoEi6jmTbJxwMZz2q0wAQBm+fIxiqlqTtEeBuXP4UtyzL5SwAtuYA0XBItooDPtUZ6mqt8QLZyOA1XoEwrEsME5xjpVDVtwtmwMAA4xVR3FLY8U+Icm7W1BPAhBAHfJNcuinZuADKvUd66Dx4W/twICMrGvJrAEhUEcHOc5r0aXwo8qr8bGcPuGOnSmKpLZA5X3p8bfdY8D3pFIV269eAO9WZjdwSUMQcdMfzp8hdcBFwmM89TSurbTuwSeT7UW6NKXbeV2DGTTsAxlI27iB9elMkXEgBGQO6nipZVdUVZCc9OajJO3aVAI4JA5pAMOAM9qjxwRnrUpTaAeSD601gNxxQMiIJOT/CaVjnc3p0pVbaSQO3ekYYQnHLdKQDs/KAT8/YUNwQBnfnk0n91ievGKQ/KSc/SmA5Tlyxxj1A601Dt3tzzTsYO1T25PpSIN0gGcA+/FIByD72SQFHBpsILKeh28mkYckdu/0oQZbuFoAXI8vPqfSkb5Y+PqKQf6v3zQwbaBxnOMUAaWhziC72MTiUY+h7V0qqJVIGDxjB9a4oP9xkO0g9fSuqs7jz4lm4GcZA71nOPU2py6Fgq0ZUEAirdrcPbygqPlI5x2qN8gAEZz69hREFLbekg7H+Ie1Z2Zumb8Tq0e5ASAeR6fSrEX+tUAHjnK9xVCwISPkYPYev/wBaraFCy7iRg8EHoaZtE24WztU9OoJ61etnCnC8CstHCxcg4I49as29xkDZkhuMd6Vh3sdLazAYBY9O5rSMiOpIB+Xgg+tcpaXHzKC3zAnHtWta3gOS/rg57/8A1qycSr3Ll5NsVlYHHoeRWNO+1sq4BHr0rUm+eHDdz+f0rHvLU7iGzjHU1pTaQpCG5kBBZEPupxVm2JZjtGO/JqnbRiMKpLEenFadrDmTIUc+1aSYQWpr6au6RRkLk4zjvXX2u9IUVlYnPysD09KwNJtgVAIDuOQDXS2yDMaAHLHJ74/GuSpI3L8St56kgbTw2D3+lWfL3pKzMGK9ABjHHSqyRq0MgjOBnII4yamU4+XdgsMBh6+9YAZ0sRWSNYuI+uAOlPeJ+UPBALZP8s1oCOQMmcEKOv8AjSCFJDKu3dnkEjvVKQrHGa3qFro4ja/mMXmZVAEZsn8BWavijQ/J3PelWwDt8mTr+VdrdLuAd9qBQWHckAV55HqPifUDpksd9YQrqqyNbx/Z93l7eQhPuB17VpGzRlNu5rWU1vqNoLmy3SW7MQWKkHg9MHmipfDt1Nd6NDPfzLJcCSRJ2wFxIrEFAB2GOveioluXHVHjcFreWM6+bHtS44jPHIq/DOrbsHHy/nVXVtRF3ekDIjt28tOMcd8++c1nySNG4UZ3DsD27V1ysjnp3a1OrsLk+YsSpueTgAf56VbnZ1LROVYL329+4rL0OTM6SKwSZfmRm6E+hrcUF41d/lCud2CM89OankTVzS9hkcSN8wY46YUVZZdkWT1U/SkcRwyYicOZB1yeKSZWJYAo+4cc9qhK4NksM4JVpCqs3tWlBMjIoMysx7E1zMRCzgBFCDsQTWhbXSlmLNgdgEwK3itDJu5tugdgS4wODiqlyo3Nh1A6YC4JqxC7SEZfLEcYqRkYLhlG/wDvZxmk5qJUY8xXsoyQxAyuM8jvWlZyqMKyqwzjHSqcYSQDq+TyEBNW5IY4Hw8rhm+6hIyPwrNy5kXyqLLrujibynLcgewFVLlYhE/JIA5yc4pY2dbYqQWReSR3+tVLtlXcEG8tyR6fWuZ3NUZUp2yup5XAxgetRQQ7JQzEZIIBHcVbChpHKtjP94VWkPlBnOFj/h29c0XExMBlklDDJGMelXrW3Z0Qsx9WGO9QwAlF+XCvyfYetX4FBO0g7TjDUXHYbICrAIH5zn2qjqW54Xye23BrWuApBIyprKvSojYE8DkmkmKR4N47YnxRcjGQAgz+Fc84Yhiv51veNT/xVF+wHRgBn6CsLJVSMcE56kV6lL4UeTV+NjukIJI/CmuAp2pyDzmkO7dtCr7ZpwkU4YhUB7DtVmZIzA+WvBOPmPf/APVUEewxld2CDyM5z+FPcjcxyGAPB9aGQruYhcN2/wAKdwCX50Bz3xluhqMk5J6+opUUBCe5Pf0pXH70Aj5iO/akBHkgnH500hgMnvUhUbfwzQRwDznHegCAjIODx1JpjAMvBxipmA+bHY9ajxkMB1zn6CgYNxHnuDk04DzFRQec0xeQAfXrSjqRntikA4MPNJPHOKZkK5xjrxSyfLEoI60AgofagAzsdiB8vTjtTchUP949KfnI2qOOp96aRvAC+vAoAUrtQc/WmE/KPalVvlYEZPSlYEbQevXjmgBV+aTGODWx4em4khY52tu/4CetY2drMQNue1W9IYpfRfNgOduaUtUVF2Z2CpiIKexyPcGphGDh1OSR0qO2X93h8DHAz2HpVuKPaexNZNnVFD7aTC+WR0qW3lK5WQ9+/eo9p5YdCcD6VOkYk+6OnXI5FI2ReMzFVCOAgPY8jFTK4MiuFO84yM43VmtG+AMDcDxUqFnKLxuJBCk8/gaomR3V1pMa6RFcWSXH22FttxGf4geQyjvjocVQtpXZhwPc96r6VrF9BPBPPcPJJCSY5c/MM8FSO4PSrPmxzyvJGgSMsSqd156ZonboKlfZmzbHCgDk9ufzqe5ttxQIfvH8Kz7PlAuzqecVrW8ghDYxs9+TXMzosUxZYcLjB57VqWlh5PUfMewqxHGNm5twZuuBnn1q/FAwYM3BJwMjNQ5spE9jHtUmPa2ev1rYtziGN1TaB94g81UtEKbmQb9vYcZrQi2FWG7LbcFM9KyZZOF2xsAWKPycdTU0Mqs8f3iHGFJHSqqFt8J4z0GOnSrCAJK218MRllboKQF7eMFpECAEDk449abcxNGFMAUhgcgnrUCN5TbpdxViFC46H61YcZOX2qw5PtQIovCfKBG0PnJz0FcVbaXpuo+H7ibR4NVWG1uXubIxMFkZ+h8jdxtPIwa9EdYSYoXljDThsRlwGfj5gB34rg7SfV9Ds10zTdT8NXNpbkrbTXF35bxpk8Mo+9jPXNaRM5NXJtBtbJ/DdodHjleBmckzj94HJO/f/tZzmir2g2q6foKIL+K6EryPJcxEESSsxLEY4xk9KKl7lrY+cHVt4K5JY7mz3NSfK0rdmBJB9a0Z7J40JDZHb6elUZoDG5cZAOMiuq9znWjNfQpWguUaRd0XKt34NdlDAiRlSp3ZG8HGPY1w+mZRic4PYV1Gnyb0IjwWOPXFUnZFS1ZdnGSMRIw7en51YaBXbagKfiOKEVcIMgY7Y4HqanEX71WUgA9wOlZN2HYo/YX3AoGJXr3qRLdgMgkHrgnOPfFbSI0qja5LjgHbUhtwXP3csMZOMkVSnZEuF9ijZxFW3kkg8ZJxWjaNCVAWPDA4yRk1LHaAMsgJI6YxUjRLC+4OBIeMHpj2rKc7mkI2EWNDK/kkIy9c5ArNdiJzi6jUnhtsYJ/A9qnmmZ5is6K8HoDyaTekpQqscYJ4QCpjJoppMbPDKUCb8qvIVTxn3Pc+1MZVhdWZkOe4HU96dLD5UJ2vvO/JDHJ//XVaRvNTbkFQcECk9QTsQAh5HkGCxO33xmoSgaX2Ynr/ACqa3iSOVwBgsDz60xnEd2I95xjj3pJCbuKiFW24OMlfrVpn8hSOTnHPpS4LYJ4YHqf51nXTkK29iM980tyi+k/mkqASc8H2qjqUYAVxyTxn2qe12lCCAVPJ9qq6o2RtJx6gHpRbUTPA/GbbvEmpHDHMvIz6AVj/ACuGwDx6n9K0vFL/APE/1Je6zHB9RWVuGwD8R/jXqw+FHkVNZsRhtkz1A4OfWlKg4y4xjj2/CiTLALk46njvSnBUKFwCcHNUQNXiVVOCc9OxpzL8pI+XBwPSmyArsyM8cY7UuPlwvJzkj8KAAv5hO7AIAB96QvmYFgc4wM8ilXaR06fexTmZWZtxGMcDFADVXcWGRjrnGKa6gAEE+nNOmkO1eyjggCkJHVcke4oAjK/NheQf1qPpKQcYNTkAock+1Q4+cbieR2FAyLocZ4pxDbN3HFNHytx2p6nKknPvSAcp3uDjgVGvMmOOKFOAXx+FIoGQcjn07UAPGQMjg5xSRn5vpSKSMA4+9SvhW9ielADP4SQODThlMY5DDFJj5dvf1oQ8deR0oAMYQYHJODTlLIUPfOR+FNHLA9jSs3AUgcdxQB3djdfbIEn9eW7D/Oa10jwAP7wzxXK+FJM25QjcA23H1rqrViQEY4IOOawnodtJ3RKsecEAkdORUkQ2sPm471LGo47/AE9amMB4xjB5561nzWNkg8sMMY/H1quoKSBT90dD6e1Xok5GW+U8/jU6W4dge2eQaSnYbjcihUO+RuBA45rSg3rggKVPU5qKKAZz7jpWhAh3bduBnOaHMFGxLaTeWSGxjGQPWtu1cTIGPXHA9fSsSa33n5EJI/CtLSlaEKm4DnPIqZNNFm7EcqdwJLAYUGtSByM78BMdPT3qrErEEqqgEdc96mRcSHzhuVuq+hrBjW5pWpzj5vmXqFH3hU4yz7yQjMcZXv6ZrOt54jlgNsjjgHrV+KQK6I+FbGR3qblsWRzbWzqu/IPr69asWtwLhN2CCE47frVCacIEVgZN7EDA4NXYA6MAEAGCCT29hQBdEqhEUqWJxhuvHrVolgWQYYYGfXFZ6qmUcthgvCgZq6js5VWPHc0wJJordpobgwJJNDu2O2Mx5GDg9gRxXm1mxvbM3Vl4D0aS2d38pzcAGTk5K5XkHHFekkBfMKw5Unpj7+RyMV5lc3Q0S4k0vS/FEAsLcsnz2Dzta5OSvmL8pxk9elaQMp2vqT6VrzSWlnZtpMGnW135htTbybkWRD86MMAq3WirVt4et4rzRfs2pifToVeWJuGMsr53TFhx36UVsqbkroSqcujPNFB8sqQCuByf1qjLCvQnjoPetG2w9uw78GqsmADuxuB4HrWf2h9CBIlR+mGx1Wug04yBRkjt0Fc6sgEwYk5HBrorIowA2srcEMR6elaLYk2oW3hACFHQ+matJHxtJ5HQj+VZ/nExq3AjzwSOauRyIu1/lCY6g96zaZadiyZXWMoNw992KtWqtKiMTjHXIqowjkG0E5PIb2qeCSNpAI2PyDocjH+NFtNRXV7mq04VAARtxy2Ohqncs0gVt+VHcdqUpG+S7ZHTGeM1CW8iLaow2eEJrI0VinJNIZNw3cjoRVm12nkptc8kHtT7yHeoOV9znpVWP5QUBO04y/pV2uiX5EsrBiGG5SrcjHX3qBAPPYyqdnXpip5ApZyS4GAMjv6YqRolMGMjoMew/wAanZCK10uEEse30CjtWQGZrrPIx1JrZuDmRs8eWvLetUIYllmUtnA7jvVJ2QIIZHeeSMrhVUfM3Q1HcxF5ChUBWXkA1cMKxLtweOeDkmoonE0hEJGQcc9qhFiQxBFXPpjHoKoagoLuMZycj2Fa0ygIMn5s/d9c1lagx2ADjGMj1pIUj5/8SDOvX+eQJ2PPessBSH34Xnk4rS8Q5bXL4HjM7fzrMycqSAGHUV6sPhR48/iYbwrbjyvtSyHKjnGCCPelCgxeYCMNxzSIoEZA+bAxyMYPtVEhu3IckdehpI+ArjqDyv8AjTlZTjcPLIGMHv8AjTUO5NwHGcGgAQFgxYgAntTV+eUg/eHOadGpUDJwMc+9DqVdXX+HjPrQBIg+Y7s5Hp0pp/1eDw5NJu2kOGySc59qcclmOAAeaAI143ZHy+nvTGyZCQCRt7U8hiGA5I5zSMDjcBgAc4PWgCBsY759BTd21mA5BFSY6NUbdz36YpDAgCMdyw4pwxgOfuk4xSE5jUEc0hXIK9hzQAgG5yTkD3pZPnUe3elBDMpwBgUiEZJ7Z6UALg4bJ4FM6BT604H5exIOTSAE444JoAG4TOPekI5UjOPSlAG7aScE4pZchlxwKAN7wq37+eM8ZANdpbEFvmIyBgVw/hoj7RKBncQCPzrtLdsDIzmueruddHY0YcZAPQnH0q6pyvzDIB4I7isw7kYN/D7Vo27KYwQDzWDZ1IsDG4eh6e9W4BlcgcjpmoY03d+Ow96sxRur4cYU9qhsaLUSbThV59D2q6sLCRAV6jp61HAiSSZUncMcY61eiiCsrnlgcZ9qm5Q+O3wGcg5J+70q5awnGQpPcE0qbXVmzwPTtVmHaFRxnb/Oi4i9b5AKqRnG4D+dS7my23HXOD1x7VWgIO8hcMOVq1tCrg4xj72ehpMaC3jHmj92ScZUmtWFy0Y3kEYxiqO9AyqDycfMDViBm3t2QLnOKkskLrLDG0g2sDwCe9W4d/lspfcC3r6+lVzGiqAfmPBGKRlUNt3FcjO4cZx2pgWRciGc+ZgRgY5HP4VetruOVD5Tr538QYcAeuKyMQsgSdOFYEMT3qeOVEmwv32JVm6fLTSA2ShYMI3AUn5j3XPcVx2i6tN4Z0OLRrrRNR+2QswJgtvNiussTv3Dj5s85rpV1OztUjlnureHe3lhppAgbHYZ61EPEWlJGY31exyjZAW5UAj86qJnJanM6XYz6Z4eSK9i+zz+ZJN9nQ5EIdiwjH0BxRTfDiNqHh9JN7Ts15ckOG3ZXzWxz6YorrjUsjOyZ5vbKVwuBg9MVTvoSwYsuOc49K0YHDRkjCkHFRXS7ztmBGDnI9a5EyrGB+8WRdoO5T17Gui02dljwzAr6daptbKZQVYgsPXqPSpwxgXAVVGPvDrXRGSZDTTNZZh5QO5drdMjBqWCUzhkEYO3nkdax45iVBLY5+/jNadm8YILN0yParULkymbNo3mAbgw29MdBWhH5X3vMXJ4I71iqxOGibGB/eNaMExABACt1OCTROKCMmWllVYto4AORn1pi3EczqHIJzyDzj8apvIEQlslic7m/wAKhjEolL7VWPoMGudw7GyZuPDE8JAc7WzjHJqCJI1ISNWQcEkt1PvSWksUYKSl2LjOR29qRJ9rbY48RdCW5Y/jU2GiQxqQJWO8r3PAqs16gRk2lVVqs+ai27BYsgckZ61nLbGabzOVQ/eB7UWVtRXJLt3dWAXgjIA7in2cLDAI+UjOTU0Fu0fExJOcliOx6CpmCrIABnHygCob6FpEMsbD+IAjAJ9BVSG32NwOrH8fer07syAKACfvexqCLgBdxOBx9aV7DIJZSZDgDcOCfasnUP8Aj44OQRycVs3HGfmPPGcVkX5JU7QNnt1FNEtnzzruBrF6Nx3LM/X61TYhz8xB3DH096v+I+Na1DCgDzm/Dms4ruI59wRXqx+FHkz+JjSNu0MCFye/FOQM0GCcqD070xj8pBPGfTrT5EIKlQOeuO4pkAoH2chsbl9e9EWRtAOVPSklLbOnsMU0FVIB7dAaAJTnBUZIB5NGdwIBA55HpSq4UgKBs5JHqKYdySggAK/GCc0AOYMUI29KesgYDAy2OQaZuVs5OM+lPVFyewC569KpCAjpg8kc+1RNnkenBGKf8/Hc9h1zRJyCScY5oC5XcDaQOh70kmFAIHHpUjj5FIHQ5pkwzux1AzSGRZGwcYBNDLg7lBxSyHBTPAx0oPV/pSGDHc24DA6UzHynv/SnR9TzSKAVOOhODSAU9OB8w60jHIIxg5pFIDEelK33cnBNAADkHAwM/rTegJIoz+tOY4K7eTQBr+F8C+k7jyyQPxrs4DjAyOB0rg9Em+zX8THoxKkeua7YsBtCsT6YrKpG7Omk7I1oGLoQT9K0YcLwAOB61hW0rZGSD0z7VrxOoxzyOTXNKJ1xdzStyhDP0yOOeKtrInlBW+mfSqca8AIcDrVi2ba2HwQeKyZZp2shjkA7Afn+NaEci7VyMgDK45J+lZ8IJYFeeOUB7+oqwMqVKgD0+tSM1BKUtmKgDdyB1xT7SYMUIIwRlh2qkkvRCQGYcZojlPnKpXAzyapbAdFCpZFOVUhuOe1WCAwUmM5OVx/jVGykR4t5Py1bWQfwnPbNSNK45lTG1gowMH/61XbW4RwFVgCRt49KrxwqZAzPjcCAD6+tJb2qrMJWVldSVBz1osFy8pYyiMpuyvL59Kmc/u1KHazdA3fnmo4HUEAZ8xWIORjFLIxjVXKhgtIa1HRLudztLE8hWHHHarIjL+WzKqcc470qSI+FK7lbOSO31p0eY5JNozgZwTxRcYTafpuoW4W+sre4WM7U8xMhSe4HrVeLw3oRlnVdG09mGBzbiqPiG+vPtmkabp9ytnJqErh7gqHZFVN2EB43GobXWL3w3qUdr4ilS80+4O211HaEYSf885AOB7HvWkLmcmrnSx2lvaWot7OBYLcZ2xRKFCnqTgepork/DOtT6j4fM19KWlE06eYzc4EhAXj0HFFdMYNIzueb2jDGOmTjmnqGSYGTqVwcngj1qCBgGUYx357mpVuFdWMYD4bBHofSuM0LEMaF1BCrx0I606SzXDg8ZPOORTN6sOR6EYPNXcArnBbjPNUmJoy1syjEopBU87elXLbfuB+cMp5FT2jBpmiXk4yxb09KvqEYgZB29QRzW/tGjNxHwwuUjcA9exzj61YCqp3OwyOGFQ28wBKkFVxwD0qrPdt57eU0SAjoyZJNWrzI+EtzPE7sA4bp3ptvP5iAcErkcZrO+0OUK5AY91QZFTQyNGoyCyY+8xxUyhYqMrmispiGcAP/ABepphu3BATlzVR5DKMquQTksD/SmRq4lMufmxjjjAojFFOT6Ggk7vKVQgkH5/Qe1aa7QquqnpjI6D/69ZdtGIpAUQAE5x03V0EcCzxo91zsOVVD1qZtWHG/Ur7ZWJR1K8DAzyPc09IlMIYkqCOuOmO9X+fPeRApYjBz0BqLy3GVHzZJGW7/AErmerNDPuikSBFf5nGR9PWqEblwWLDGf8/jV69hk2Z27SBtHFUraEqHIGze276GnbQLjLnBDley/rWRcZ2gZHIwa2LgEowwDn8sCsi7X5ZCzYHahCZ4F4nXGu6kv/TduM+9ZbMN2DkMOOO9bPi8GPxLqCtnJk3ce44rDZVJVmyD7+tenB+6jyqnxMfGoCMGTgknOe1MXKnjOw8c1JC5VXXaDk9fSmR5LYP61ZAfwY3HIYfSnSsiSEhgB2PXNMVFaRxu68jPekdgvQYI4IPegCR/ncsBxnnHGKdnCBW5IPXoTUUbggkrz2FEgJPQ4B4z1pgSyAbFDKc4qQnauATyOhqJjvUnGcDipAjYGGGFXJye1NCFXIOR1I64pjjcWCgg+mKlUhSQwJIPQ9DQTyxOA/Xj+VUBXcoyKvO49T2qCToQARjrUzp90Dg5zTZACxY96gZC4ARG655+lRtwvynJapHGQuPu0hwAcjGOgFIYiEAlSOT3pD8q54wT070H5Qyn7wNDDgFsc96QAceZkdDSAEkmhsbVx09aMgP04xQAMAQo96VfvnJOR0pG42tSoSJM+vNACoxDKw6oQf1rt45s+SwxtYA5riBy55x64rq9Hk8zT4cjlVIB+lRNGtJ6mzZtuIJGCeuK1oZPlySASeMelZNpgwqR144HpWjHtYA5OSTx/wDWrOS0OqDsasM6jG4549K0bOQEt8u3jPrmueG4PuXBA/zitOxlkDbscg8/SuacTdO50Vuu4hhkAjbirsartjTeeDnPpWbC5bLKfcfWrFtvjfEeWwSTu96yKLh8sM5AyVY5HpTbY4f+JgSTz296cxY4OzBYc4HemwZEqozEgAcY6mmNI17LcUJkbPuP0q+IwztglWUDp0NUYtwjTB2sf4sdfatHlwCVwhGG5qWPYn3YjUKFeVPvDoavw/LvJY8kZB52+9UYiDIRHjgAEkc/WrMcmPu44bLFuhHtQBYZSJA7vjbk4A6/WkVjuUoAwY855470/japOMk7eOgFJGgW3kMJIRDzn60BYGyJDGoIG3KsD+lT2U7M4KjODgr1Joby/tPyBjlcg9qbbgQhDEqeXzu9c+tAzO8Sx6Tc2iReILiCEMxeBzL5ZBHdW6giob/W/DN/pTWd9qenyJIux0M4II9T7+9WvEVhZ6npE1pcCNV++sxA/ckc7gT6Vm2V14dEMME0ulPcooDPtjXe3qB2zWtMzluZelW1vY2Ih0m4WfTg7lJBIHyScnnvg0VavGsoFbC7SGyixqFjGevSiu2K03Iu1ocBbsTsYnI7461YMIUFohtLthh61noxjjUkfMOhHStOzl80diQOea8+xQ4w+ajhk+U9ADyKs2ayBkiLblC8Z6/nSRjcHVlZCBjOOcetPVxDkgkg+n86F2HcvSqInIQAiTjafX2qjcMwyvmfNnBzRJf7wUADt2qGOZZN4HG3rxnmuiEGZyaRfDny8hjxg1FeI7NuRgeM5OBipYmjODIMYX5dveppUVwC+DGc8KOlXrEz0ZkpGAxbHJOWYtwa0o/ursAMZGeKIoIS4UqxK9Mn+dW4o0JYJkA8ZPes5zuaRjYZH8zEKAD+WKuR2uW3cEkYznimRLtRG2gnuRV2HcQWjULkZUNWXMzTlLNjDthwmxnHUkZIrVtIHZWXeWG3liwFZsGGiV2yjAYwBxVtWKpsGOT8x6k+wqGUky9CYTArTDLb8YPT60yVMybkcbD0A7UsLgIVyNjcD5etDxj55iw2d2H9KRNmZk6/vCjFg2Op9KgYBMrn5icg+gq3eYH3s+WVwPUmqcoy4A6rkj3pgUJ13SfIxA7e9Y98qlyu3jt7ituZAUJjwFPVazL6MjZkgkDPXtQB4V8RofK8UzMv3ZUVv0xXNE4lQooJHY813HxXhI1SzmVeDGQQPY5rhDhhnODnGBXpUn7iPNrK02OAJztIB7Uoy5LAsGHB4oCAMFB+cc89qah2u/OM+vetDEZyAxxkZ6+lOKqVVvUnPHSgDAK85PYU7cNmFzzgY9KAGEZUFCARk5pfMzgtgsPWjOfu9U6nFPTa7rvxg8EgUAEYDswbqf1qcAAhdxAHc9qgQkMwI4A496evYMSOh6VSEPikIjOCOvTFLIRv3JwQO/SmyYRzwWHt3pR80h2HgcYJ6VQEWck7gAAKjcFUB/vcfSpypG7uxzUMikLj+LrUtAiCRcLzjK+lNcnKk9f50/HGPXimORnJPTipYxHcsDu5cnBNNk+4AevQUrcrkdzRjc2B3HNIYjHBwOQKDx1xyKAMk8dqQcsuaAFPQDsBzSqcgZ4IHX1pM43Z70gwD17UACN1GOa6DwzIxjkTPCnI/GufB+QjHXoa1/DMwS+MTHAkUqPr2pS2Lg9TsLT/AFZ+mRzzVxOJVbHAHPvVOzbDDnPY1oQKrKRzyOOKxbO2CLltGRFvBwd2PyrSgi2gsehxnFY8ILHAbB75Nbtm4MeHJLdCO2PWsKjN0XbWISREhiMj8qv2+YlCSH61RhACs4HOQCKvwsJMk84xn/arApF8BEKoTkk9R2zUixAyMW4I4V6hikVblGVCA4IBH8jVqN433JjAY8+lK5SLlsW8lVYgEcECp0cYCKTnqKpDJY7cnAwSB+lWLYeXgP8AMw+7kc/TNAGrHsUguQrManVgvAC7B157VVVSyKTjJ5x6UjbXYEKdjDBIpBYvmUBIo0G6P1Hb0pFnjdmSRhg8cHg1Wg4jPlNjaCpUjoaS3iikeMyKC+ckj1oGrGxEzFAVAIHQmmSSKWBjKhVP5HvVdGxGSfu7sj6U6QkOQFYZ6sOlMRzPjTBfTmvLeS50yGVmuYYwW3DHylgOSAeorIvNX8JtaGM29tISP9Utmd2PQDHWt/Xp763uNP0/TZoo5ruRgLiVd/lqq5JA7msK5u9Qs9QTT9YkilM7AW18kflhm/uMOgb09a2pmUtzO8NtKlhFHNuRQXKpKctGmcqv1xiil8PSzXVh59yS0wmkXhQOFcjkUV1cyISfQ5pGRYk6gMCefX3q3YuFK8HG7Bx296oEl1Zd3UDntVvRpj5e1sqe+R1rjtoWdJACPvsC45yO49KhvVQowUY29RSo/kZEhDbuRjjio7lWk3AcYHHuKEtRGVHEVm3DAI54649qu2soDMd3B5Bx0+tRRbQpjzkDkmo9jBi+WUg8OvIP1rsgYzNpVQDG5SGGSAcgmrloNoJHzqpyV9PwrEilleTD+U7AfKcitiyEkgIZdpzyqmqlqTEmAb5+FyDng9qlhVyoJO5TyBjpVr7KXhDgbUUgYx+tWLa2DLtfII5z61xTsdMSrHlAMKSzEVowRBTlODimGMRhvmyw7nt+FSWuASA24nnBrM0L0RUKqy/fbgYqxGu3K7eW7sM5ojTcQACGUAggVJHJs3EASdue5zSYCghFXAxjg8dO1NcIqsCmVAyOeCaepjAzG2CGOVNRsGAbDd6RJVlTcxJ5CnOTxVRULBSG+bnr1q1cqzZCkHODk+tU3fYxXjKgc/0qhMgdMMWHAyWYe9Zl/EDvIJ6ZBNa+0kO/BOBntmsu53M2SoBweD1oEeU/Fa3J0+CcDPly7c/Ud68yaIbQynJbmvYviDB5/h2+xklFD4x3BBrx7cVYdfL+nSu/Dv3bHBiV71yHbuYBTlj3NPVcSJuxyDTdwRyWHUY9xSs2/APJI61ujnBwUlbHQ/pTJCwYYHB7U8oTOBvAwO9NIJmGcsQOaAFEg8w8ABl5PrTlO4MvQEdKVcM5DDPdRmomzkFcDHPNAD+UlB65HQ9qlz5mzdtB6cVGQ24vgnkcnin8GT5unfAqkIc+N4AIbHbFLH+8DZUgdMDuaZtLFk3EBqkVnZOV5x1poBFQnILHcDg8VG3DsCeRxmpZFAVXTIwSDk5BqNz1PQt1oYFa4GMEen51E+CGx+VTvy5Hp0qFhhhwcAc1DGiPJJGMZHenNw4YHBJ5pEH7tiOuaTOUHPOaQx2AN2eGpik7Mdyc0r8MM96TpjngGgBxI259KFOH3dvekYc9Dz6UMRyR06D3oAAOSemTUySeRPE6dVIaovr2FGSdp9aGC01PRbZg0KydNy5rUtVLL907u4rm/Dson05Bn5lypzXTWTKwwRhh0Ga5ZOx6NN3Vy3Em4kogBP6EVftyNyhhhvT1NVo13DkgY5FXIo8yfMQSegNc8nc2L8bsik4Bwc/hV2E4RvLA+YcH3qhDuKbgOeh56+1XLR93GCMnG3P61AzVRSUVnXJA5A9am2lkbyxtZehqpC371kLfKRitCLcAWDgoMgjHWpZRLG3Td8ocEHHYgVYSWNXAzkBR65xVaNuowWKHjNXIhkDywMqM89vamNFtN4RQcN83BHoakiDY2kHIJ47VExG1R2zu+hpu0P64b5gfekMfHIBEfNOGdiu5e3PFWUBRdhK+Yfm+oqNDs5ZV3ZHNTHyS7BZt0wXIU0CHQlFMgctt34HP3fapzGV5wGBzhqg3+TglVZj1YdjipIlOzMfGUJdge/0oB9zO1PS7bULVI74yCSKQyQywsUeJumVPanalp1vqNm1neReZbt1Jznjoc9j71neIrq5hSK3t5/ILI8stzgMYYoxlyB3bkAe5qtcWK2mm2t8h1a1ecqHnkuDI0JfhTIhOCCSMgDjNXF2JaRY03QotItGt7bey7mcNK2WOTnrRWvol3/aenFZI0FyhaKdVJIDoSDj2OMj60VXO+4kkeM2YGwAbchcEVYt45VIO7jPH09DVbTfur/vVsWv/AB8gdt1UzOJeaNXhG6Qqw+UN6HtUhLmIK/Ei9cDvUkQBZsj+D+tOuuv/AAEVNxlMWYdyXDI3Zxx+dTCzaNSqKWU/ePrVqy5C55+XvVyL7g+preMmiJIybdBHIIynurBc8fWtK1jdgrjIIboDUlsAJAAMDPSr1uBiTgferSU9CYxSZfhRyuWzjvg9frVmOKJYicDJHHrTLX/j2/D+tKpPlH8a45djoihko3qNqDc3HPpUllYNHcCTjbjG0VHB91604j85/wBypbNCwiKC43vgjPvVdzscbcK2CmfQ/T1q2oG2PgdDVeUDa/HektxAvAVZAGOzluvNRYbzwXU46cHr71Zj+6v0qun/ACy/z3pmZFONhVUyxwfmPSqpSNj8ykknJPb61ZuP9Wf96oJPvkdttAivcAlgw5XYQ2O5rHuyoMZZjuYHgVt3XCwY4+Y/yrFu/uj6NTA5fW4VuLS4hz/rEZfpxivAnRoncFwWUlT719C3Q6fU/wA68C1cAard4H/LZ/511Ybdo5MT0Kowykk9DxxTAPmyOOcUD/WCnjofrXWcYgBEvJ4HAPrRMSGV04K8U5iS4+lRSfeagCSRSXJbIwD0qNT/AKsevenJ0NJB1H40ASRFlQh8lc8HrT0dBH1O7PT1psv3h9KY33VPfiqQEq42nDfNnj3p6sSx44/kaSMDzm47U+Dq31poQY+VcjC561DODvYggrnIx0FSS/el/Ckm/wCPp/oKbAgx+9OB94Aiq77g5B7d6nk+5H9T/Oo5vuN9azYyLBBx3xmmLkhjUh/1n4Uw/wCsakMDkt69zQMEZ7U4fdamL9xaAFDHvihuEVRjg5NIOjU6T/VLQAjkselKOMEdRxTm+830qNvuigZ0nhSfaZ4jzyHFdvaOpw2K868M/wDISH/XM13+nfcb/eFctX4jroP3TXiZdxGTzV1GG8rgls5FZ0P35frWhD94/wC7XNI6kWo3JbGMgirbvtUMpwM5z3FUl+6n41MeY1zUlIuwSyI5JHPc1sW7+dEoAKr1OOufesi2/wBav0FXySGbBI4FIp6GhBuAPO5weM1JsYXUUodgB1HQc9qaOkf41bbl5c/3aYJk6SnYpUjIPbv9akRv3eXJJj+fI71m2v37v6f0q/BwsIHTbSKZbDK6xlWBB5xjqKcgVJCJvlbOF45I9M0RgYh49aWVQfKyAfnHWkIlSIrGFjOUU4yTyKniPlgqAehzn3p8oAWXAA/dCoIj/rfoKTBamB4htbyeeJra3WURI6GLdt86Jxh1B9ehHuKrtPcz20NtLJrF+sRUrZy2YgyV5Alm6FQQM464rpzyiZ/56VBM7edGu47TL0zTTsDjcr6EPsUCwyZkundpZ5BwGkY5bHtk4+gorRCqdmQDz6UVdxbH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory plaques are present on the extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29252=[""].join("\n");
var outline_f28_36_29252=null;
var title_f28_36_29253="Androgenetic alopecia";
var content_f28_36_29253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63010&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Androgenetic alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 342px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This man developed gradual thinning of hair on the vertex and frontoparietal areas of the scalp. Bitemporal recession is evident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29253=[""].join("\n");
var outline_f28_36_29253=null;
var title_f28_36_29254="Keratoacanthoma centrifugum marginatum";
var content_f28_36_29254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73851&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Keratoacanthoma centrifugum marginatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large plaque with peripheral hyperkeratosis and central atrophy is present on the extremity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29254=[""].join("\n");
var outline_f28_36_29254=null;
var title_f28_36_29255="Pediatric sepsis management guidelines";
var content_f28_36_29255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Recommendations for stepwise management of hemodynamic support in infants and children with sepsis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 801px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Algorithm for time sensitive, goal-directed stepwise management of hemodynamic support in infants and children. Proceed to next step if shock persists. (1) First hour goals&mdash;Restore and maintain heart rate thresholds, capillary refill &le;2 sec, and normal blood pressure in the first hour/emergency department. Support oxygenation and ventilation as appropriate. (2) Subsequent intensive care unit goals&mdash;If shock is not reversed, intervene to restore and maintain normal perfusion pressure (mean arterial pressure [MAP]-central venous pressure [CVP]) for age, central venous O",
"    <sub>",
"     2",
"    </sub>",
"    saturation &gt;70 percent, and CI &gt;3.3, &lt;6.0 L/min/m",
"    <sup>",
"     2",
"    </sup>",
"    in pediatric intensive care unit (PICU).",
"    <div class=\"footnotes\">",
"     Hgb: hemoglobin; PICCO: pulse contour cardiac output; FATD: femoral arterial thermodilution; ECMO: extracorporeal membrane oxygenation; CI: cardiac index; CRRT: continuous renal replacement therapy; IV: intravenous; IO: interosseous; IM: intramuscular.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. Crit Care Med 2009; 37:666. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29255=[""].join("\n");
var outline_f28_36_29255=null;
var title_f28_36_29256="Techniques for preimplantation sex selection";
var content_f28_36_29256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Techniques for preimplantation sex selection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29256/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29256/contributors\">",
"     Kristin Bendikson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29256/contributors\">",
"     Catherine Racowsky, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29256/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29256/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29256/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29256/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/36/29256/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques for preimplantation sex selection are available, but the use of these procedures is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major reasons why couples desire to control the sex of their progeny:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Personal preference for a child (or children) of a specific sex",
"     </li>",
"     <li>",
"      To achieve a \"balanced\" family with children of both sexes",
"     </li>",
"     <li>",
"      To avoid a sex-linked genetic disease",
"     </li>",
"     <li>",
"      To avoid diseases with unequal sex incidence",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Personal preference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Social and economic conditions foster different types of preferences for children of a specific sex. These preferences may be related to a desire for children who will carry on the family name, support elderly parents, keep property within the family, perform specific religious rituals, or contribute more to the family's economic status [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/2\">",
"     2",
"    </a>",
"    ]. Personal preference may involve only the first-born child's sex or the sex of all offspring. In some cultures, this preference is so profound that selective abortion, which is universally condemned by government and medical institutions, has resulted in skewing of national sex ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. The ethics of sex preselection for personal preference are beyond the scope of this discussion, but have been reviewed in a report by the ethics committee of the American Society for Reproductive Medicine (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Ethics'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/8\">",
"     8",
"    </a>",
"    ] and elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Family balance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Couples with one or more children of a particular sex may strongly prefer to have a child of the opposite sex to \"balance\" the family [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/9\">",
"     9",
"    </a>",
"    ]. The couple's effort to balance sexes sometimes leads to a larger family size than they would have otherwise desired. Therefore, the ability to preselect sex could help couples control both the size and sex make-up of their families. However, it has been suggested that sex allocation in mammals may result from an adaptive process involving the suitability of a mother to conceive an offspring of a particular sex; therefore, attempting to create a balanced family may be harmful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the sex ratio (ie, proportion of male to female births) for whites, blacks, and",
"    <span class=\"nowrap\">",
"     Asians/Pacific",
"    </span>",
"    Islanders is 105, 104, and 106 males to 100 females, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/11\">",
"     11",
"    </a>",
"    ]. Thus, the probability of delivering a boy in any pregnancy is about 51 percent; this probability remains constant and is independent of the sex of previous siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] and parental age [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/14\">",
"     14",
"    </a>",
"    ]. Interestingly, the sex ratio appears to be higher (more males per 100 females) early in gestation, but may be lower in pregnancies conceived with ICSI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     X-linked disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are over 350 X-linked diseases, many of which can be severely debilitating or fatal. They occur in approximately 1 in 1000 births. In most cases, these disorders are carried by females and expressed only in males.",
"   </p>",
"   <p>",
"    Identifiable mutations and markers for X-linked diseases are not always known. In families without an identifiable mutation or other marker, determination of affected offspring through prenatal or preimplantation diagnosis is not possible. Therefore, the only way to be certain of having an unaffected child is to continue only those pregnancies with female progeny. Sex preselection can prevent situations in which couples struggle with the decision to terminate a pregnancy with a possibly unaffected male (when there is no test for prenatal diagnosis) or an affected male (when prenatal diagnosis shows the disease is present).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Unequal sex incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some non-Mendelian disorders are distributed with unequal sex incidence. Diseases with a higher male incidence are autism spectrum disorders, pyloric stenosis, Hirschsprung disease and otosclerosis. Diseases with a higher female incidence include breast cancer, systemic lupus erythematosus, and Graves disease. A couple may opt for sex selection in order to avoid having a child with a specific disorder if no genetic marker is available [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/16\">",
"     16",
"    </a>",
"    ]. For example, with autism, if a couple has more than one child with autism, their risk of having an affected child with their next pregnancy is 25 percent, so this couple may opt for sex selection to decrease their odds of having an affected child.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OVERVIEW OF METHODS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sex of a child depends upon whether fertilization of the haploid ovum occurs with a haploid spermatozoon containing an X or a Y chromosome. This process is affected by a variety of factors and attempts to influence it have been practiced as long ago as ancient Greece. Currently, scientific techniques used to select sex have focused on preconception sex selection, which utilizes techniques for sperm separation prior to fertilization, and preimplantation genetic diagnosis (PGD), which selects the desired sex after fertilization and prior to implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATIENT CONTROLLED INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of publications in the lay press have purported to help parents determine the sex of their child. Timed intercourse and diet are the two most common methods, but neither is effective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Preconception Sex Selection Diet is based on the theory that a couple can improve their chances of having a female infant by increasing dietary intake of both calcium and magnesium; to improve chances of having a male offspring, dietary intake of sodium and potassium should be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/17\">",
"     17",
"    </a>",
"    ]. Follow-up studies have not been able to verify these claims.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Timed intercourse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timing intercourse for sex selection is based upon the belief that Y-bearing sperm move faster, but do not live as long, as X-bearing sperm. However, studies which have attempted to correlate the sex of offspring with timing of intercourse have reported conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. There is no strong evidence that timing plays an influential role in sex selection.",
"   </p>",
"   <p>",
"    Time to pregnancy is considered a measure of fertility in couples not using contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/22\">",
"     22",
"    </a>",
"    ]. Interestingly, it has been postulated that the time to pregnancy affects the secondary sex ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/23\">",
"     23",
"    </a>",
"    ]. The proposed mechanism is that environmental factors that affect sperm or oocyte quality may also affect sex. However, analysis of pooled data from large population surveys does not support this hypothesis: no association was found between the sex ratio and time to pregnancy, either within individual datasets or in the pooled analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SPERM SEPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preconception sex selection utilizes the process of sperm separation whereby semen is separated into X-bearing and Y-bearing sperm. Sperm carrying the desired sex is used for fertilization via intrauterine insemination or in vitro fertilization. Separation of sperm can be accomplished through a variety of techniques that rely on well-established principles regarding human spermatozoa [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/24\">",
"     24",
"    </a>",
"    ]. As an example, Y-bearing sperm are known to have smaller heads, enhanced swimming ability, and a lower net negative charge than X-bearing sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The techniques and results discussed below, although promising, have not been found to be as reliable as initially reported. When fluorescence in situ hybridization (FISH) has been used to determine the Y- and X-bearing sperm concentrations of separated fractions, these techniques were not shown to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/29-34\">",
"     29-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Sephadex column",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sperm are fractionated through a column of Sephadex-G 50 and Locke's solution, which seems to improve overall spermatozoa motility in the final fractions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In one study, some samples had only a 6 percent change in the proportion of X and Y spermatozoa while other samples showed increases of as much as 37 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Modified swim up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Swim-up techniques are based on the principle of motility; therefore, the top layer of the supernatant will disproportionately be populated by faster moving Y-bearing sperm, while the slower X-bearing sperm will disproportionately remain at the bottom portion. The upper layer of supernatant is removed and centrifuged, and the resulting pellet used for insemination. In one study, the proportion of males born from singleton pregnancies was approximately 90 percent in the group treated by a modified method of swim-up sperm preparation prior to insemination [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Albumin gradient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spermatozoa are separated by filtering semen through columns of albumin solutions of differing concentrations. It has been hypothesized that the male sperm can be isolated because they reach the bottom more quickly due to their assumed ability to move more quickly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/25,37,39-43\">",
"     25,37,39-43",
"    </a>",
"    ]. Some studies claim isolates containing 43 to 76 percent male sperm can be achieved with this method [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/25,37\">",
"     25,37",
"    </a>",
"    ]. However, confirmatory studies with reliable molecular techniques have not been able to replicate even a small enhancement in concentration of male sperm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Percoll",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sperm are filtered through a gradient of multiple layers of Percoll at different concentrations. X- and Y-bearing sperm are separated with low speed centrifugation based upon their size and weight. Because X-bearing sperm are thought to be larger and denser than Y-bearing sperm, they tend to migrate through the gradient more quickly and can be isolated from the Y-bearing sperm. Y-bearing sperm concentrations of 77 to 85 percent have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When studies used FISH analysis to confirm sex concentrations after Percoll separation were performed, only a slight enhancement of X-bearing sperm was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/46\">",
"     46",
"    </a>",
"    ]. Apparently, Percoll interferes with the stain that was used to identify sex in the sperm, leading to the artificially elevated counts of X-bearing sperm in previous studies. Therefore, although a small increase in X-bearing sperm may be noted, it is not enough to alter sex ratios when used in clinical practice.",
"   </p>",
"   <p>",
"    As discussed above, when FISH was used to determine whether these sperm separation techniques produced isolates enriched by X- or Y-bearing sperm, the proportions were approximately 50-50 and not significantly different from untreated sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/29-34\">",
"     29-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Flow cytometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;In flow cytometry, sperm are sorted by sex based upon the amount of genetic material the spermatozoa carries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/47\">",
"     47",
"    </a>",
"    ]. Human X-bearing sperm are 2.8 percent heavier than Y-bearing sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The process involves coating the sperm with a nontoxic fluorescent dye (Hoechst 33342: bisbenzimide) that binds to the outside of the DNA helix. It preferentially binds to triplet adenine and thymine base pairs in the minor groove and is reversible at 37C. Ultraviolet (UV) beams are passed across the dyed spermatozoa to excite the fluorochrome. The spermatozoa containing more genetic material, the X-bearing sperm, will have increased fluorescent intensity and be recognized by a fluorescence detector and then sorted to separate the X- and Y-bearing sperm.",
"   </p>",
"   <p>",
"    In contrast to the methods described above, flow cytometry has had consistent success in sperm separation as documented by FISH. Microsort holds the patent on flow cytometry for sperm sorting, which is available at limited facilities in the United States and only to those families at risk of transmitting a X-linked disease or to couples desiring family balancing (ie, selecting for the sex that comprises less than 50 percent of the children in a family). Microsort technology purports to increase the percentage of X-bearing sperm to 88 percent in a X-sorted sample and to increase the percentage of Y-bearing sperm to 74 percent in Y-sorted samples. The success rates in terms of pregnancies achieved of desired sex are 93 percent for females and 82 percent for males. The process costs approximately $3400 per sort plus some additional costs.",
"   </p>",
"   <p>",
"    A large amount of sperm is lost in the sorting process due to lack of orientation, undetermined fluorescence, or undesired sex. After undergoing sorting, it is not unusual to end up with a sample containing 100,000 to 300,000 motile sperm from a sample that originally started with over 50 million motile sperm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/49\">",
"     49",
"    </a>",
"    ]. Thus, this process is appropriate only for those couples where the male has a normal sperm count. Either intrauterine insemination or IVF is required because extraction of semen is necessary for the separation process.",
"   </p>",
"   <p>",
"    There have been concerns regarding mutagenicity of both the bisbenzimide dye and the UV light [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Increased embryo loss has been seen in animals after application of flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Additionally, ultraviolet light has been shown to cause some chromosomal abnormalities in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/54\">",
"     54",
"    </a>",
"    ]. There are also reports of mutagenicity in mouse spermatozoa after use of bisbenzimide; however, the level of the dye used was much higher than the levels used with flow cytometry [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/55\">",
"     55",
"    </a>",
"    ]. Other studies have shown no mutagenic affects from the combination of the bisbenzimide dye and UV exposure during the sorting process [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/45,56,57\">",
"     45,56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No abnormalities have been noted in the several hundred animals that have been born after undergoing flow cytometry. The first human baby born from the Microsort process was in 1995; over 1200 children have been born subsequently. In 1998, follow-up of 29 children exposed to this sorting process found them to be normal and healthy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/49\">",
"     49",
"    </a>",
"    ]. Although flow cytometry appears to be safe, more long-term data are needed to confirm efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREIMPLANTATION GENETIC DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preimplantation genetic diagnosis (PGD) refers to a process of cell biopsy and genetic analysis before implantation. Typically, blastomeres are biopsied from cleavage stage embryos when the cells are still totipotent. However, polar bodies can be biopsied from oocytes and trophectoderm from blastocysts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An embryo's karyotype can be identified as male or female using either FISH to examine chromosomal karyotype or polymerase chain reaction (PCR) to identify a specific allele. For the purpose of sex selection, FISH is the predominant technique employed. Regardless of the technique used (FISH or PCR), the analysis is usually performed within 48 hours to allow for transfer of embryos at or before the blastocyst stage.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For FISH, dual fluorescence is used for concurrent detection of both the X and Y chromosome. Correct identification of sex is almost 100 percent. Misdiagnosis can be avoided with the use of dual FISH, which simultaneously detects both X and Y specific sequences [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. In addition to sex identification, FISH can identify aneuploidy involving either sex chromosome. Errors due to contamination are very unlikely; however, nuclei can be lost when spreading a single blastomere, which would preclude obtaining a diagnostic result [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For PCR, several strategies have been developed [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/24\">",
"       24",
"      </a>",
"      ]. In one method, females are identified by amplification of an X-specific allele and males are identified by amplification of both an X and a Y allele. Another approach is coamplification of homologous X and Y-linked genes with the same primers to ensure that the primers worked. There are several potential sources of failure when PCR amplification is used, including total PCR failure and DNA contamination [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. Potential sources of DNA contamination are from the operators themselves, cumulus cells surrounding the embryos, or excess sperm embedded in the zona.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PGD is very expensive, typically ranging from $2500 to $5000, and is only offered in conjunction with IVF. It is also inefficient; approximately only one-half of the embryos successfully diagnosed are acceptable for transfer. Sperm separation techniques can be used in conjunction with PGD to increase the number of male or female embryos available to probe [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Theoretically, the loss of one cell at a totipotent state from a cleavage stage embryo should not have long term effects on implantation, the developing fetus, or the resulting human. Human studies have shown no adverse effects from biopsy to the viability, metabolism, or development of the blastocyst [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/64\">",
"     64",
"    </a>",
"    ]. However, there are studies that have shown unequal distribution of regulatory proteins in early stage cleavage embryos [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/65\">",
"     65",
"    </a>",
"    ]. It is still unclear how PGD may impact embryonic development following removal of a blastomere and what the resulting long-term effects will be. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link&amp;anchor=H15#H15\">",
"     \"Preimplantation genetic diagnosis\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ETHICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both Microsort and PGD have created the potential for parents to choose the sex of their children. But who should have access to these techniques? Should they be available only to assist in avoidance of an X-linked disease or should everyone have the option of controlling the sex of their offspring?",
"   </p>",
"   <p>",
"    Those who oppose the use of sex selection believe it could reinforce sex biases or lead to sex ratio imbalances. This is especially relevant in countries where males are highly prized, and sex ratio imbalances already exist. As an example, in some areas of China, there are 117 males to 100 females and in one rural district of India the ratio is 187 males to 100 females; whereas the worldwide norm is 105 males to 100 females [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. A Gallup Global Study reported only parents in Spain and Iceland had a preference for female offspring [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even in the United States, a survey of clinics using albumin gradients for sex selection reported that over 80 percent of couples seeking sex selection desired a male child [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/25\">",
"     25",
"    </a>",
"    ]. However, one subsequent study observed that if PGD were offered for sex selection of a first born child, nulliparous women did not significantly prefer one sex over the other [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/69\">",
"     69",
"    </a>",
"    ] and another noted that sex choices in the US varied among ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/70\">",
"     70",
"    </a>",
"    ]. A web based questionnaire assessing preferences for sex of children was answered by 1197 individuals with the following preferences: a family with an equal number of boys and girls (50 percent), more boys than girls (7 percent), more girls than boys (6 percent), only boys (5 percent), only girls (4 percent), and no preference (27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another important issue is the potential psychological harm done to children, regardless of whether they are the desired or undesired sex [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/72\">",
"     72",
"    </a>",
"    ]. Parents may be disappointed when the child of a selected sex does not behave in the expected sex-specific ways. There is also concern about the creation and destruction of excess embryos for the sole purpose of selecting an embryo of a particular sex [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proponents of sex selection believe that historically couples have been given many choices in reproductive matters, both legally and ethically. Therefore, individuals should be able to exercise their reproductive choices unless substantial harm to other individuals or to society in general occurs. Furthermore, with selection of sex prior to implantation, postconception selection with pregnancy termination, which is common in many countries, can be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Position of major medical societies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     American Society for Reproductive Medicine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Society for Reproductive Medicine (ASRM) is the governing body for fertility specialists in the United States. In 1994, the Ethics Committee of the ASRM first stated its approval for the use of reproductive technologies to decrease the chance of having a child with a genetic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/75\">",
"     75",
"    </a>",
"    ]. They have subsequently issued reports in support of preconception sex selection and PGD under certain circumstances, both having been reviewed most recently in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/8,76,77\">",
"     8,76,77",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Preconception sex selection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Should be considered experimental and treated accordingly",
"     </li>",
"     <li>",
"      Couples should be counseled about having unrealistic expectations about the preferred sex",
"     </li>",
"     <li>",
"      Couples need to be fully informed of the risks of failure. Couples desiring sex selection for family balancing must be willing to accept children of the opposite sex if selection fails",
"     </li>",
"     <li>",
"      Couples should be offered the opportunity to participate in research to track and assess the safety, efficacy, and demographics of preconception sex selection",
"     </li>",
"     <li>",
"      Acceptable indications include avoiding an X-linked disease and family balancing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preimplantation genetic diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of IVF with PGD is ethically acceptable for sex selection when a medical indication exists. In patients undergoing IVF, PGD for sex selection for non-medical reasons should not be encouraged. However, the initiation of IVF with PGD solely for nonmedical sex selection should be discouraged.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     American College of Obstetricians and Gynecologists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American College of Obstetricians and Gynecologists Committee on Ethics opposed meeting parental requests for sex selection for personal reasons, such as family balancing, due to concerns that \"such requests ultimately support sexist practices\" [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9489449\">",
"    <span class=\"h1\">",
"     POSTIMPLANTATION SEX SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex selection can be achieved after implantation by prenatal sex determination followed by pregnancy termination if the child is not of the desired sex. Traditionally, identification of fetal sex has been determined by karyotype analysis of fetal chromosomes obtained by chorionic villus sampling (first trimester) or amniocentesis (second trimester). Both are invasive and expensive procedures with procedure-related risks. Alternatively, ultrasound examination can be used to visualize the fetal genitalia, usually in the second trimester. Although sexual differentiation takes places between weeks 6 and 9 of gestation, the external genitalia appear similar on ultrasound examination until 11 to 12 weeks of gestation and 100 percent accuracy of sex prediction is not achieved until 13 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/79\">",
"     79",
"    </a>",
"    ]. Sonography is noninvasive, relatively inexpensive, and widely available.",
"   </p>",
"   <p>",
"    Fetal sex can also be determined by polymerase chain reaction (PCR) analysis for Y chromosome sequences in cell free fetal DNA in maternal blood, which can be measured as early as 5 weeks of gestation and rapidly falls after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. Most research studies have reported over 90 percent accuracy using the PCR technique in the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/79,83\">",
"     79,83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1448?source=see_link&amp;anchor=H8#H8\">",
"     \"Prenatal diagnosis using cell-free fetal nucleic acids in maternal blood\", section on 'Fetal sex determination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2005, commercial companies began marketing first trimester sex identification kits directly to the public. Women who purchase these kits use the enclosed equipment to send a few drops of their blood to the laboratory. The techniques used by the company and data regarding accuracy have not been disclosed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/84\">",
"     84",
"    </a>",
"    ], and the company states that test results should not to be used for medical decision making.",
"   </p>",
"   <p>",
"    The procedure used for this diagnosis is crucial for ensuring accuracy. This was illustrated in a National Institute of Child Health and Human Development study that collected 20 mL of peripheral blood from 20 pregnant women between 10 and 20 weeks of gestation and sent aliquots to five laboratories for sex identification [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/85\">",
"     85",
"    </a>",
"    ]. The sensitivity of the assay for detection of male DNA when the fetus was male varied from 31 to 97 percent among centers.",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA), which regulates the manufacturers of genetic tests, and the Center for Disease Control and Prevention (CDC), which promotes health and quality of life, have warned the public some of these tests lack scientific validity, and others provide medical results that are meaningful only in the context of a full medical evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29256/abstract/86\">",
"     86",
"    </a>",
"    ]. They suggest that genetic tests should be performed in a specialized laboratory, and the results should be interpreted by a doctor or trained genetics counselor because of the complexities involved in both the testing and the interpretation of the results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major indications for sex selection are personal preference for a child (or children) of a specific sex, desire to achieve a \"balanced\" family with children of both sexes, and to avoid sex-linked genetic diseases or diseases more prevalent in a particular sex. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preimplantation techniques to select sex utilize techniques for sperm separation prior to fertilization or preimplantation genetic diagnosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Overview of methods'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Sperm separation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Preimplantation genetic diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postimplantation methods to select sex include ultrasound for determination of fetal sex, analysis of free fetal DNA in maternal serum, and fetal chromosome analysis by chorionic villus sampling or amniocentesis, followed by pregnancy termination if the fetus is not of the desired sex. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Overview of methods'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Patient controlled interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/1\">",
"      Puri S, Nachtigall RD. The ethics of sex selection: a comparison of the attitudes and experiences of primary care physicians and physician providers of clinical sex selection services. Fertil Steril 2010; 93:2107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/2\">",
"      Jesudason S, Baruch S. Sex selection: what role for providers. Contraception 2012; 86:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/3\">",
"      Fathalla M. The missing millions. People Planet 1998; 7:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/4\">",
"      Kristof ND. China: ultrasound abuse in sex selection. Womens Health J 1993; :16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/5\">",
"      Westley SB. Evidence mounts for sex-selective abortion in Asia. Asia Pac Pop Policy 1995; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/6\">",
"      Chan CL, Yip PS, Ng EH, et al. Gender selection in China: its meanings and implications. J Assist Reprod Genet 2002; 19:426.",
"     </a>",
"    </li>",
"    <li>",
"     www.unfpa.org.in/publications/16_Map%20brochure_English.pdf (Accessed 3/7/05).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/8\">",
"      Preconception gender selection for nonmedical reasons. Fertil Steril 2004; 82:232S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/9\">",
"      Pennings G. Family balancing as a morally acceptable application of sex selection. Hum Reprod 1996; 11:2339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/10\">",
"      Grant VJ. Sex predetermination and the ethics of sex selection. Hum Reprod 2006; 21:1659.",
"     </a>",
"    </li>",
"    <li>",
"     Martin, JA, Hamilton, BE, Ventura SJ, et al. Births: Final data for 2009. Natl Vital Stat Rep 2009. file://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_01.pdf (Accessed on November 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/12\">",
"      Lippert T, Skjaerven R, Salvesen KA. [Why do some women only give birth to boys or to girls?]. Tidsskr Nor Laegeforen 2005; 125:3414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/13\">",
"      Biggar RJ, Wohlfahrt J, Westergaard T, Melbye M. Sex ratios, family size, and birth order. Am J Epidemiol 1999; 150:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/14\">",
"      Ein-Mor E, Mankuta D, Hochner-Celnikier D, et al. Sex ratio is remarkably constant. Fertil Steril 2010; 93:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/15\">",
"      Luke B, Brown MB, Grainger DA, et al. The sex ratio of singleton offspring in assisted-conception pregnancies. Fertil Steril 2009; 92:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/16\">",
"      Folstein SE, Rosen-Sheidley B. Genetics of autism: complex aetiology for a heterogeneous disorder. Nat Rev Genet 2001; 2:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/17\">",
"      Stolkowski J, Lorrain J. Preconceptional selection of fetal sex. Int J Gynaecol Obstet 1980; 18:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/18\">",
"      Shettles, LB. Factors influencing sex ratios. Int J Gynecol Obstet 1970; 8:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/19\">",
"      A prospective multicentre study of the ovulation method of natural family planning. IV. The outcome of pregnancy. World Health Organization. Fertil Steril 1984; 41:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/20\">",
"      Gray RH. Natural family planning and sex selection: fact or fiction? Am J Obstet Gynecol 1991; 165:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/21\">",
"      Joffe M, Bennett J, Best N, Jensen TK. Sex ratio and time to pregnancy: analysis of four large European population surveys. BMJ 2007; 334:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/22\">",
"      Joffe M, Key J, Best N, et al. Studying time to pregnancy by use of a retrospective design. Am J Epidemiol 2005; 162:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/23\">",
"      Smits LJ, de Bie RA, Essed GG, van den Brandt PA. Time to pregnancy and sex of offspring: cohort study. BMJ 2005; 331:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/24\">",
"      Reubinoff BE, Schenker JG. New advances in sex preselection. Fertil Steril 1996; 66:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/25\">",
"      Beernink FJ, Dmowski WP, Ericsson RJ. Sex preselection through albumin separation of sperm. Fertil Steril 1993; 59:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/26\">",
"      Cui KH, Matthews CD. X larger than Y. Nature 1993; 366:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/27\">",
"      Kaneko S, Oshio S, Kobayashi T, et al. Human X- and Y-bearing sperm differ in cell surface sialic acid content. Biochem Biophys Res Commun 1984; 124:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/28\">",
"      Sumner AT, Robinson JA. A difference in dry mass between the heads of X- and Y-bearing human spermatozoa. J Reprod Fertil 1976; 48:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/29\">",
"      Beckett TA, Martin RH, Hoar DI. Assessment of the sephadex technique for selection of X-bearing human sperm by analysis of sperm chromosomes, deoxyribonucleic acid and Y-bodies. Fertil Steril 1989; 52:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/30\">",
"      Lobel SM, Pomponio RJ, Mutter GL. The sex ratio of normal and manipulated human sperm quantitated by the polymerase chain reaction. Fertil Steril 1993; 59:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/31\">",
"      Vidal F, Moragas M, Catal&agrave; V, et al. Sephadex filtration and human serum albumin gradients do not select spermatozoa by sex chromosome: a fluorescent in-situ hybridization study. Hum Reprod 1993; 8:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/32\">",
"      Han TL, Flaherty SP, Ford JH, Matthews CD. Detection of X- and Y-bearing human spermatozoa after motile sperm isolation by swim-up. Fertil Steril 1993; 60:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/33\">",
"      Wang HX, Flaherty SP, Swann NJ, Matthews CD. Assessment of the separation of X- and Y-bearing sperm on albumin gradients using double-label fluorescence in situ hybridization. Fertil Steril 1994; 61:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/34\">",
"      Wang HX, Flaherty SP, Swann NJ, Matthews CD. Discontinuous Percoll gradients enrich X-bearing human spermatozoa: a study using double-label fluorescence in-situ hybridization. Hum Reprod 1994; 9:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/35\">",
"      Steeno O, Adimoelja A, Steeno J. Separation of X- and Y-bearing human spermatozoa with the sephadex gel-filtration method. Andrologia 1975; 7:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/36\">",
"      Quinlivan WL, Preciado K, Long TL, Sullivan H. Separation of human X and Y spermatozoa by albumin gradients and Sephadex chromatography. Fertil Steril 1982; 37:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/37\">",
"      Brandriff BF, Gordon LA, Haendel S, et al. Sex chromosome ratios determined by karyotypic analysis in albumin-isolated human sperm. Fertil Steril 1986; 46:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/38\">",
"      Check JH, Katsoff D. A prospective study to evaluate the efficacy of modified swim-up preparation for male sex selection. Hum Reprod 1993; 8:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/39\">",
"      Ericsson RJ, Langevin CN, Nishino M. Isolation of fractions rich in human Y sperm. Nature 1973; 246:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/40\">",
"      Dmowski WP, Gaynor L, Rao R, et al. Use of albumin gradients for X and Y sperm separation and clinical experience with male sex preselection. Fertil Steril 1979; 31:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/41\">",
"      Evans JM, Douglas TA, Renton JP. An attempt to separate fractions rich in human Y sperm. Nature 1975; 253:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/42\">",
"      Ross A, Robinson JA, Evans HJ. Failure to confirm separation of X- and Y-bearing human sperm using BSA gradients. Nature 1975; 253:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/43\">",
"      Jaffe SB, Jewelewicz R, Wahl E, Khatamee MA. A controlled study for gender selection. Fertil Steril 1991; 56:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/44\">",
"      Kaneko S, Yamaguchi J, Kobayashi T, Iizuka R. Separation of human X- and Y-bearing sperm using percoll density gradient centrifugation. Fertil Steril 1983; 40:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/45\">",
"      Watkins AM, Chan PJ, Patton WC, et al. Sperm kinetics and morphology before and after fractionation on discontinuous Percoll gradient for sex preselection: computerized analyses. Arch Androl 1996; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/46\">",
"      Flaherty SP, Matthews CD. Application of modern molecular techniques to evaluate sperm sex selection methods. Mol Hum Reprod 1996; 2:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/47\">",
"      Johnson LA, Welch GR, Keyvanfar K, et al. Gender preselection in humans? Flow cytometric separation of X and Y spermatozoa for the prevention of X-linked diseases. Hum Reprod 1993; 8:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/48\">",
"      Pinkel D, Lake S, Gledhill BL, et al. High resolution DNA content measurements of mammalian sperm. Cytometry 1982; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/49\">",
"      Fugger EF, Black SH, Keyvanfar K, Schulman JD. Births of normal daughters after MicroSort sperm separation and intrauterine insemination, in-vitro fertilization, or intracytoplasmic sperm injection. Hum Reprod 1998; 13:2367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/50\">",
"      Ashwood-Smith MJ. Human sperm sex selection. Safety of human sperm selection by flow cytometry. Hum Reprod 1994; 9:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/51\">",
"      Munn&eacute; S. Flow cytometry separation of X and Y spermatozoa could be detrimental for human embryos. Hum Reprod 1994; 9:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/52\">",
"      Cran DG, Johnson LA, Miller NG, et al. Production of bovine calves following separation of X- and Y-chromosome bearing sperm and in vitro fertilisation. Vet Rec 1993; 132:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/53\">",
"      Johnson LA, Flook JP, Hawk HW. Sex preselection in rabbits: live births from X and Y sperm separated by DNA and cell sorting. Biol Reprod 1989; 41:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/54\">",
"      Matsuda Y, Tobari I. Chromosomal analysis in mouse eggs fertilized in vitro with sperm exposed to ultraviolet light (UV) and methyl and ethyl methanesulfonate (MMS and EMS). Mutat Res 1988; 198:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/55\">",
"      Duran, RE, Olive, PL. Cytotoxicity, mutagenicity and DNA damage by Hoechst 33342. J Histochem Cytochem 1982; 30:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/56\">",
"      Catt SL, Sakkas D, Bizzaro D, et al. Hoechst staining and exposure to UV laser during flow cytometric sorting does not affect the frequency of detected endogenous DNA nicks in abnormal and normal human spermatozoa. Mol Hum Reprod 1997; 3:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/57\">",
"      Vidal F, Blanco J, Fugger EF, et al. Preliminary study of the incidence of disomy in sperm fractions after MicroSort flow cytometry. Hum Reprod 1999; 14:2987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/58\">",
"      Griffin DK, Wilton LJ, Handyside AH, et al. Dual fluorescent in situ hybridisation for simultaneous detection of X and Y chromosome-specific probes for the sexing of human preimplantation embryonic nuclei. Hum Genet 1992; 89:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/59\">",
"      Delhanty JD, Griffin DK, Handyside AH, et al. Detection of aneuploidy and chromosomal mosaicism in human embryos during preimplantation sex determination by fluorescent in situ hybridisation, (FISH). Hum Mol Genet 1993; 2:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/60\">",
"      Harper JC, Coonen E, Ramaekers FC, et al. Identification of the sex of human preimplantation embryos in two hours using an improved spreading method and fluorescent in-situ hybridization (FISH) using directly labelled probes. Hum Reprod 1994; 9:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/61\">",
"      Kanavakis E, Traeger-Synodinos J. Preimplantation genetic diagnosis in clinical practice. J Med Genet 2002; 39:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/62\">",
"      Levinson G, Fields RA, Harton GL, et al. Reliable gender screening for human preimplantation embryos, using multiple DNA target-sequences. Hum Reprod 1992; 7:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/63\">",
"      Levinson G, Keyvanfar K, Wu JC, et al. DNA-based X-enriched sperm separation as an adjunct to preimplantation genetic testing for the prevention of X-linked disease. Hum Reprod 1995; 10:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/64\">",
"      Hardy K, Martin KL, Leese HJ, et al. Human preimplantation development in vitro is not adversely affected by biopsy at the 8-cell stage. Hum Reprod 1990; 5:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/65\">",
"      Antczak M, Van Blerkom J. Temporal and spatial aspects of fragmentation in early human embryos: possible effects on developmental competence and association with the differential elimination of regulatory proteins from polarized domains. Hum Reprod 1999; 14:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/66\">",
"      Lai-wan CC, Blyth E, Hoi-yan CC. Attitudes to and practices regarding sex selection in China. Prenat Diagn 2006; 26:610.",
"     </a>",
"    </li>",
"    <li>",
"     file://updateox.com/india/district-wise-sex-ratio-in-india-2011-census/ (Accessed on June 15, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/68\">",
"      Van Balen F. Attitudes towards sex selection in the Western world. Prenat Diagn 2006; 26:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/69\">",
"      Missmer SA, Jain T. Preimplantation sex selection demand and preferences among infertility patients in Midwestern United States. J Assist Reprod Genet 2007; 24:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/70\">",
"      Gleicher N, Barad DH. The choice of gender: is elective gender selection, indeed, sexist? Hum Reprod 2007; 22:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/71\">",
"      Dahl E, Gupta RS, Beutel M, et al. Preconception sex selection demand and preferences in the United States. Fertil Steril 2006; 85:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/72\">",
"      Sills ES, Palermo GD. Preimplantation genetic diagnosis for elective sex selection, the IVF market economy, and the child--another long day's journey into night? J Assist Reprod Genet 2002; 19:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/73\">",
"      Meseguer M, Garrido N, Remoh&iacute; J, et al. Gender selection: ethical, scientific, legal, and practical issues. J Assist Reprod Genet 2002; 19:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/74\">",
"      Dawson K, Trounson A. Ethics of sex selection for family balancing. Why balance families? Hum Reprod 1996; 11:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/75\">",
"      Ethical considerations of assisted reproductive technologies. By the Ethics Committee of the American Fertility Society. Fertil Steril 1994; 62:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/76\">",
"      Robertson JA. Sex selection for gender variety by preimplantation genetic diagnosis. Fertil Steril 2002; 78:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/77\">",
"      Ethics Committee of the American Society of Reproductive Medicine. Sex selection and preimplantation genetic diagnosis. Fertil Steril 2004; 82 Suppl 1:S245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/78\">",
"      Committee on Ethics, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 360: Sex selection. Obstet Gynecol 2007; 109:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/79\">",
"      Avent ND, Chitty LS. Non-invasive diagnosis of fetal sex; utilisation of free fetal DNA in maternal plasma and ultrasound. Prenat Diagn 2006; 26:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/80\">",
"      Lo YM, Tein MS, Lau TK, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998; 62:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/81\">",
"      Lo YM, Zhang J, Leung TN, et al. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999; 64:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/82\">",
"      Birch L, English CA, O'Donoghue K, et al. Accurate and robust quantification of circulating fetal and total DNA in maternal plasma from 5 to 41 weeks of gestation. Clin Chem 2005; 51:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/83\">",
"      Martinhago CD, de Oliveira RM, Tomit&atilde;o Canas Mdo C, et al. Accuracy of fetal gender determination in maternal plasma at 5 and 6 weeks of pregnancy. Prenat Diagn 2006; 26:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/84\">",
"      Bianchi DW. At-home fetal DNA gender testing: caveat emptor. Obstet Gynecol 2006; 107:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29256/abstract/85\">",
"      Johnson KL, Dukes KA, Vidaver J, et al. Interlaboratory comparison of fetal male DNA detection from common maternal plasma samples by real-time PCR. Clin Chem 2004; 50:516.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2006/safety06.htm#Genetic. (Accessed on August 03, 2006).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7419 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29256=[""].join("\n");
var outline_f28_36_29256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Personal preference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Family balance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      X-linked disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Unequal sex incidence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OVERVIEW OF METHODS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATIENT CONTROLLED INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Timed intercourse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SPERM SEPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Sephadex column",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Modified swim up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Albumin gradient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Percoll",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Flow cytometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREIMPLANTATION GENETIC DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ETHICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Position of major medical societies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - American Society for Reproductive Medicine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - American College of Obstetricians and Gynecologists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9489449\">",
"      POSTIMPLANTATION SEX SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1448?source=related_link\">",
"      Prenatal diagnosis using cell-free fetal nucleic acids in maternal blood",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_36_29257="Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction";
var content_f28_36_29257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Trials of conservative versus early invasive therapy in unstable angina and non-ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29257/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29257/contributors\">",
"     Michael Simons, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29257/contributors\">",
"     Julian M Aroesty, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29257/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29257/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29257/contributors\">",
"     Allan S Jaffe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29257/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29257/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/36/29257/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is at present no accurate method of predicting which patients with unstable angina (UA) will progress to myocardial infarction (MI) and which patients will stabilize on medical therapy alone. Similarly, it is unclear which patients would benefit from revascularization among patients with a non-ST segment elevation (non-Q wave) MI (NSTEMI), which cannot be distinguished from UA until serum enzymes show evidence of an acute infarction.",
"   </p>",
"   <p>",
"    Given these uncertainties in predicting the response to therapy and prognosis, two diagnostic approaches have evolved: conservative versus early invasive therapy. The latter involves prompt catheterization of all patients with UA or NSTEMI after the initiation of medical therapy, usually within 4 to 48 hours of admission.",
"   </p>",
"   <p>",
"    The early invasive strategy of coronary angiography followed by revascularization, if appropriate, is aimed at improving long-term prognosis. This should be distinguished from immediate attempts to attain reperfusion via thrombolysis or primary percutaneous coronary intervention (PCI) in an attempt to limit myocardial injury.",
"   </p>",
"   <p>",
"    Thrombolytic therapy is beneficial in patients with ST elevation MI (STEMI), but is not effective in UA or NSTEMI and may be harmful. Coronary arteriography, performed in the acute period following NSTEMI, demonstrates that the infarct-related artery is not occluded in 60 to 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The nonoccluding thrombi that are present are primarily grayish-white (ie, platelet-rich), and therefore less likely to respond to thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, thrombi are almost always reddish (ie, fibrin-rich) in patients with STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, microvascular perfusion is often reduced in patients with UA or NSTEMI; as a result, the ongoing mechanism of ischemia is more likely embolization and endothelial dysfunction rather than epicardial vessel occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The features of the invasive or conservative approaches in patients with UA and NSTEMI (also called non-ST elevation acute coronary syndromes) and the clinical trials that have evaluated them will be reviewed here. Specific recommendations related to revascularization in the non-ST elevation acute coronary syndromes (ACS) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONSERVATIVE APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The conservative strategy begins with rapidly intensifying medical therapy consisting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low molecular weight heparin, an intravenous beta blocker, and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    for symptoms. For patients not undergoing PCI, the benefit of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor is primarily seen in those at high risk of further cardiac events. This includes patients with elevated levels of troponin I or T patients with a TIMI risk score &ge;4, and patients with continuing ischemia or other high-risk features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who become asymptomatic on this regimen are given several days to \"cool off,\" intravenous medications are discontinued, and, if the patient is still symptom free, exercise testing is performed, most often with some form of myocardial imaging (nuclear or echocardiography). Persistence of symptoms, symptom recurrence, or a positive stress test lead to prompt cardiac catheterization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The advantage of the conservative strategy is that it limits the use of cardiac catheterization, which probably reduces the incidence of unnecessary revascularization. The main disadvantage is prolonged length of hospitalization that frequently involves the use of expensive coronary care unit beds, and some diagnostic uncertainty associated with noninvasive testing of coronary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EARLY INVASIVE APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early invasive strategy begins with the same intensive medical regimen, with two potential differences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      has been associated with an increase in major bleeding and reoperation for bleeding in patients who need to undergo CABG. However, concern about CABG appears to be a diminishing problem as progressively fewer patients with a non-ST elevation ACS require this procedure (8 percent in preliminary data from the ISAR-COOL trial). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor should be considered for most patients with a non-ST elevation ACS undergoing PCI. We generally prefer",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      in this setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=see_link\">",
"       \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the patient has stabilized, prompt catheterization and subsequent revascularization, if appropriate, are performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the TACTICS-TIMI 18 and RITA 3 approach described below, catheterization is usually performed within 4 to 48 hours of admission. This approach is consistent with data from the ISAR-COOL study, which demonstrated a significant benefit from catheterization within six hours compared to catheterization at three to five days (see",
"    <a class=\"local\" href=\"#H10\">",
"     'ISAR-COOL trial'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The invasive strategy leads to a significant reduction in the hospital length of stay at the expense of some unnecessary catheterizations. In addition, most of the trials discussed below found a reduction in the incidence of death or nonfatal MI with an early invasive strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative merits of these two approaches have been tested in a number of randomized trials, most of which included patients with both UA and NSTEMI. Among patients in the early invasive arm, the following general observations were made in the large FRISC II and TACTICS-TIMI 18 trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary angiography revealed either normal vessels or no vessel with &ge;50 percent stenosis in 13 to 14 percent. In TACTICS-TIMI 18, this was more likely to occur in women than men (17 versus 9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/9\">",
"       9",
"      </a>",
"      ]. Possible mechanisms for myocardial ischemia in the absence of significant epicardial coronary disease include rapid clot lysis, vasospasm, and coronary microvascular disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=see_link&amp;anchor=H10#H10\">",
"       \"Classification of unstable angina and non-ST elevation myocardial infarction\", section on 'Absence of significant coronary disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Early revascularization was performed in 61 to 71 percent.",
"     </li>",
"     <li>",
"      Among patients undergoing early revascularization, CABG was performed in 33 to 42 percent of patients, most often for three vessel or left main disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     TIMI IIIB trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;TIMI IIIB was a randomized, double-blinded trial of therapeutic strategies and thrombolysis in patients with UA and NSTEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/10\">",
"     10",
"    </a>",
"    ]. TIMI IIIB randomly assigned 1473 patents seen within 24 hours of an episode of rest angina in a 2x2 factorial design to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    or placebo, and to a conservative or early invasive approach. All patients were treated with a standard anti-ischemic regimen including intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in the conservative arm underwent catheterization only if they developed evidence of recurrent ischemia, including recurrent chest pain with electrocardiographic changes, prolonged ST segment depressions on ambulatory Holter monitoring, or a positive predischarge exercise test.",
"     </li>",
"     <li>",
"      Patients assigned to the early invasive strategy underwent cardiac catheterization and angiography within 18 to 48 hours, followed by revascularization by balloon angioplasty or CABG if indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major results are summarized in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef81299 \" href=\"UTD.htm?3/45/3805\">",
"     table 1",
"    </a>",
"    ). There was",
"    <strong>",
"     no significant difference",
"    </strong>",
"    in the rates of death and nonfatal MI between invasive and conservative therapy at six weeks (7.5 versus 8.2 percent) or one year (10.8 versus 12.2 percent). The frequency of death, MI, or a positive exercise test at six weeks was also similar in the two groups, except for patients over age 65 who had a significant benefit from invasive therapy (8 versus 15 percent).",
"   </p>",
"   <p>",
"    Patients assigned to the invasive strategy had significant reductions in initial hospital stay (10.2 versus 10.9 days), the rate of rehospitalization at six weeks and at one year (26 versus 33 percent), and the number of antianginal medications required.",
"   </p>",
"   <p>",
"    The lack of major benefit in TIMI IIIB may have been related to the high crossover to invasive therapy in the conservative group. Of the 733 patients assigned to the conservative approach, revascularization was performed in 58 percent by one year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of the thrombolytic arm of TIMI IIIB are discussed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     VANQWISH trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The VANQWISH trial randomly assigned 920 patients with an NSTEMI to an early invasive strategy (coronary angiography followed by revascularization as dictated by anatomic findings) 72 hours after the last episode of chest pain or an early conservative strategy with angiography and revascularization only if there were spontaneous ischemia associated with ST segment changes or if a thallium stress test suggested the presence of residual ischemia (eg, ST segment depression &ge;2 mm, redistribution defects in two or more different territories, or one redistribution defect associated with increased lung uptake of thallium) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There was no benefit from the invasive approach, which was only performed in 44 percent of patients in this arm. To the contrary, at the time of hospital discharge, the primary endpoint of death or nonfatal MI occurred significantly more frequently in the invasive group (7.8 versus 3.2 percent). Both the primary endpoint and mortality were still increased in the invasive group at one year but not at two years.",
"   </p>",
"   <p>",
"    Subset analysis revealed that the two approaches were associated with similar outcomes except for three groups of patients who clearly did worse with early invasive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Those who received thrombolysis",
"     </li>",
"     <li>",
"      Those without ST segment depression",
"     </li>",
"     <li>",
"      Those without a prior MI",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     FRISC II trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the FRISC II trial, 2457 patients with unstable coronary disease were randomly assigned after 48 hours to an invasive (catheterization followed by revascularization within seven days) or noninvasive approach (angiography for a positive exercise test, refractory or severe angina, or MI) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/7\">",
"     7",
"    </a>",
"    ]. All patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers, and low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    until revascularization in the invasive group or for at least five days in the noninvasive group. At six months, the following outcomes were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of death or MI was significantly lower in the invasive group (9.4 versus 12.1 percent in the noninvasive group); the difference was primarily due to a lower rate of MI (7.8 versus 10.1 percent), while the difference in mortality was not significant at six months (1.9 versus 2.9 percent) but was significant at one year (2.2 versus 3.9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/14\">",
"       14",
"      </a>",
"      ]. The invasive approach was also associated with a 50 percent reduction in angina and the need for readmission.",
"     </li>",
"     <li>",
"      The greatest benefit with invasive therapy was seen in high risk patients who had ST depression on the electrocardiogram (ECG)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biochemical markers of myocardial damage [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/7,15,16\">",
"       7,15,16",
"      </a>",
"      ]. Patients with both findings had a marked reduction in death or MI at one year (13.2 versus 22.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/16\">",
"       16",
"      </a>",
"      ]. The benefit was primarily seen in patients with more marked or more widespread ST segment depression [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/17\">",
"       17",
"      </a>",
"      ], particularly if associated with T wave abnormalities in &ge;6 leads [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A possible explanation for the prognostic importance of these findings was their more frequent association with three vessel and left main disease (46 versus 22 percent in those with and without ST depression; and 49 versus 17 percent in patients with both ST depression and elevated troponins compared to those with neither finding) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4521?source=see_link\">",
"     \"Electrocardiogram in the prognosis of myocardial infarction or unstable angina\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reduction in the rate of the combined endpoint of death or MI was sustained at one year&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/14\">",
"     14",
"    </a>",
"    ]. The differences in each endpoint considered separately (death or MI) were both independently significant. At five years, there was still a significant reduction in the composite endpoint (19.9 versus 24.5 percent), but the benefit was limited to men and the mortality benefit was no longer significant [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Effect in women'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     TACTICS-TIMI 18 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of an invasive strategy in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    was evaluated in the TACTICS-TIMI 18 trial, which randomly assigned 2220 patients presenting with UA or an NSTEMI to an invasive strategy (catheterization within 4 to 48 hours and revascularization with angioplasty or CABG if feasible) or conservative medical therapy; all patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , beta blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and tirofiban for 48 to 108 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normal vessels were more likely to occur in women than men (17 versus 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At six months, the primary endpoint (death, MI, rehospitalization for an ACS) was significantly lower with an invasive strategy (15.9 versus 19.4 percent for conservative approach, odds ratio 0.78). This benefit was due to reductions in MI or rehospitalization for an ACS; there was no mortality benefit from invasive therapy at either 30 days (2.2 versus 1.6 percent) or 6 months (3.3 versus 3.5 percent).",
"   </p>",
"   <p>",
"    The reduction in the primary endpoint with the invasive approach was seen only in those patients who had an elevation of serum troponin I concentration (&ge;0.1",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    upon presentation to the hospital (15 versus 25 percent for a conservative approach), even if the elevation was only minimal (0.1 to 0.4",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    (4.4 versus 16.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/20\">",
"     20",
"    </a>",
"    ]. No improvement was noted with the invasive approach in those with serum troponin I concentrations below 0.1",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    A substudy from TACTICS-TIMI 18 suggested that an invasive approach may be beneficial in women who have elevations of C-reactive protein (CRP) or brain natriuretic peptide (BNP) as well as troponins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Effect in women'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     RITA 3 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;RITA 3 compared early angiography and revascularization with conservative therapy in 1810 patients with a non-ST elevation ACS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/22\">",
"     22",
"    </a>",
"    ]. All patients were eligible for either approach, and all received optimal medical therapy, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    as the antithrombin. Exclusion criteria included new Q waves, CK or CK-MB twice the upper limit of normal at randomization, MI within the previous month, PCI within the previous year, and CABG at any time. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At four months, an early invasive strategy was associated with a lower rate of the coprimary endpoint of death, nonfatal MI, or refractory angina (9.6 versus 14.5 percent, odds ratio 0.66, 95% CI 0.51-0.85); this benefit was entirely due to a reduction in refractory angina (defined as an episode of angina with new ischemic ECG changes) and persisted at one year.",
"     </li>",
"     <li>",
"      At one year, there was no difference between the two groups in the coprimary endpoint of death or nonfatal MI (7.6 versus 8.3 percent, risk ratio 0.91, 95% CI 0.67-1.25). However, symptoms of angina were improved in the interventional group and there was a significant reduction in MI at one year (9.4 versus 14.1 percent) if the new",
"      <span class=\"nowrap\">",
"       ACC/ESC",
"      </span>",
"      definition of MI, which includes elevated serum troponins, was used. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"       \"Criteria for the diagnosis of acute myocardial infarction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to the equivocal benefit at one year, prespecified follow-up at a median of five years revealed that the interventional group had significant reductions in death or nonfatal MI (16.6 versus 20.0 percent, odds ratio 0.78, 95% CI 0.61-0.99) and in cardiovascular death or nonfatal MI (12 versus 15 percent, odds ratio 0.74, 95% CI 0.56-0.97) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/23\">",
"       23",
"      </a>",
"      ]. The benefits were primarily seen in patients at highest risk (29.2 versus 48.5 percent, odds ratio 0.44, 95% CI 0.25-0.76).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefits of an early invasive strategy were similar and of the same magnitude at five year follow-up in both the RITA 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/23\">",
"     23",
"    </a>",
"    ] and FRISC II trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     ISAR-COOL trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the ISAR-COOL trial, 410 intermediate-to-high risk patients with a non-ST elevation ACS plus either ST segment depression or an elevation in serum troponin T were treated with maximal antithrombotic therapy including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    ). Patients were then randomly assigned to a very early versus delayed invasive strategy (median time to catheterization 2.4 versus 86 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/24\">",
"     24",
"    </a>",
"    ]. There were two major findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The early invasive strategy, when compared with the delayed invasive strategy, was associated with a significant reduction in death or large MI (new Q waves in two or more contiguous leads, new left bundle branch block, or elevation in serum CK-MB to at least five times the upper limit of normal) at 30 days (5.9 versus 11.6 percent).",
"     </li>",
"     <li>",
"      The benefit was entirely due to a reduced incidence of events prior to diagnostic catheterization in the early invasive group (0.5 versus 6.3 percent); there was no difference in the incidence of events after catheterization (5.4 versus 5.3 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ISAR-COOL demonstrates the benefit of a very early invasive strategy compared to waiting three to five days. It does not address the relative efficacy of a very early invasive strategy to waiting one to two days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gradation of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate to high risk groups have been identified that benefited most from early invasive therapy. These included patients with one or more of the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated serum troponins in FRISC II and TACTICS-TIMI 18 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/16,20,25\">",
"       16,20,25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      ST depression on the ECG in FRISC II, TACTICS-TIMI 18, and TIMI IIIB [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/8,15-17,20,26\">",
"       8,15-17,20,26",
"      </a>",
"      ] and, in FRISC II, the degree of and the number of leads with ST depression [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Age greater than 65 in TIMI IIIB [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In women in TACTICS-TIMI 18, elevated troponins, CRP or BNP [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/21\">",
"       21",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H15\">",
"       'Effect in women'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, in the five-year follow-up from the RITA 3 trial, the benefit was primarily seen in patients at highest risk at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although small elevations in cardiac enzymes in ACS are thought to reflect small, localized areas of infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/27\">",
"     27",
"    </a>",
"    ], the adverse prognosis associated with this finding may be related to worse underlying disease. In FRISC II and TACTICS-TIMI 18, any elevation in serum troponin T increased the likelihood of severe three vessel disease, an unstable plaque with thrombus and downstream microembolization, and impairment of coronary flow; these factors are all associated with an increased risk for reinfarction and death [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients with a greater elevation in serum troponin T were more likely to have persistent occlusion of the culprit vessel, associated with left ventricular dysfunction and a higher mortality, but a lower risk of reinfarction.",
"   </p>",
"   <p>",
"    A variable definition of ST segment depression has been used in the different trials. Some found an adverse effect of ST depression of &ge;0.1 mV (1 mm) in &ge;1 or &ge;2 leads [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/26\">",
"     26",
"    </a>",
"    ], while analyses of other trials documented an adverse effect from ST depression of &ge;0.05 mV (0.5 mm) in &ge;1 lead [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/8,16,29\">",
"     8,16,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     TIMI risk score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI risk score is based upon data from TIMI 11B and ESSENCE in which seven variables at presentation were independently predictive of outcome in patients with a non-ST elevation ACS; a value of one was assigned when a factor was present and 0 when it was absent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &ge;65 years",
"     </li>",
"     <li>",
"      Presence of at least three risk factors for CHD",
"     </li>",
"     <li>",
"      Prior coronary stenosis of &ge;50 percent",
"     </li>",
"     <li>",
"      Presence of ST segment deviation on admission ECG",
"     </li>",
"     <li>",
"      At least two anginal episodes in prior 24 hours",
"     </li>",
"     <li>",
"      Elevated serum cardiac biomarkers",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in prior seven days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    causing a worse outcome, prior aspirin use seems to be a marker for more underlying vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/31\">",
"     31",
"    </a>",
"    ]. In terms of its specific effect, prior aspirin use appears to reduce the severity of new ACS.",
"   </p>",
"   <p>",
"    A higher TIMI risk score correlated significantly with increased numbers of events (all-cause mortality, new or recurrent MI, or severe recurrent ischemia requiring revascularization) at 14 days (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"     calculator 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Score of",
"      <span class=\"nowrap\">",
"       0/1",
"      </span>",
"      - 4.7 percent",
"     </li>",
"     <li>",
"      Score of 2 - 8.3 percent",
"     </li>",
"     <li>",
"      Score of 3 - 13.2 percent",
"     </li>",
"     <li>",
"      Score of 4 - 19.9 percent",
"     </li>",
"     <li>",
"      Score of 5 - 26.2 percent",
"     </li>",
"     <li>",
"      Score of",
"      <span class=\"nowrap\">",
"       6/7",
"      </span>",
"      - 40.9 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The TIMI risk score has been validated by applying it to the PRISM-PLUS database [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=see_link&amp;anchor=H7#H7\">",
"     \"Risk stratification after unstable angina or non-ST elevation myocardial infarction\", section on 'TIMI risk score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When applied to TACTICS-TIMI 18, the TIMI risk score identified patients who might benefit from an early invasive strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/8\">",
"     8",
"    </a>",
"    ]. In terms of the primary endpoint (death, MI, rehospitalization for an ACS at six months):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients at low risk (score 0 to 2), there was no difference in outcome between the invasive and conservative approaches (12.8 versus 11.8 percent)",
"     </li>",
"     <li>",
"      There was a significant reduction in the primary endpoint with the invasive approach in patients at intermediate risk (score 3 to 4, 16.1 versus 20.3 percent) and particularly in those at high risk (score 5 to 7) (19.5 versus 30.6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful meta-analysis of the major trials of 9212 patients but not including ICTUS addressed the outcomes of routine compared to a selective invasive strategy at different time periods [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      From randomization to hospital discharge, a routine invasive strategy was associated with a significant",
"      <strong>",
"       increase",
"      </strong>",
"      in mortality (1.8 versus 1.1 percent, odds ratio [OR] 1.60, 95% CI 1.14-2.25), an almost significant increase in nonfatal MI (3.7 versus 3.0 percent, OR 1.24, 95% CI 0.99-1.56), and a significant increase in death or MI (5.2 versus 3.8 percent, OR 1.36, 95% CI 1.12-1.66).",
"     </li>",
"     <li>",
"      From hospital discharge to the end of follow-up, a routine invasive strategy was associated with a significant",
"      <strong>",
"       reduction",
"      </strong>",
"      in mortality (5.2 versus 7.3 percent, odds ratio [OR] 0.76, 95% CI 0.62-0.94), a significant reduction in nonfatal MI (3.8 versus 6.6 percent, OR 0.56, 95% CI 0.0.46-0.67), and a significant reduction in death or MI (7.4 versus 11.0 percent, OR 0.64, 95% CI 0.55-0.75).",
"     </li>",
"     <li>",
"      From randomization to the end of follow-up, a routine invasive strategy was associated with a nonsignificant reduction in mortality (6.7 versus 7.9 percent, odds ratio [OR] 0.92, 95% CI 0.77-1.09), a significant reduction in nonfatal MI (7.3 versus 9.4 percent, OR 0.75, 95% CI 0.0.65-0.88), and a significant reduction in death or MI (12.2 versus 14.4 percent, OR 0.82, 95% CI 0.72-0.93).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By the end of follow-up, a routine invasive strategy was also associated with significant reductions in Canadian Cardiovascular Society class III-IV angina (11.2 versus 14 percent) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 2",
"    </a>",
"    ) and in rehospitalization (32.5 versus 41.3 percent). It would be expected that these differences would now be greater because of the greater use of aggressive antiplatelet therapy with PCI and the availability of drug-eluting stents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to these overall long-term benefits, there was no significant reduction in death or nonfatal MI among patients without any elevation in serum troponins or other cardiac biomarker (7.7 versus 8.5 percent, OR 0.90, 95% CI 0.72-1.14). This finding is consistent with the above suggestion of lack of significant benefit in patients at low risk (TIMI risk score 0 to 2) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ICTUS trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICTUS trial, which was published in 2005 after the meta-analysis, included 1200 patients with a non-ST elevation ACS who had chest pain, an elevated serum cardiac troponin T, and either ECG evidence of ischemia or a documented history of coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The patients were randomly assigned to an early invasive strategy or a selectively invasive strategy in which angiography was performed only for refractory angina, hemodynamic or arrhythmic instability, or significant ischemia on the predischarge exercise stress test. All were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , and, at the time of PCI,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and intensive statin therapy were recommended.",
"   </p>",
"   <p>",
"    Catheterization (98 versus 53 percent) and revascularization (76 versus 40 percent) were more likely to be performed in the early invasive group during the initial hospitalization. The median time to revascularization was 23 hours with the early invasive strategy and 11.8 days with the selective invasive strategy.",
"   </p>",
"   <p>",
"    The primary endpoint was a composite of death, nonfatal MI, or rehospitalization for angina within one year. The trial failed to show a benefit from an early invasive strategy as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in the incidence of the primary endpoint (22.7 versus 21.2 percent with the selective strategy). Although all patients had an elevated serum cardiac troponin T concentration, the presence of additional high risk features (eg, older age, ST segment depression, or a more marked elevation in serum cardiac troponin T) did not predict a better outcome with an early invasive strategy in contrast to other studies&rsquo; trials above.",
"     </li>",
"     <li>",
"      There was a significant increase in MI with an early invasive strategy (mostly periprocedural); although a less stringent CK-MB elevation was required, the increase in MI persisted when using the definitions from FRISC II or TACTICS-TIMI 18.",
"     </li>",
"     <li>",
"      Rehospitalization was significantly less common with an early invasive strategy (7.4 versus 10.9 percent).",
"     </li>",
"     <li>",
"      After five years of follow-up, the rates of death and MI remained similar in the two groups of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It cannot be determined with confidence why the results in this trial are different from those in FRISC II, TACTICS-TIMI 18, RITA 3, and the meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/33\">",
"     33",
"    </a>",
"    ]. An important factor was the long duration of hospitalization in the selective invasive group (mean 11.3 days), during which 40 percent of patients underwent revascularization; this is not the standard for non-ST elevation acute coronary syndromes in the United States.",
"   </p>",
"   <p>",
"    Given these concerns, the much larger number of patients in the meta-analysis (9212 versus 1200 in ICTUS), and the improved five-year outcomes in RITA 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/23\">",
"     23",
"    </a>",
"    ], we continue to recommend an early invasive strategy in patients at increased risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Effect in women",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is whether the benefit of an early invasive approach in appropriately selected patients applies to women. In FRISC II and RITA 3, the favorable effect of early invasive therapy was seen only in men [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/22,36\">",
"     22,36",
"    </a>",
"    ] and, in FRISC II, this difference was persistent at five years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/19\">",
"     19",
"    </a>",
"    ]. However, three other observations found that women benefit from an early invasive therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In TACTICS-TIMI 18, the benefit of early invasive therapy was equivalent in women and men overall and in patients with elevated troponin T [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study evaluated 1450 consecutive patients (29 percent women) with a non-ST elevation ACS treated with very early revascularization primarily by percutaneous coronary intervention with stenting [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/37\">",
"       37",
"      </a>",
"      ]. Women had better outcomes, as the primary endpoint, death, or nonfatal MI at 20 months, occurred significantly less often in women (adjusted hazard ratio 0.51 compared to men). This may have been due at least in part to lower baseline risk, since women were less likely to have had a previous MI or three vessel disease (29 versus 42 percent).",
"     </li>",
"     <li>",
"      A post hoc analysis from the CURE trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      therapy in non-ST elevation ACS found that women, compared to men, were less likely than men to undergo an invasive strategy and were more likely to develop refractory ischemia and to be rehospitalized for chest pain (16.6 versus 13.9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/38\">",
"       38",
"      </a>",
"      ]. This increase in risk was most prominent in women at high risk (as determined from the TIMI risk score) (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=see_link\">",
"       calculator 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The factors responsible for these conflicting findings are not well understood. A possible contributing factor is that women in FRISC II and RITA 3 were at lower risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/9,39\">",
"     9,39",
"    </a>",
"    ]; in such patients, the benefit from revascularization would be less and the procedural risk might be a more important determinant of outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/39\">",
"     39",
"    </a>",
"    ]. Consistent with this hypothesis are the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In TACTICS-TIMI 18, women with low TIMI risk scores (0 to 2) (see",
"      <a class=\"local\" href=\"#H12\">",
"       'TIMI risk score'",
"      </a>",
"      above) or no elevation in serum troponin T had a nonsignificant trend toward a worse outcome with early invasive therapy; men with these features had no benefit but no suggestion of harm [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/9\">",
"       9",
"      </a>",
"      ]. Compared to men, women who underwent PCI had a significantly higher risk of major bleeding (8.3 versus 2.9 percent).",
"     </li>",
"     <li>",
"      In FRISC II, the excess risk in women was due to a high mortality rate with CABG [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/36\">",
"       36",
"      </a>",
"      ]. In contrast, the peri-CABG mortality was not so high in TACTICS-TIMI 18 and the above observational study, which contributed to the beneficial effect of early intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/9,37\">",
"       9,37",
"      </a>",
"      ]. Any increase in CABG risk in women is largely related to comorbid conditions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11258?source=see_link&amp;anchor=H21#H21\">",
"       \"Management of coronary heart disease in women\", section on 'Bypass surgery'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A related issue is that the optimal approach to accurate assessment of risk in women may differ from that in men. This was suggested by an analysis from TACTICS-TIMI 18, which found that women were more likely to have elevations of CRP and BNP, and less likely to have elevations of troponins and CK-MB, than men, despite similar levels of risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/21\">",
"     21",
"    </a>",
"    ]. When a multimarker approach incorporating CRP, BNP, and troponins was used, women with any positive marker benefited from an invasive strategy, while those with no positive markers benefited from a conservative strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Effect in the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected elderly patients may derive a greater benefit from an invasive strategy than younger patients, although with an increased risk of bleeding complications. This was suggested by an analysis from TACTICS-TIMI 18 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29257/abstract/40\">",
"     40",
"    </a>",
"    ]. Of the 2220 trial participants, 962 (43 percent) were &ge;65 years of age. Elderly patients were more likely to have a TIMI risk score &ge;3 than younger patients (91 versus 63 percent). In an analysis by age, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients &ge;65 years of age, an early invasive strategy compared to a conservative strategy significantly reduced the incidence of death or MI at 30 days (5.7 versus 9.8 percent) and six months (8.8 versus 13.6 percent). In contrast, the benefit of an invasive strategy was not significant for younger patients at 30 days (3.9 versus 4.9 percent) or six months (6.1 versus 6.5 percent).",
"     </li>",
"     <li>",
"      Among patients &gt;75 years of age, the advantage of an early invasive strategy in reducing the incidence of death or MI at six months was even more marked (10.8 versus 21.6 percent).",
"     </li>",
"     <li>",
"      Among patients &gt;75 years of age, an early invasive strategy significantly increased the frequency of major bleeding during the index hospitalization (16.6 versus 6.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One limitation of this analysis is that the study excluded patients with major comorbidities, including a history of stroke, renal dysfunction, bleeding disorder, or clinically important systemic disease. Patients with severe heart failure, cardiogenic shock, or secondary angina were also excluded. As a result, the findings may not be applicable to some higher-risk elderly patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for choosing an early invasive strategy or initial conservative therapy in patients with a non-ST elevation ACS, based on these clinical trials, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/1\">",
"      Liebson PR, Klein LW. The non-Q wave myocardial infarction revisited: 10 years later. Prog Cardiovasc Dis 1997; 39:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/2\">",
"      Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischemic cardiac pain at rest. Results of the Thrombolysis in Myocardial Ischemia (TIMI IIIA) Trial. Circulation 1993; 87:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/3\">",
"      Kerensky RA, Wade M, Deedwania P, et al. Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol 2002; 39:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/4\">",
"      Wong GC, Morrow DA, Murphy S, et al. Elevations in troponin T and I are associated with abnormal tissue level perfusion: a TACTICS-TIMI 18 substudy. Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction. Circulation 2002; 106:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/5\">",
"      Jang IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/6\">",
"      Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 1992; 326:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/7\">",
"      Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/8\">",
"      Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/9\">",
"      Glaser R, Herrmann HC, Murphy SA, et al. Benefit of an early invasive management strategy in women with acute coronary syndromes. JAMA 2002; 288:3124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/10\">",
"      Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994; 89:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/11\">",
"      Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 1995; 26:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/12\">",
"      Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998; 338:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/13\">",
"      Heggunje PS, Wade MJ, O'Rourke RA, et al. Early invasive versus ischaemia-guided strategies in the management of non-Q wave myocardial infarction patients with and without prior myocardial infarction; results of Veterans Affairs Non-Q Wave Infarction Strategies in Hospital (VANQWISH) trial. Eur Heart J 2000; 21:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/14\">",
"      Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet 2000; 356:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/15\">",
"      Diderholm E, Andr&eacute;n B, Frostfeldt G, et al. ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease; the FRISC II ECG substudy. The Fast Revascularisation during InStability in Coronary artery disease. Eur Heart J 2002; 23:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/16\">",
"      Diderholm E, Andr&eacute;n B, Frostfeldt G, et al. The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy. Am Heart J 2002; 143:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/17\">",
"      Holmvang L, Clemmensen P, Lindahl B, et al. Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment. J Am Coll Cardiol 2003; 41:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/18\">",
"      Jacobsen MD, Wagner GS, Holmvang L, et al. Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study population. Eur Heart J 2005; 26:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/19\">",
"      Lagerqvist B, Husted S, Kontny F, et al. 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet 2006; 368:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/20\">",
"      Morrow DA, Cannon CP, Rifai N, et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001; 286:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/21\">",
"      Wiviott SD, Cannon CP, Morrow DA, et al. Differential expression of cardiac biomarkers by gender in patients with unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis In Myocardial Infarction 18) substudy. Circulation 2004; 109:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/22\">",
"      Fox KA, Poole-Wilson PA, Henderson RA, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002; 360:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/23\">",
"      Fox KA, Poole-Wilson P, Clayton TC, et al. 5-year outcome of an interventional strategy in non-ST-elevation acute coronary syndrome: the British Heart Foundation RITA 3 randomised trial. Lancet 2005; 366:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/24\">",
"      Neumann FJ, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment (\"cooling-off\" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 2003; 290:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/25\">",
"      Kleiman NS, Lakkis N, Cannon CP, et al. Prospective analysis of creatine kinase muscle-brain fraction and comparison with troponin T to predict cardiac risk and benefit of an invasive strategy in patients with non-ST-elevation acute coronary syndromes. J Am Coll Cardiol 2002; 40:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/26\">",
"      Solomon DH, Stone PH, Glynn RJ, et al. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. J Am Coll Cardiol 2001; 38:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/27\">",
"      Ricciardi MJ, Wu E, Davidson CJ, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. Circulation 2001; 103:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/28\">",
"      Lindahl B, Diderholm E, Lagerqvist B, et al. Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy. J Am Coll Cardiol 2001; 38:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/29\">",
"      Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol 1997; 30:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/30\">",
"      Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/31\">",
"      Borzak S, Cannon CP, Kraft PL, et al. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol 1998; 81:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/32\">",
"      Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J 2002; 23:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/33\">",
"      Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA 2005; 293:2908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/34\">",
"      de Winter RJ, Windhausen F, Cornel JH, et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005; 353:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/35\">",
"      Damman P, Hirsch A, Windhausen F, et al. 5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol 2010; 55:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/36\">",
"      Lagerqvist B, S&auml;fstr&ouml;m K, St&aring;hle E, et al. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators. J Am Coll Cardiol 2001; 38:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/37\">",
"      Mueller C, Neumann FJ, Roskamm H, et al. Women do have an improved long-term outcome after non-ST-elevation acute coronary syndromes treated very early and predominantly with percutaneous coronary intervention: a prospective study in 1,450 consecutive patients. J Am Coll Cardiol 2002; 40:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/38\">",
"      Anand SS, Xie CC, Mehta S, et al. Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. J Am Coll Cardiol 2005; 46:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/39\">",
"      Hochman JS, Tamis-Holland JE. Acute coronary syndromes: does sex matter? JAMA 2002; 288:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29257/abstract/40\">",
"      Bach RG, Cannon CP, Weintraub WS, et al. The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes. Ann Intern Med 2004; 141:186.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 85 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29257=[""].join("\n");
var outline_f28_36_29257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONSERVATIVE APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EARLY INVASIVE APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TIMI IIIB trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VANQWISH trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FRISC II trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TACTICS-TIMI 18 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RITA 3 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ISAR-COOL trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gradation of risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - TIMI risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ICTUS trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Effect in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Effect in the elderly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/85\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/85|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/45/3805\" title=\"table 1\">",
"      Early invasive Rx TIMI IIIB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 2\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?5/34/5665?source=related_link\" title=\"calculator 1\">",
"      Calculator: Thrombolysis in Myocardial Infarction (TIMI) score for unstable angina or non ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28505?source=related_link\">",
"      Classification of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4521?source=related_link\">",
"      Electrocardiogram in the prognosis of myocardial infarction or unstable angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/63/11258?source=related_link\">",
"      Management of coronary heart disease in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/43/2746?source=related_link\">",
"      Risk stratification after unstable angina or non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_36_29258="Postmenopausal hormone therapy and cardiovascular risk";
var content_f28_36_29258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postmenopausal hormone therapy and cardiovascular risk",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29258/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29258/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29258/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29258/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29258/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29258/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29258/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/36/29258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/36/29258/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/36/29258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The net benefit of estrogen or combined estrogen-progestin replacement therapy in postmenopausal women is still uncertain. Based upon extensive observational data, it was believed that estrogen was cardioprotective; as a result, estrogen therapy was routinely prescribed for both primary and secondary prevention of coronary heart disease (CHD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, data from the Heart and",
"    <span class=\"nowrap\">",
"     Estrogen/Progestin",
"    </span>",
"    Replacement Study (HERS-I and -II), other small controlled trials, and two meta-analyses, did not confirm a protective effect on the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/1-13\">",
"     1-13",
"    </a>",
"    ], and the Women's Health Initiative (WHI) combined estrogen-progestin trial reported an increase in CHD risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/14\">",
"     14",
"    </a>",
"    ]. The WHI unopposed estrogen trial did not report an increase in CHD events, although stroke and venous thromboembolism were increased as was seen in the combined estrogen-progestin trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, follow-up analysis suggests that younger postmenopausal women taking postmenopausal hormone therapy (unopposed or combined) are",
"    <strong>",
"     not",
"    </strong>",
"    at increased risk for CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most now agree that estrogen is still a reasonable therapy when used short-term for menopausal symptoms, but it should not be prescribed for either primary or secondary prevention of CHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The impact of estrogen therapy on cardiovascular risk will be reviewed here. The discussion will include both cardiovascular outcomes and the effect of estrogen therapy on serum lipid values, blood pressure, and body weight. Other aspects of estrogen therapy are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CORONARY HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although initial observational studies suggested benefit from HT for both primary and secondary prevention of CHD, this has not been confirmed in subsequent large trials. Factors including the older age and greater weight of the WHI population, as well as the estrogen type, route of administration, and dose may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cardiovascular effects of estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of effects of estrogen could affect the risk of cardiovascular disease. However, it is not known how these effects influence the overall risk of CHD with postmenopausal hormone therapy. Examples of potential beneficial effects of estrogen include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An improvement in lipid profiles, primarily with oral estrogens (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Lipids'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Enhanced endothelial function, which may occur in young healthy women, but not older postmenopausal women with coronary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Improved insulin sensitivity, although data are inconsistent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examples of potential adverse effects include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in serum triglyceride concentrations with oral estrogens (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Lipids'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Prothrombotic effects including a reduction in serum fibrinogen, factor VII, and antithrombin III with oral estrogen (less affected by transdermal estrogen) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      An increase in hepatic synthesis of vascular inflammatory markers such as C-reactive protein (primarily oral preparations) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Effects of progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Synthetic progestins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    , the progestin used in the WHI and HERS trials described below, may negate some of the effects of estrogen on lipids and endothelial function [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. Natural progesterone has been less well studied, but does not appear to negate the effects of estrogen on serum lipids (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Lipids'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Both unopposed conjugated estrogen and combined conjugated estrogen-progestin therapy increase C-reactive protein (CRP) concentrations. In one study, the increase in CRP was positively or negatively correlated with IL-6 with combined estrogen-progestin therapy or unopposed estrogen, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/24\">",
"     24",
"    </a>",
"    ]. This suggests a noninflammatory pathway for stimulation of CRP with unopposed estrogen, but an inflammatory one when progestin is added.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beginning in the late 1980s, there was a shift from prescribing short-term estrogen therapy for postmenopausal women for symptoms to prescribing it long-term (more than five years) for prevention of disease, particularly CHD. This prevention strategy was based on over 30 observational studies, almost all of which demonstrated a striking protective effect of estrogen on the heart [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. In addition to the observational data, angiographic and autopsy studies suggested an antiatherogenic effect of estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, initial publications from the Women's Health Initiative (WHI) trial suggested that postmenopausal hormone therapy is not effective for primary prevention of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The WHI trial was a set of clinical trials, including two estrogen therapy trials, in healthy postmenopausal women aged 50 to 79 years.",
"   </p>",
"   <p>",
"    One of the trials (combined continuous estrogen-progestin regimen [conjugated estrogen 0.625 mg and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (MPA) 2.5",
"    <span class=\"nowrap\">",
"     mg/day]",
"    </span>",
"    versus placebo in over 16,000 women) was discontinued three years early due to an increased risk of breast cancer, stroke, CHD, and venous thromboembolism over an average follow-up of 5.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/14\">",
"     14",
"    </a>",
"    ]. Although there were significant benefits (reduction in risk of fractures and colon cancer), there was concern that the risks of estrogen-progestin therapy outweighed the benefits in some women.",
"   </p>",
"   <p>",
"    The WHI unopposed estrogen (conjugated estrogen 0.625 mg) versus placebo trial in nearly 11,000 women who had undergone hysterectomy (and therefore did not require a progestin) was also discontinued (one year early), due to an increased risk of stroke and a calculation that suggested no overall health benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Combined estrogen-progestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the initial reports from the WHI, the hazard ratio (HR) for CHD (nonfatal myocardial infarction or death due to CHD) in the overall cohort taking combined estrogen-progestin trial was 1.24 (95% CI 1.0-1.5) (",
"    <a class=\"graphic graphic_figure graphicRef76930 \" href=\"UTD.htm?5/38/5742\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/30\">",
"     30",
"    </a>",
"    ]. However, subsequent analysis suggests that the increased risk may be confined to older women (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Timing of exposure'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Other factors, including body mass index, presence of vasomotor symptoms, additional coronary risk factors (including diabetes, hypertension, family history, and smoking),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or statin use, and C-reactive protein were not significantly related to CHD risk with HT. Biochemical predictors of risk and the possible effect of age and years from menopause are discussed below (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Predictors of risk'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Timing of exposure'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    There was a significant increase in stroke and venous thromboembolic events (VTE) (",
"    <a class=\"graphic graphic_figure graphicRef74704 \" href=\"UTD.htm?15/51/16190\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef64173 \" href=\"UTD.htm?11/0/11277\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Stroke'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Venous thromboembolism'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The risk of breast cancer was increased, while the risk of fracture and colon cancer was decreased, as discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absolute risk of any adverse event (breast cancer, CHD, stroke, or venous thromboembolism) occurring in an individual was",
"    <strong>",
"     extremely low",
"    </strong>",
"    (19 additional events per year per 10,000 women with HT versus placebo).",
"   </p>",
"   <p>",
"    A second, multicenter trial (WISDOM), similar in design and patient population to the WHI, enrolled 5692 women, but was discontinued after the publication of the early results from the WHI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/31\">",
"     31",
"    </a>",
"    ]. However, after a median follow-up of 12 months, an excess risk of CHD events and venous thromboembolism, but not stroke, was observed in the overall cohort receiving combined estrogen-progestin group compared with placebo. There were too few events to analyze risk based upon patient age or years from menopause (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Timing of exposure'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Unopposed estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the excess overall CHD risk observed in the combined estrogen-progestin trial, the WHI reported a hazard ratio (HR) for CHD of 0.95 (95% CI 0.70-1.16) in the unopposed estrogen trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/15\">",
"     15",
"    </a>",
"    ]. There was a suggestion of a protective effect in the younger women (ages 50 to 59) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Timing of exposure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The discrepancies in CHD risk between the unopposed estrogen and the combined estrogen-progestin trials suggest that the progestin played an important role in the increased CHD risk seen with combined therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other effects of unopposed estrogen included an increase in stroke and venous thromboembolic complications (similar to that seen with combined therapy). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Stroke'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Venous thromboembolism'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Predictors of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Predictors of CHD risk were subsequently examined in a nested, case-control study of 359 CHD cases and 820 controls from the combined trials with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After adjustment for the presence of cardiovascular disease, statin therapy and diabetes mellitus, baseline levels of several thrombotic, inflammatory, and lipid biomarkers (including factor VIII, D-dimer, interleukin-6, LDL cholesterol, HDL cholesterol, and triglycerides) were associated with CHD events.",
"     </li>",
"     <li>",
"      Only LDL cholesterol modified the effect of treatment, as women with high baseline LDL cholesterol concentrations were at greater risk for CHD if given postmenopausal hormone therapy.",
"     </li>",
"     <li>",
"      Postmenopausal hormone therapy affected levels of several biomarkers (increases in C-reactive protein, HDL, triglycerides, and decreases in LDL), but the changes were not associated with a change in CHD risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Timing of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a primate model [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/35\">",
"     35",
"    </a>",
"    ], two observational studies in postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], a meta-analysis of clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/38\">",
"     38",
"    </a>",
"    ], a coronary angiographic study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/39\">",
"     39",
"    </a>",
"    ], and secondary analyses from the WHI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/17,32\">",
"     17,32",
"    </a>",
"    ] all suggest that the timing of exposure to postmenopausal estrogen therapy is an important factor in determining subsequent cardiovascular risk. This has been referred to as the \"timing hypothesis.\"",
"   </p>",
"   <p>",
"    The WHI population was an older population (mean age 63 years) when compared with most observational studies; the older age at the time of postmenopausal hormone therapy initiation would be expected to be associated with more subclinical atherosclerosis at baseline, with advanced or complex atherosclerotic lesions that may be more susceptible to the prothrombotic, proinflammatory effects of estrogen. In contrast, women with presumably normal endothelium who start estrogen soon after menopause may derive cardiovascular benefit because advanced, unstable atherosclerotic plaques have not yet formed. This hypothesis is supported by the following observations from the WHI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subgroup analyses based upon the original dataset suggested a nonsignificant reduction in CHD risk in women ages 50 to 59 in the unopposed estrogen trial [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/32\">",
"       32",
"      </a>",
"      ]. In the same group, coronary revascularization was significantly less frequent in the estrogen compared with placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent combined analysis of the two WHI hormone therapy trials that included 13 additional cases of CHD, women who started postmenopausal hormone therapy closer to menopause appeared to have a lower risk of CHD compared with women further from menopause [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the age groups of 50 to 59 years, 60 to 69 years, and 70 to 79 years, the hazard ratios for CHD were 0.93, 0.98, and 1.26, with absolute excess risks of -2, -1, and +19 per 10,000 person-years. This trend did not reach statistical significance.",
"     </li>",
"     <li>",
"      For women &lt;10, 10 to 19, or &ge;20 years since menopause, hazard ratios for CHD were 0.76, 1.10, and 1.28, respectively, with absolute excess risks of -6, +4, and +17 per 10,000 person-years (p for trend = 0.02).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A possible reduction in total mortality was seen in younger women; HR for ages 50 to 59, 60 to 69, and 70 to 79 years were 0.70, 1.05, and 1.14, respectively.",
"   </p>",
"   <p>",
"    In the WHI-Coronary Artery Calcium Study, an ancillary substudy performed in younger women ages 50 to 59, evidence of subclinical atherosclerosis, as measured by coronary-artery calcium scores on electron beam CT, was lower in those assigned to unopposed estrogen when compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the Women&rsquo;s Ischemia Syndrome Evaluation Study (WISE) of 654 postmenopausal women undergoing coronary angiography for suspected ischemia, ever users of hormone therapy had a lower prevalence of coronary artery disease (CAD) compared with never users (age adjusted OR 0.41; 95% CI 0.28-0.69) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/39\">",
"     39",
"    </a>",
"    ]. Women with natural (but not surgical) menopause who had started their hormone therapy before age 55 years had less severe CAD than never users. In contrast, the severity of CAD in women who started hormone therapy after age 55 was similar to that for never users.",
"   </p>",
"   <p>",
"    Most now agree that age or time since menopause influences the risk-benefit ratio associated with hormone therapy, most importantly with respect to coronary heart disease. In spite of these reassuring data, postmenopausal hormone therapy is indicated only for management of menopausal symptoms in younger women, not for primary prevention of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/41\">",
"     41",
"    </a>",
"    ]. For women who are recently menopausal, the improvement in vasomotor symptoms must still be weighed against other potential risks of treatment, but coronary disease is not usually a major factor in the equation.",
"   </p>",
"   <p>",
"    A clinical trial is in progress to examine whether earlier initiation of estrogen therapy is associated with a decreased risk of CHD (the KEEPS trial [Kronos Early Estrogen Prevention Study]). This trial is described in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other specific recommendations regarding estrogen therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Type of estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of estrogen may also be important in determining risk. Both the WHI and the HERS trials employed conjugated equine estrogen-progestin therapy (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Secondary prevention'",
"    </a>",
"    below). In comparison, the Estrogen in Prevention of Atherosclerosis Trial (EPAT) randomly assigned 222 healthy, postmenopausal women to unopposed oral 17-beta-estradiol (1",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/28\">",
"     28",
"    </a>",
"    ]. Estradiol therapy was associated with a decreased risk of atherosclerosis (as measured by carotid artery intima-media thickness [CIMIT]). Higher serum concentrations of sex hormone binding globulin (SHBG) and estrogen were inversely correlated with CIMIT progression after controlling for age and body mass index. The association was partially mediated by beneficial effects on lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, 17-beta-estradiol may not be effective when given with a progestin. This was illustrated in a trial of 321 postmenopausal women in whom the combination of 17-beta-estradiol (1",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    with a progestin (gestodene) produced no reduction in intima-medial progression after one year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from one population-based case-control study suggests a possible lower risk of MI and stroke with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/39/29303?source=see_link\">",
"     esterified estrogens",
"    </a>",
"    when compared with conjugated estrogens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/44\">",
"     44",
"    </a>",
"    ]. This observation has not been confirmed in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a number observational and angiographic studies had strongly suggested that women with CHD derive the greatest benefit for prevention of subsequent coronary events and survival [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/45-49\">",
"     45-49",
"    </a>",
"    ], clinical trial data have",
"    <strong>",
"     not",
"    </strong>",
"    confirmed these benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/1-5,7-10,50\">",
"     1-5,7-10,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The HERS-I trial (Heart and",
"    <span class=\"nowrap\">",
"     Estrogen/Progestin",
"    </span>",
"    Replacement Study) was a randomized, blinded, placebo-controlled secondary prevention trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/1\">",
"     1",
"    </a>",
"    ]. In this study, 2763 postmenopausal women under the age of 80 with a history of CHD were randomly assigned to receive the same regimen used in the WHI (0.625 mg of conjugated equine estrogen plus 2.5 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    daily) or placebo for an average of four years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/1\">",
"     1",
"    </a>",
"    ]. Findings from this trial included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference between the two groups in the incidence of CHD events despite a net 11 percent decrease in serum low density lipoprotein (LDL) cholesterol concentrations and 10 percent increase in serum high density lipoprotein (HDL) cholesterol concentrations in the hormone cohort.",
"     </li>",
"     <li>",
"      More CHD events occurred in the hormone group during the first year of therapy, with a subsequent trend toward a reduction in risk in years four and five.",
"     </li>",
"     <li>",
"      A post-hoc analysis of HERS-I did not identify any subgroup in which estrogen therapy was beneficial or harmful [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/7\">",
"       7",
"      </a>",
"      ]. However, polymorphisms of platelet genes were reported to be predictors of CHD risk in a subsequent report [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another post hoc analysis, combined oral estrogen and progestin therapy appeared to reduce the risk of developing type 2 diabetes mellitus. However, this effect is insufficient to recommend HT as a diabetes prevention strategy in women with CHD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"       \"Postmenopausal hormone therapy: Benefits and risks\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The HERS-II trial was a continuation of HERS-I in which 93 percent of HERS-I participants enrolled in an unblinded follow-up study for 2.7 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lower rates of CHD events in the estrogen&ndash;progestin group in years four and five did",
"      <strong>",
"       not",
"      </strong>",
"      persist in the follow-up years.",
"     </li>",
"     <li>",
"      Over the 6.8 years of HERS-I and HERS-II, continuous estrogen-progestin therapy did not reduce the risk of CHD events in women with established CHD (HR 0.99, 95% CI 0.84-1.14) (",
"      <a class=\"graphic graphic_figure graphicRef62591 \" href=\"UTD.htm?22/34/23085\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      There were no differences in women taking statins or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other data have confirmed the lack of efficacy of estrogen-progestin therapy for secondary prevention of CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/4,5,8,9,14\">",
"     4,5,8,9,14",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a subgroup analysis of women with preexisting CHD in the WHI combined estrogen-progestin trial, subsequent risk of a CHD event was increased (HR 1.44, 95% CI 0.77-2.70), although the number of women in this group was small [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/14,30\">",
"       14,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Women's Angiographic Vitamin and Estrogen (WAVE) Trial, combined estrogen-progestin therapy (the same regimen as HERS and WHI), was associated with a nonsignificant worsening of coronary stenosis on angiography [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/9\">",
"       9",
"      </a>",
"      ]. When patients with intercurrent death or myocardial infarction were included, a significant increase in coronary risk was seen. An antioxidant arm (vitamins C and E) of the trial also demonstrated possible harm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"       \"Nutritional antioxidants in coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Unopposed estrogen and type of estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from two trials suggest that neither unopposed estrogen nor a different type of orally administered estrogen is effective for secondary prevention of CHD, but an increase in CHD risk, as has been reported for combined estrogen-progestin therapy, has not been described.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the WHI trial of unopposed estrogen, a subgroup analysis of 441 women with preexisting CHD suggested that the effect of estrogen versus placebo on CHD risk was similar to that seen in women with no documented CHD (HR 1.04 and 0.91 for women with or without previous CHD, respectively). The discrepancies in CHD risk between the unopposed estrogen trial and the combined estrogen-progestin trial suggest that the progestin played an important role in the increased CHD risk seen with combined therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Esprit trial, there was no significant difference at two years between unopposed estradiol (estradiol valerate 2 mg) and placebo in the primary endpoint of reinfarction or cardiac death [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial (WELL-HART) randomly assigned 226 postmenopausal women with established CHD to oral micronized 17-beta estradiol (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      alone or with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (5 mg daily for 12 consecutive days each month), or to usual care (control group) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/50\">",
"       50",
"      </a>",
"      ]. After a median of 3.3 years of follow-up, estradiol either alone or with sequentially added medroxyprogesterone acetate had no significant effect on progression of atherosclerosis as measured by quantitative angiography (increases of 2.2, 1.2, and 1.9 percent in the unopposed estrogen, combined estrogen-progestin, and control groups, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Transdermal estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transdermal estrogen has more favorable effects than oral estrogen on markers for cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/48\">",
"     48",
"    </a>",
"    ], may be less thrombogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/52\">",
"     52",
"    </a>",
"    ], and may be associated with a lower risk of thromboembolism than oral estrogens. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Venous thromboembolism'",
"    </a>",
"    below.) However, there is no evidence to date that transdermal estrogen is safer for secondary prevention of CHD.",
"   </p>",
"   <p>",
"    In the Papworth trial, 255 postmenopausal women with ischemic heart disease were randomly assigned to transdermal preparations (estrogen alone or combined with progestin) or placebo. After an average of 31 months of follow-up, there was a nonsignificant increase in coronary disease-related events in the transdermal postmenopausal hormone therapy group when compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of epidemiologic studies of estrogen therapy and stroke risk are conflicting. The findings range from a significant reduction of risk in the National Health and Nutritional Examination Survey (RR 0.37 after adjusting for other risk factors) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/54\">",
"     54",
"    </a>",
"    ], to no effect in a large case-control study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/55\">",
"     55",
"    </a>",
"    ], to an increase only in the first six months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/56\">",
"     56",
"    </a>",
"    ], to a slight increase in stroke risk in the Nurses' Health Study (RR 1.35) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, clinical trial data suggest that oral estrogen therapy",
"    <strong>",
"     increases",
"    </strong>",
"    stroke risk:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the HERS-I trial of women with established CHD described above, there was a strong trend toward an increase in risk for fatal stroke (RR 1.61, 95% CI 0.97-3.55) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Women's Estrogen for Stroke Trial (WEST), a double-blind placebo-controlled trial in 664 postmenopausal women with established cerebrovascular disease, estrogen (oral estradiol 1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for an average of 2.8 years) had no effect on recurrent stroke or death (RR 1.0). Estrogen therapy did, however, increase the risk of fatal stroke (RR 2.9, 95% CI 0.9-9.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/58\">",
"       58",
"      </a>",
"      ]. In the WHI trial, a 31 percent increase in stroke risk was seen with combined estrogen-progestin use compared with placebo (intention-to-treat HR 1.31, 95% CI 1.02-1.68). The hazard ratios for ischemic and hemorrhagic stroke were 1.44 (95% CI 1.09-1.90) and 0.82 (95% CI 0.43-1.56), respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/59\">",
"       59",
"      </a>",
"      ]. The increased risk became evident between one and two years after randomization (",
"      <a class=\"graphic graphic_figure graphicRef74704 \" href=\"UTD.htm?15/51/16190\">",
"       figure 2",
"      </a>",
"      ) and was seen in all age groups. In the WHI trial of unopposed estrogen, stroke risk was significantly increased with CEE versus placebo (HR 1.3, 95% CI 1.1-1.77) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/15,60\">",
"       15,60",
"      </a>",
"      ]. The excess risk of stroke was similar in women with or without previous stroke (HR 1.67 and 1.39, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/15\">",
"       15",
"      </a>",
"      ]. In other subgroup analyses, the excess risk of stroke appeared to be present in women of all ages, including younger and recently menopausal women [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the follow-up analysis that combined the two WHI postmenopausal hormone therapy trials (including 13 additional cases of stroke), stroke risk did not vary significantly by age or time since menopause (HR 1.32, 95% CI 1.12-1.56) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/17\">",
"       17",
"      </a>",
"      ]. However, the low baseline risk and modest HR in women ages 50 to 59 years resulted in no absolute excess risk in stroke. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Timing of exposure'",
"      </a>",
"      above.) Similar results were reported by the Nurse&rsquo;s Health Study [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of randomized trials (including HERS, WEST, and WHI), oral estrogen therapy (with or without progestin) was associated with an increase in ischemic stroke, but not hemorrhagic stroke or transient ischemic attacks (OR 1.29, 95% CI 1.06-1.56 for ischemic stroke) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/62\">",
"       62",
"      </a>",
"      ]. In addition, among women who had a stroke, there was a trend towards more fatal stroke in those who were taking oral estrogen therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Transdermal versus oral route",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-dose transdermal estrogen therapy does not appear to increase the risk of stroke in postmenopausal women. This was illustrated in a population-based nested case-control study that included approximately 16,000 cases of stroke and 60,000 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/63\">",
"     63",
"    </a>",
"    ]. The overall rate of stroke in the cohort was 2.85 per 1000 per year. The risk of stroke was not increased in low dose (&le;50 mcg patch) transdermal estrogen users compared with nonusers (rate ratio 0.81, 95% CI 0.62-1.05), but was increased with higher transdermal doses (&gt;50 mcg patch; 1.89, 95% CI 1.15-3.11). Current users of both low dose (&le;0.625 mg equine estrogens or &le;2 mg estradiol) and high dose (&gt;0.625 mg equine estrogens or &gt;2 mg estradiol) oral hormone therapy had a higher rate of stroke than nonusers (rate ratio 1.28, 95% CI 1.15-1.42).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PERIPHERAL ARTERY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen therapy does not appear to confer protection against peripheral artery disease. Although a population-based study suggested that estrogen therapy for one year or more was associated with a decreased risk of peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/64\">",
"     64",
"    </a>",
"    ], this was not confirmed in the HERS-I trial described above in which therapy with estrogen and progestin did not significantly reduce the incidence of peripheral arterial events, defined as carotid disease, abdominal aortic aneurysm, and lower extremity arterial disease (relative hazard 0.87 compared with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the WHI, which used a similar case definition for peripheral artery disease, combined conjugated estrogen-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    therapy neither favorably nor unfavorably affected risk of peripheral arterial events (HR 0.89, 95% CI 0.63-1.25) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/66\">",
"     66",
"    </a>",
"    ]. Data from the WHI unopposed estrogen trial are not yet available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     VENOUS THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies, a small trial, and a meta-analysis published before the WHI evaluated the association between estrogen therapy and venous thromboembolism (VTE) and suggested that HT caused approximately a twofold increase in VTE risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/67-72\">",
"     67-72",
"    </a>",
"    ], particularly in women with the factor V Leiden mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. A limitation in interpreting these reports is that they had significant design limitations (eg, inconsistent or unreliable methods for diagnosing VTE, widely varying patient ages, lack of adjustment for confounding factors, and marked variations in estrogen preparation and dosing).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Women's Health Initiative",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most definitive clinical data come from the WHI trial and are consistent with previous estimates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/76\">",
"     76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VTE risk was increased approximately twofold in the estrogen-progestin group compared with placebo (HR 2.06, unadjusted 95% CI 1.6-2.7). The increase in risk was similar for both deep vein thrombosis and pulmonary embolism, and was particularly high in women with a previous event (HR 3.9).",
"     </li>",
"     <li>",
"      The rates of VTE were 3.5 and 1.7 per 1000 person-years in the estrogen-progestin and placebo groups, respectively.",
"     </li>",
"     <li>",
"      The increased risk was highest in the first year of therapy, but persisted for the five years of follow-up (",
"      <a class=\"graphic graphic_figure graphicRef64173 \" href=\"UTD.htm?11/0/11277\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Both older age and obesity were associated with additional excess risk, but the risk was not significantly altered by smoking,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , or statin use.",
"     </li>",
"     <li>",
"      The presence of factor V Leiden further increased the risk of VTE in women receiving estrogen-progestin therapy compared with placebo (HR 6.7, 95% CI 3.1-14.5). Other genetic variants did not modify the risk of VTE with estrogen therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"       \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    VTE risk in the WHI was also increased with unopposed CEE when compared with placebo (HR 1.32, 95% CI 0.99-1.75) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/77\">",
"     77",
"    </a>",
"    ], which was lower than that seen in the combined estrogen-progestin trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar twofold increase in VTE risk was noted in the HERS trials. There was a suggestion that risk was slightly decreased in women who also took daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (HR 1.68 and 4.23, unadjusted 95% CI 0.96-2.92 and 1.41-12.7 for aspirin versus no aspirin therapy, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;One possible mechanism for the increased VTE risk is an increase in activated protein C resistance that has been reported with both unopposed estradiol and combined estradiol-progestin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Type of oral estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of oral estrogen used may affect VTE risk. As an example, in a population-based, case-control study of peri- and postmenopausal women ages 30 to 89 years (586 with venous thrombosis and 2268 healthy controls), women taking conjugated estrogens, but not esterified (plant-derived) estrogens, were at increased risk of VTE when compared to non-estrogen users (OR 1.7, 95% CI 1.2-2.2 and 0.9, 95% CI 0.7-1.2, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/79\">",
"     79",
"    </a>",
"    ]. Among estrogen users, the risk was higher when combined with progestin compared with unopposed estrogen use (OR 1.6, 95% CI 1.1-2.3).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Route of estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transdermal estrogen, which has little effect on hemostasis, may be associated with a lower VTE risk. This was illustrated in a multicenter case-control study in postmenopausal women that included 271 cases of VTE and 610 controls matched for age, center, and admission date [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/80\">",
"     80",
"    </a>",
"    ]. The odds ratios for VTE in current users of oral or transdermal estrogen compared to nonusers were 4.2 (95% CI 1.5-11.6) and 0.9 (95% CI 0.4-2.1), respectively. In a prospective cohort study from the same investigators, neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    nor micronized progesterone appeared to be associated with VTE risk, while nonpregnane progestins (nomegestrol acetate and promegestone) were associated with excess risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis that included the case-control study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/80\">",
"     80",
"    </a>",
"    ], as well as three others, no excess risk of venous thromboembolism was observed in women taking transdermal estrogen (OR 1.2 [95% CI 0.1-1.7]), even in those with prothrombotic mutations or high body mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/82\">",
"     82",
"    </a>",
"    ]. Similar results were reported in a population-based cohort study published after the meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/83\">",
"     83",
"    </a>",
"    ]. The cohort included 23,505 cases of VTE matched with 231,562 controls. The risk of VTE was not increased with transdermal estrogen alone (rate ratio [RR] 1.01, 95% CI 0.89-1.16) or combined with progestin (RR 0.96, 95% CI 0.77-1.20). In contrast, VTE risk was increased with current use of oral estrogen alone (RR 1.49, 95% CI 1.37-1.63), estrogen combined with a progestin (RR 1.54, 95% CI 1.44-1.65), and increased with estrogen dose. Risks were highest during the first year, and disappeared four months after stopping therapy. There are currently no clinical trial data comparing the effect of transdermal and oral estrogen preparations on VTE risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prothrombotic mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the WHI, the presence of factor V Leiden, but not other prothrombotic mutations, further increased the risk of VTE in women receiving estrogen-progestin therapy compared with placebo. In a case-control study of 235 postmenopausal women with documented VTE and 554 control subjects without VTE, transdermal estrogen, unlike oral estrogen, did not confer additional risk in women who carried a prothrombotic mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher doses of estrogen, such as those used in oral contraceptives, may be associated with higher VTE risks when compared with postmenopausal hormone therapy doses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/85\">",
"     85",
"    </a>",
"    ]. In addition, low-dose postmenopausal hormone therapy, such as 0.3 mg conjugated estrogen, has fewer effects on coagulation and inflammatory markers than standard dose therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, there is a small but significant increase in risk of thromboembolism with current HT, but for healthy postmenopausal women, the absolute risk is extremely low. Older age, obesity, and the presence of factor V Leiden may be associated with additional excess risk, but the risk does not appear to be altered by smoking,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , or statin use.",
"   </p>",
"   <p>",
"    Although thromboembolic risk may be affected by the type and dose of estrogen and the route of its administration, data are not yet sufficient to recommend one type of estrogen over another. Recommendations for postmenopausal hormone therapy use are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"     \"Treatment of menopausal symptoms with hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the impact of estrogen therapy on mortality are conflicting, with observational studies reporting a reduction in mortality, while the HERS trial found no effect. A meta-analysis of available trials of postmenopausal estrogen therapy concluded that overall mortality was reduced for users under age 60 years, but not over 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/87\">",
"     87",
"    </a>",
"    ]. As noted above, follow-up analysis combining both WHI trials suggested a possible reduction in mortality with postmenopausal hormone therapy in younger postmenopausal women. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Timing of exposure'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     LIPIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral estrogen has a proven beneficial effect on serum lipid concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/88-90\">",
"     88-90",
"    </a>",
"    ], which can be negated in part by progestin therapy. One study, for example, randomly assigned women to treatment with 0.625 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/23/35184?source=see_link\">",
"     conjugated equine estrogens",
"    </a>",
"    (Premarin) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/88\">",
"     88",
"    </a>",
"    ]. Estrogen had the following effects on mean serum lipid concentrations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      LDL cholesterol fell by 15 percent",
"     </li>",
"     <li>",
"      HDL cholesterol increased by 16 percent",
"     </li>",
"     <li>",
"      Triglycerides increased by 24 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These effects appear to be independent of age, with similar results noted in women over age 74 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/90\">",
"     90",
"    </a>",
"    ]. Estrogen may also lower lipoprotein(a) [Lp(a)] levels by approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/89,91,92\">",
"     89,91,92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"     \"Lipoprotein(a) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of oral estradiol (1",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is similar to that of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/23/35184?source=see_link\">",
"     conjugated equine estrogens",
"    </a>",
"    (Premarin), while",
"    <strong>",
"     transdermal",
"    </strong>",
"    estradiol has a lesser effect than oral estrogen preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/88\">",
"     88",
"    </a>",
"    ]. The lack of effect with transdermal estrogen presumably reflects decreased exposure of the liver to estrogen (compared with oral therapy) due to avoidance of the first-pass effect on the liver. However, another study which treated women for much longer with varying doses of transdermal estradiol found that the serum total and LDL cholesterol concentrations decreased in a dose-dependent fashion after two years of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymorphisms of the estrogen receptor-alpha (ER-alpha) gene may be associated with an augmented HDL cholesterol rise with estrogen therapy. In a study of 309 postmenopausal women with coronary disease participating in the Estrogen Replacement and Atherosclerosis trial (ERA) (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Secondary prevention'",
"    </a>",
"    above), those with an IVS1-401",
"    <span class=\"nowrap\">",
"     C/C",
"    </span>",
"    genotype had a more significant increase in serum HDL cholesterol (limited to subfraction 3) with estrogen than other women (13.1 versus 6.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [0.34 versus 0.16",
"    <span class=\"nowrap\">",
"     mmol/L],",
"    </span>",
"    respectively, p = 0.04) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/94\">",
"     94",
"    </a>",
"    ]. There were similar changes in several closely related genotypes and in women receiving either unopposed estrogen or combined estrogen-progestin therapy. Thus, certain ER-alpha polymorphisms may predict the serum HDL cholesterol response to estrogen therapy, but the clinical consequences of this effect are unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=see_link\">",
"     \"HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Women with hyperlipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations were made in healthy postmenopausal women. The effect of hormone replacement in women with hypercholesterolemia (baseline serum cholesterol concentration 305",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [7.9",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    was evaluated in a study of 58 postmenopausal women randomly assigned to 1.25 mg conjugated estrogen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in a crossover design (with an eight-week washout in between) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/89\">",
"     89",
"    </a>",
"    ]. Compared with simvastatin, postmenopausal hormone therapy produced the following changes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A smaller decrease in total cholesterol &mdash; 14 versus 26 percent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"     </li>",
"     <li>",
"      A smaller decrease in LDL-cholesterol &mdash; 24 versus 36 percent",
"     </li>",
"     <li>",
"      A similar elevation in HDL-cholesterol &mdash; 7 percent",
"     </li>",
"     <li>",
"      A reduction in Lp(a) &mdash; 27 percent versus no change with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"     </li>",
"     <li>",
"      An increase in triglycerides &mdash; 29 percent versus 14 percent decrease with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One limitation of this trial is that the dose of conjugated estrogen used (1.25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    was twice the usual replacement dose. Nevertheless, the percentage changes in lipid values are similar to those seen in the other studies of postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/88,91\">",
"     88,91",
"    </a>",
"    ]. Furthermore, another trial of hypercholesterolemic postmenopausal women showed similar results when estrogen was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     pravastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/95\">",
"     95",
"    </a>",
"    ]. In terms of serum LDL cholesterol, combination therapy appears to be better than estrogen alone but not better than a statin alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/95,96\">",
"     95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperlipidemic women who are receiving combined cyclic estrogen-progestin therapy may have significant fluctuations in lipoprotein concentrations depending upon the phase of the cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/97\">",
"     97",
"    </a>",
"    ]. Thus, when considering lipid-lowering therapy, it is important to determine if this fluctuation is occurring in an individual woman and, if so, to consistently measure lipoproteins during the same hormonal phase (preferably the one which demonstrates the poorest results).",
"   </p>",
"   <p>",
"    Because of a presumed cardioprotective effect and the above observations, estrogen was recommended in the past as first-line therapy for hyperlipidemia in women with CHD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/98\">",
"     98",
"    </a>",
"    ]. However, this recommendation is no longer applicable because of the lack of cardiovascular protection noted in the WHI and HERS trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/1,2,14,99\">",
"     1,2,14,99",
"    </a>",
"    ]. Statins should be the first choice for lipid-lowering therapy in most women with CHD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Effect of progestins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A progestin is routinely administered with estrogen in women with an intact uterus to diminish the risk of endometrial hyperplasia cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Progestins",
"    <strong>",
"     attenuate",
"    </strong>",
"    some of the beneficial lipid effects of estrogen. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (MPA) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    decrease serum HDL cholesterol by 8 to 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/100\">",
"     100",
"    </a>",
"    ]. However, the net effect of oral estrogen plus MPA on serum HDL cholesterol is still beneficial, although not as beneficial as when estrogen is given alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. Furthermore, addition of a progestin has little effect on the estrogen-induced reduction in serum LDL cholesterol (",
"    <a class=\"graphic graphic_figure graphicRef64173 \" href=\"UTD.htm?11/0/11277\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/101-103\">",
"     101-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The progestin in both the WHI and HERS trials was MPA (2.5",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    In the WHI, serum LDL cholesterol concentrations decreased, while serum HDL cholesterol and triglyceride concentrations increased more in the HT group than placebo (-12.7, 7.3, and 6.9 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the WHI trial of unopposed estrogen (conjugated estrogen 0.625",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    the changes in serum total, LDL, and HDL cholesterol concentrations were -2.3, -13.7, and +15.1 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/15\">",
"     15",
"    </a>",
"    ]. Serum triglyceride concentrations increased by 25 percent in the estrogen group. Further details of the WHI trials are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Type of progestin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of progestin appears to be important with regard to serum HDL cholesterol. MPA lowers serum HDL cholesterol much less than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"     levonorgestrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/100\">",
"     100",
"    </a>",
"    ], while oral micronized progesterone seems to have little or",
"    <strong>",
"     no adverse effect",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/100,101,104\">",
"     100,101,104",
"    </a>",
"    ]. This issue was best addressed in the Postmenopausal",
"    <span class=\"nowrap\">",
"     Estrogen/Progestin",
"    </span>",
"    Interventions (PEPI) Trial in which 875 women were randomly assigned to placebo or one of four treatment arms consisting of conjugated estrogen (0.625",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    alone or with cyclic or continuous medroxyprogesterone or cyclic micronized progesterone (200",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 12 days per month) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/101\">",
"     101",
"    </a>",
"    ]. Serum HDL cholesterol concentrations rose by 5.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.14",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    with estrogen alone, 4.1",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.11",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    with estrogen plus micronized progesterone, and only 1.2 to 1.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.03 to 0.04",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    with medroxyprogesterone (",
"    <a class=\"graphic graphic_figure graphicRef65403 \" href=\"UTD.htm?14/24/14734\">",
"     figure 5",
"    </a>",
"    ). Estrogen, with or without progestin, reduced plasma Lp(a) levels by 17 to 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Continuous versus cyclic combined regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis evaluated the results in over 300 women from six randomized, double-blind clinical trials comparing continuous estrogen-progestin therapy (0.625 mg conjugated estrogens and 2.5 mg medroxyprogesterone, the most commonly prescribed regimen in the United States) and cyclic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/106\">",
"     106",
"    </a>",
"    ]. Overall, the effects were equivalent with the two regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in serum total cholesterol concentration of 14 to 15",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.36 to 0.39",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      A reduction in serum LDL cholesterol concentration of 17 to 18",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.44 to 0.46",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      An elevation in serum HDL cholesterol concentration of 2 to 3",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.05 to 0.08",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Effect on triglycerides",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potentially negative effect of estrogen therapy is its tendency to raise triglyceride concentrations by as much as 24 to 29 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/88,89\">",
"     88,89",
"    </a>",
"    ], although a smaller increase of 6.9 percent was noted in the WHI combined estrogen-progestin, but not the unopposed estrogen trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .) Transdermal estrogen preparations do not raise triglycerides concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     BLOOD PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Replacement doses of estrogen have little effect on blood pressure. The WHI combined estrogen-progestin trial noted only a small increase (1.5 mmHg) in systolic pressure compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/14\">",
"     14",
"    </a>",
"    ]; a similar difference between the hormone and placebo groups of 1.1 mmHg was noted in the WHI trial of unopposed estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, the PEPI trial found that estrogen, with or without progestins, did not affect blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/101\">",
"     101",
"    </a>",
"    ]. These findings are in contrast to the frequent elevation in blood pressure seen when higher doses of estrogen are given for oral contraception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37859?source=see_link\">",
"     \"Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     BODY WEIGHT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports suggest that the effect of estrogen on body weight is either neutral or slightly beneficial. A prospective, nonrandomized study of the Rancho Bernardo cohort of 651 women followed for 15 years found that estrogen therapy had no effect on body weight [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/107\">",
"     107",
"    </a>",
"    ], while the randomized, placebo-controlled PEPI trial found the women treated with estrogen gained significantly less weight than those treated with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/101\">",
"     101",
"    </a>",
"    ]. A large osteoporosis prevention trial also reported that postmenopausal women receiving HT gained less weight than women receiving placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Body fat distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estrogen therapy also has a neutral or favorable effect on body fat distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/107,109\">",
"     107,109",
"    </a>",
"    ]. The pattern of regional fat distribution plays an important additional role in the excess death associated with obesity. Abdominal obesity (also called upper body, male-type, android, or visceral obesity) is associated with an increased risk of hypertension, diabetes, and dyslipidemia compared with female-type or gynoid obesity, in which the excess weight accumulates in the femoral and gluteal regions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Rancho Bernardo cohort of 651 women found that body fat distribution was similar in women who did or did not take estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/36/29258/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=see_link\">",
"       \"Patient information: Menopause (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/59/26546?source=see_link\">",
"       \"Patient information: Menopause (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"       \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102371434\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although initial publications from the Women&rsquo;s Health Initiative reported an excess risk of CHD with combined estrogen-progestin therapy, secondary analyses from the WHI data from a primate model, two observational studies in postmenopausal women, a meta-analysis of clinical trials, and a coronary angiographic study all suggest that the excess CHD risk appears to be confined to older postmenopausal women or those who are &gt;10 years postmenopause. This has been referred to as the \"timing hypothesis.\" (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Timing of exposure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a small but significant increase in risk of thromboembolism with current HT, but for healthy postmenopausal women, the absolute risk is extremely low. Older age, obesity, and the presence of factor V Leiden may be associated with additional excess risk. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Venous thromboembolism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a combined analysis of the two WHI postmenopausal hormone therapy trials, an increased risk of stroke was observed, that did not vary significantly by age or time since menopause (HR 1.32, 95% CI 1.12-1.56). However, the low baseline risk and modest HR in women ages 50 to 59 years resulted in no absolute excess risk in stroke. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of menopausal symptoms with hormone therapy is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=see_link\">",
"       \"Treatment of menopausal symptoms with hormone therapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=see_link\">",
"       \"Menopausal hot flashes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/1\">",
"      Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998; 280:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/2\">",
"      Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/3\">",
"      Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/4\">",
"      Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/5\">",
"      Alexander KP, Newby LK, Hellkamp AS, et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol 2001; 38:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/6\">",
"      Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002; 137:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/7\">",
"      Furberg CD, Vittinghoff E, Davidson M, et al. Subgroup interactions in the Heart and Estrogen/Progestin Replacement Study: lessons learned. Circulation 2002; 105:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/8\">",
"      Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study. a prospective, observational study. Ann Intern Med 2001; 135:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/9\">",
"      Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002; 288:2432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/10\">",
"      Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002; 360:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/11\">",
"      Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG 2006; 113:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/12\">",
"      Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005; 162:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/13\">",
"      Tannen RL, Weiner MG, Xie D, Barnhart K. A simulation using data from a primary care practice database closely replicated the women's health initiative trial. J Clin Epidemiol 2007; 60:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/14\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/15\">",
"      Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/16\">",
"      Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006; 163:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/17\">",
"      Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/18\">",
"      Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 2004; 304:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/19\">",
"      Rosano GM, Vitale C, Fini M. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Ann N Y Acad Sci 2006; 1092:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/20\">",
"      Yeboah J, Reboussin DM, Waters D, et al. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J 2007; 153:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/21\">",
"      Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Thromb Haemost 2007; 97:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/22\">",
"      Sumino H, Ichikawa S, Kasama S, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006; 189:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/23\">",
"      Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001; 104:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/24\">",
"      Reuben DB, Palla SL, Hu P, et al. Progestins affect mechanism of estrogen-induced C-reactive protein stimulation. Am J Med 2006; 119:167.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/25\">",
"      Manson JE, Martin KA. Clinical practice. Postmenopausal hormone-replacement therapy. N Engl J Med 2001; 345:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/26\">",
"      Grodstein F, Manson JE, Colditz GA, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/27\">",
"      Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/28\">",
"      Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 135:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/29\">",
"      Christian RC, Harrington S, Edwards WD, et al. Estrogen status correlates with the calcium content of coronary atherosclerotic plaques in women. J Clin Endocrinol Metab 2002; 87:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/30\">",
"      Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/31\">",
"      Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007; 335:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/32\">",
"      Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006; 166:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/33\">",
"      Hulley SB, Grady D. The WHI estrogen-alone trial--do things look any better? JAMA 2004; 291:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/34\">",
"      Rossouw JE, Cushman M, Greenland P, et al. Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy. Arch Intern Med 2008; 168:2245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/35\">",
"      Mikkola TS, Clarkson TB. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc Res 2002; 53:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/36\">",
"      Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt) 2006; 15:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/37\">",
"      Stram DO, Liu Y, Henderson KD, et al. Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause 2011; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/38\">",
"      Salpeter SR, Walsh JM, Greyber E, Salpeter EE. Brief report: Coronary heart disease events associated with hormone therapy in younger and older women. A meta-analysis. J Gen Intern Med 2006; 21:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/39\">",
"      Shufelt CL, Johnson BD, Berga SL, et al. Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Menopause 2011; 18:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/40\">",
"      Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007; 356:2591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/41\">",
"      Manson JE, Bassuk SS. Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause? Am J Epidemiol 2007; 166:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/42\">",
"      Karim R, Hodis HN, Stanczyk FZ, et al. Relationship between serum levels of sex hormones and progression of subclinical atherosclerosis in postmenopausal women. J Clin Endocrinol Metab 2008; 93:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/43\">",
"      Angerer P, St&ouml;rk S, Kothny W, et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis : a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001; 21:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/44\">",
"      Lemaitre RN, Weiss NS, Smith NL, et al. Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch Intern Med 2006; 166:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/45\">",
"      O'Keefe JH Jr, Kim SC, Hall RR, et al. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/46\">",
"      Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997; 79:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/47\">",
"      O'Brien JE, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996; 28:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/48\">",
"      Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990; 150:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/49\">",
"      Shlipak MG, Angeja BG, Go AS, et al. Hormone therapy and in-hospital survival after myocardial infarction in postmenopausal women. Circulation 2001; 104:2300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/50\">",
"      Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003; 349:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/51\">",
"      Bray PF, Howard TD, Vittinghoff E, et al. Effect of genetic variations in platelet glycoproteins Ibalpha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood 2007; 109:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/52\">",
"      Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17:3071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/53\">",
"      Clarke SC, Kelleher J, Lloyd-Jones H, et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. BJOG 2002; 109:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/54\">",
"      Finucane FF, Madans JH, Bush TL, et al. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med 1993; 153:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/55\">",
"      Angeja BG, Shlipak MG, Go AS, et al. Hormone therapy and the risk of stroke after acute myocardial infarction in postmenopausal women. J Am Coll Cardiol 2001; 38:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/56\">",
"      Lemaitre RN, Heckbert SR, Psaty BM, et al. Hormone replacement therapy and associated risk of stroke in postmenopausal women. Arch Intern Med 2002; 162:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/57\">",
"      Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001; 103:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/58\">",
"      Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001; 345:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/59\">",
"      Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003; 289:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/60\">",
"      Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006; 113:2425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/61\">",
"      Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008; 168:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/62\">",
"      Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/63\">",
"      Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010; 340:c2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/64\">",
"      Westendorp IC, in't Veld BA, Grobbee DE, et al. Hormone replacement therapy and peripheral arterial disease: the Rotterdam study. Arch Intern Med 2000; 160:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/65\">",
"      Hsia J, Simon JA, Lin F, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation 2000; 102:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/66\">",
"      Hsia J, Criqui MH, Rodabough RJ, et al. Estrogen plus progestin and the risk of peripheral arterial disease: the Women's Health Initiative. Circulation 2004; 109:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/67\">",
"      Jick H, Derby LE, Myers MW, et al. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/68\">",
"      Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/69\">",
"      Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/70\">",
"      Miller J, Chan BK, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/71\">",
"      P&eacute;rez Gutthann S, Garc&iacute;a Rodr&iacute;guez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/72\">",
"      H&oslash;ibraaten E, Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/73\">",
"      Glueck CJ, Wang P, Fontaine RN, et al. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V Leiden mutation (resistance to activated protein C). Am J Cardiol 1999; 84:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/74\">",
"      Rosendaal FR, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/75\">",
"      Herrington DM, Vittinghoff E, Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002; 22:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/76\">",
"      Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/77\">",
"      Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 166:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/78\">",
"      Post MS, Rosing J, Van Der Mooren MJ, et al. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol 2002; 119:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/79\">",
"      Smith NL, Heckbert SR, Lemaitre RN, et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004; 292:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/80\">",
"      Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/81\">",
"      Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010; 30:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/82\">",
"      Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/83\">",
"      Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost 2010; 8:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/84\">",
"      Straczek C, Oger E, Yon de Jonage-Canonico MB, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005; 112:3495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/85\">",
"      Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/86\">",
"      Koh KK, Shin MS, Sakuma I, et al. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 2004; 24:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/87\">",
"      Salpeter SR, Cheng J, Thabane L, et al. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009; 122:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/88\">",
"      Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/89\">",
"      Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/90\">",
"      Binder EF, Williams DB, Schechtman KB, et al. Effects of hormone replacement therapy on serum lipids in elderly women. a randomized, placebo-controlled trial. Ann Intern Med 2001; 134:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/91\">",
"      Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arterioscler Thromb 1994; 14:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/92\">",
"      Tuck CH, Holleran S, Berglund L. Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arterioscler Thromb Vasc Biol 1997; 17:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/93\">",
"      Ory SJ, Field CS, Herrmann RR, et al. Effects of long-term transdermal administration of estradiol on serum lipids. Mayo Clin Proc 1998; 73:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/94\">",
"      Herrington DM, Howard TD, Hawkins GA, et al. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med 2002; 346:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/95\">",
"      Davidson MH, Testolin LM, Maki KC, et al. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997; 157:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/96\">",
"      Sbarouni E, Kyriakides ZS. The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. J Am Coll Cardiol 1998; 32:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/97\">",
"      Weintraub MS, Grosskopf I, Charach G, et al. Fluctuations of lipid and lipoprotein levels in hyperlipidemic postmenopausal women receiving hormone replacement therapy. Arch Intern Med 1998; 158:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/98\">",
"      Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/99\">",
"      National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/100\">",
"      Ottosson UB, Johansson BG, von Schoultz B. Subfractions of high-density lipoprotein cholesterol during estrogen replacement therapy: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985; 151:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/101\">",
"      Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/102\">",
"      Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. Medical Research Council's General Practice Research Framework. BMJ 1996; 312:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/103\">",
"      Davidson MH, Maki KC, Marx P, et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000; 160:3315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/104\">",
"      Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metab 1991; 73:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/105\">",
"      Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation 1998; 97:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/106\">",
"      Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/107\">",
"      Kritz-Silverstein D, Barrett-Connor E. Long-term postmenopausal hormone use, obesity, and fat distribution in older women. JAMA 1996; 275:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/108\">",
"      Jensen LB, Vestergaard P, Hermann AP, et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. J Bone Miner Res 2003; 18:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/36/29258/abstract/109\">",
"      Haarbo J, Marslew U, Gotfredsen A, Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 1991; 40:1323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7409 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29258=[""].join("\n");
var outline_f28_36_29258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H102371434\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CORONARY HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cardiovascular effects of estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Effects of progestins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Combined estrogen-progestin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Unopposed estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Predictors of risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Timing of exposure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Type of estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Unopposed estrogen and type of estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Transdermal estrogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      STROKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Transdermal versus oral route",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PERIPHERAL ARTERY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      VENOUS THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Women's Health Initiative",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Type of oral estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Route of estrogen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prothrombotic mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      LIPIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Women with hyperlipidemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Effect of progestins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Type of progestin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Continuous versus cyclic combined regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Effect on triglycerides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      BLOOD PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      BODY WEIGHT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Body fat distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102371434\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7409\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7409|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/38/5742\" title=\"figure 1\">",
"      Womens health initiative risk of heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/51/16190\" title=\"figure 2\">",
"      Womens health initiative risk of stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/0/11277\" title=\"figure 3\">",
"      HRT and PE WHI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/34/23085\" title=\"figure 4\">",
"      HRT and CHD HERS II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/24/14734\" title=\"figure 5\">",
"      Estrogen progestin on lipids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37859?source=related_link\">",
"      Effect of oral contraceptives and postmenopausal hormone therapy on blood pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/2/39978?source=related_link\">",
"      HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/53/25434?source=related_link\">",
"      Menopausal hot flashes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/59/26546?source=related_link\">",
"      Patient information: Menopause (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=related_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=related_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=related_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/42/40615?source=related_link\">",
"      Treatment of menopausal symptoms with hormone therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_36_29259="Ddx cavitary lung lesions";
var content_f28_36_29259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of radiographic cavitary lung lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Necrotizing infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaerobic bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Staphylococcus aureus, Enterobacteriaceae, Pseudomonas aeruginosa,",
"Legionella, Haemophilus influenzae type B, Nocardia, Actinomyces",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        M. tuberculosis, M. avium, M. kansasii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Fungi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Aspergillus, Coccidioides, Histoplasma, Blastomyces, Cryptococcus, Mucor, Pneumocystis carinii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-infectious diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bland embolism with infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary sequestration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullae or cysts with air fluid level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchiectasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Empyema with air fluid level",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29259=[""].join("\n");
var outline_f28_36_29259=null;
var title_f28_36_29260="Reference range eNO";
var content_f28_36_29260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reference ranges derived from the multivariate model in normal subjects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Atopy status*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Smoking status",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference range for F",
"        <small>",
"         E",
"        </small>",
"        <sub>",
"         NO",
"        </sub>",
"        (ppb)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Female",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"3\">",
"        No atopy",
"       </td>",
"       <td class=\"sublist_other\">",
"        Current smoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        5.9-30.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Ex-smoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        6.4-32.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Nonsmoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.5-37.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"3\">",
"        Atopy",
"       </td>",
"       <td class=\"sublist_other\">",
"        Current smoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        6.9-36.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Ex-smoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.6-38.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Nonsmoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        8.8-44.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Male",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"3\">",
"        No atopy",
"       </td>",
"       <td class=\"sublist_other\">",
"        Current smoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        7.5-38.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Ex-smoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        8.1-40.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Nonsmoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        9.5-47.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"3\">",
"        Atopy",
"       </td>",
"       <td class=\"sublist_other\">",
"        Current smoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        8.8-45.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Ex-smoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        9.6-48.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Nonsmoker",
"       </td>",
"       <td class=\"sublist_other\">",
"        11.2-56.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     F",
"     <small>",
"      E",
"     </small>",
"     <sub>",
"      NO",
"     </sub>",
"     : fraction of nitric oxide in expired breath.",
"     <br>",
"      * Atopy: a positive skin prick test to at least one common allergen.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Travers, J, Marsh, S, Aldington, S, et al. Reference ranges for exhaled nitric oxide derived from a random community survey of adults. Am J Respir Crit Care Med 2007; 176:238. Copyright &copy;2007 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29260=[""].join("\n");
var outline_f28_36_29260=null;
var title_f28_36_29261="Glasgow coma scale";
var content_f28_36_29261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81854%7EPEDS%2F78293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81854%7EPEDS%2F78293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glasgow coma scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"90%\">",
"     </colgroup>",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Eye opening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spontaneous",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Response to verbal command",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Response to pain",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No eye opening",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Best verbal response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oriented",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Confused",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inappropriate words",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Incomprehensible sounds",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        No verbal response",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Best motor response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obeys commands",
"       </td>",
"       <td class=\"centered\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Localizing response to pain",
"       </td>",
"       <td class=\"centered\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Withdrawal response to pain",
"       </td>",
"       <td class=\"centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion to pain",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension to pain",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"indent1\">",
"        No motor response",
"       </td>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         &nbsp;",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The GCS is scored between 3 and 15, 3 being the worst, and 15 the best. It is composed of three parameters: best eye response (E), best verbal response (V), and best motor response (M). The components of the GCS should be recorded individually; for example, E2V3M4 results in a GCS score of 9. A score of 13 or higher correlates with mild brain injury; a score of 9 to 12 correlates with moderate injury; and a score of 8 or less represents severe brain injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pediatric Glasgow Coma Scale (&le;2 years)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_left\" colspan=\"2\">",
"       Eye opening",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spontaneous",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Response to verbal command",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Response to pain",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\" colspan=\"2\">",
"       Best motor response",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spontaneous (obeys verbal command)",
"      </td>",
"      <td>",
"       6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Withdraws in response to touch (Localizes pain)",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Withdraws in response to pain",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abnormal flexion in response to pain (Decorticate posture)",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abnormal extension in response to pain (Decerebrate posture)",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\" colspan=\"2\">",
"       Best verbal response",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Smiles, oriented to sound, follows objects, interacts (Coos, babbles)",
"      </td>",
"      <td>",
"       5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cries, irritable",
"      </td>",
"      <td>",
"       4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cries in response to pain",
"      </td>",
"      <td>",
"       3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Moans in response to pain",
"      </td>",
"      <td>",
"       2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       None",
"      </td>",
"      <td>",
"       1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Pediatric GCS Total",
"      </td>",
"      <td>",
"       3 to 15",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Holmes, JF, Palchak, MJ, MacFarlane, T, Kuppermann, N. Performance of the pediatric Glasgow coma scale in children with blunt head trauma. Acad Emerg Med 2005; 12:814.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29261=[""].join("\n");
var outline_f28_36_29261=null;
var title_f28_36_29262="Guidelines for timing of delivery after 34 weeks gestation";
var content_f28_36_29262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Consensus guidelines for timing of delivery for maternal, fetal, and placental conditions after 34 weeks gestation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gestational age* at delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Placental and uterine issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Placenta previa",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        36-37 wk (grade B)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suspected placenta accreta, increta, or percreta with placenta previa",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        34-35 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prior classical cesarean (upper segment uterine incision)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        36-37 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prior myomectomy necessitating cesarean delivery",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        37-38 wk (may require earlier delivery, similar to prior classical cesarean, in situations with more extensive or complicated myomectomy) (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Fetal issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fetal growth restriction - singleton",
"       </td>",
"       <td>",
"        38-39 wk:",
"        <ul>",
"         <li>",
"          Otherwise uncomplicated, no concurrent findings (grade B)",
"         </li>",
"        </ul>",
"        <br/>",
"        34-37 wk:",
"        <ul>",
"         <li>",
"          Concurrent conditions (oligohydramnios, abnormal Doppler studies, maternal risk factors, co-morbidity) (grade B)",
"         </li>",
"        </ul>",
"        <br/>",
"        Expeditious delivery regardless of gestational age:",
"        <ul>",
"         <li>",
"          Persistent abnormal fetal surveillance suggesting imminent fetal jeopardy",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fetal growth restriction - twin gestation",
"       </td>",
"       <td>",
"        36-37 wk:",
"        <ul>",
"         <li>",
"          Dichorionic-diamniotic twins with isolated fetal growth restriction (grade B)",
"         </li>",
"        </ul>",
"        <br/>",
"        32-34 wk:",
"        <ul>",
"         <li>",
"          Monochorionic-diamniotic twins with isolated fetal growth restriction (grade B)",
"         </li>",
"         <li>",
"          Concurrent conditions (oligohydramnios, abnormal Doppler studies, maternal risk factors, co-morbidity) (grade B)",
"         </li>",
"        </ul>",
"        <br/>",
"        Expeditious delivery regardless of gestational age:",
"        <ul>",
"         <li>",
"          Persistent abnormal fetal surveillance suggesting imminent fetal jeopardy",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fetal congenital malformations",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        34-39 wk:",
"        <ul>",
"         <li>",
"          Suspected worsening of fetal organ damage (grade B)",
"         </li>",
"         <li>",
"          Potential for fetal intracranial hemorrhage (eg, vein of Galen aneurysm, neonatal alloimmune thrombocytopenia) (grade B)",
"         </li>",
"         <li>",
"          When delivery prior to labor is preferred (eg, EXIT procedure) (grade B)",
"         </li>",
"         <li>",
"          Previous fetal intervention (grade B)",
"         </li>",
"         <li>",
"          Concurrent maternal disease (eg, preeclampsia, chronic hypertension) (grade B)",
"         </li>",
"         <li>",
"          Potential for adverse maternal effect from fetal condition (grade B)",
"         </li>",
"        </ul>",
"        <br/>",
"        Expeditious delivery regardless of gestational age:",
"        <ul>",
"         <li>",
"          When intervention is expected to be beneficial (grade B)",
"         </li>",
"         <li>",
"          Fetal complications develop (abnormal fetal surveillance, new-onset hydrops fetalis, progressive or new-onset organ injury) (grade B)",
"         </li>",
"         <li>",
"          Maternal complications develop (mirror syndrome) (grade B)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple gestations: dichorionic-diamniotic",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        38 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple gestations: monochorionic-diamniotic",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        34-37 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple gestations: dichorionic-diamniotic or monochorionic-diamniotic with single fetal death",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        If occurs at or after 34 wk, consider delivery (recommendation limited to pregnancies at or after 34 wk; if occurs before 34 wk, individualize based on concurrent maternal or fetal conditions) (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple gestations: monochorionic-monoamniotic",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        32-34 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple gestations: Monochorionic-monoamniotic with single fetal death",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Consider delivery; individualized according to gestational age and concurrent complications (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oligohydramnios - isolated and persistent",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        36-37 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Maternal issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic hypertension - no medications",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        38-39 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic hypertension - controlled on medication",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        37-39 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic hypertension - difficult to control (requiring frequent medication adjustments)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        36-37 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gestational hypertension",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        37-38 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Preeclampsia - severe",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        At diagnosis (recommendation limited to pregnancies at or after 34 wk) (grade C)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Preeclampsia - mild",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        37 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes - pregestational well controlled",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        LPTB or ETB not recommended (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes - pregestational with vascular disease",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        37-39 wk (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes - pregestational poorly controlled",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        34-39 wk (individualized to situation) (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes - gestational well controlled on diet",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        LPTB or ETB not recommended (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes - gestational well controlled on medication",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        LPTB or ETB not recommended (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes - gestational poorly controlled on medication",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        34-39 wk (individualized to situation) (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Obstetric issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prior stillbirth-unexplained",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         LPTB or ETB not recommended (grade B)",
"        </p>",
"        <p>",
"         Consider amniocentesis for fetal pulmonary maturity if delivery planned at less than 39 wk (grade C)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spontaneous preterm birth: preterm premature rupture of membranes",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        34 wk (recommendation limited to pregnancies at or after 34 wk) (grade B)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spontaneous preterm birth: active preterm labor",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Delivery if progressive labor or additional maternal or fetal indication (grade B)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LPTB: late preterm birth at 34 0/7 weeks through 36 6/7 weeks; ETB: early-term birth at 37 0/7 weeks through 38 6/7 weeks.",
"     <br>",
"      * Gestational age is in completed weeks; thus, 34 weeks includes 34 0/7 weeks through 34 6/7 weeks.",
"      <br>",
"       &Delta; Uncomplicated, thus no fetal growth restriction, superimposed preeclampsia, etc. If these are present, then the complicating conditions take precedence, and earlier delivery may be indicated.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Grade of recommendations are based on the following: recommendations or conclusions or both are based on good and consistent scientific evidence (A); limited or inconsistent scientific evidence (B); primarily consensus and expert opinion (C). The recommendations regarding expeditious delivery for imminent fetal jeopardy were not given a grade. The recommendation regarding severe preeclampsia is based largely on expert opinion; however, higher-level evidence is not likely to be forthcoming because this condition is believed to carry significant maternal risk with limited potential fetal benefit from expectant management after 34 weeks.",
"        <br>",
"         &sect; Maintenance antihypertensive therapy should not be used to treat gestational hypertension.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Spong CY, Mercer BM, D'Alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet and Gynecol 2011; 118:323. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29262=[""].join("\n");
var outline_f28_36_29262=null;
var title_f28_36_29263="Dumon silicone stent";
var content_f28_36_29263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68066&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Silicone Dumon tracheal stent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small studs on the external surface help prevent migration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_36_29263=[""].join("\n");
var outline_f28_36_29263=null;
